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VI. Summary 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, 
affecting approximately 1% of the population over the age of 65. Around 5% of these 
cases can be linked to mutations in known genes, one of which is the PINK1 gene, first 
linked to PD a decade ago. Since then, over 30 mutations in PINK have been described.  
The PINK1 gene encodes an unusual serine/threonine protein kinase; uniquely among 
protein kinases, PINK1 is anchored to the mitochondria and furthermore possesses three 
unusual insertions of unknown function in the N-lobe of its kinase domain. Recently, two 
important PINK1 substrates have been identified - the ubiquitin E3 ligase Parkin and 
ubiquitin itself. Phosphorylation of both of these substrates has further been shown to be 
necessary for the activation of Parkin E3 ligase activity. At the start of this project, little 
was known about the catalytic properties of PINK1 or the effects of the identified PD-
linked mutations due to the lack of a robust in vitro assay for PINK1 activity. In addition, 
the mechanisms by which PINK1 phosphorylation activated Parkin were not understood. 
The work described in this thesis was carried out with the aim of overcoming these hurdles 
by using a PINK1 homologue from a more tractable species.  
 
In Chapter III of this thesis, I describe the identification of a PINK1 homologue from the 
insect species Tribolium castaneum (TcPINK1) and its validation as a bona fide model for 
human PINK1. The activity assay established with TcPINK1 is used to show the PINK1 
C-terminal domain is required for kinase activity and that TcPINK1 strongly prefers 
peptide substrates with a +1 proline. Interestingly, this requirement is absent when intact 
protein substrates are used. TcPINK1 is then used as a model to analyse the effects of PD-
linked disease mutations, revealing that all the tested point and truncating mutations lead to 
a decrease in kinase activity. In most cases activity is completely abolished. In Chapter IV, 
progress towards the crystal structure of TcPINK1 is described. Several TcPINK1 
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constructs were expressed and purified to homogeneity and used for crystallisation trials. 
Crystals were obtained under multiple conditions and some progress was made towards 
improving their diffraction resolution, although this project did not reach a point at which 
data could be collected. Lastly, in Chapter V, preliminary data describing the molecular 
mechanism by which PINK1 phosphorylation of the Parkin Ubl domain at residue Ser65 
leads to Parkin activation is presented. An AlphaScreen assay was used to produce data 
suggesting that PINK1 phosphorylation of the Parkin Ubl domain relieves autoinhibitory 
binding of the Ubl domain to Parkin.   
 
Overall, this work provides the PINK1 field with a useful tool in the form of a robust and 
reproducible activity for PINK1 activity using TcPINK1, which has already been utilised 
several times to facilitate discoveries in both this lab and others. Significant progress has 
been made towards determination of the crystal structure of TcPINK1, which will provide 
insight into the molecular mechanisms of PD-linked mutations and may shed light onto 
PINK1 regulation and function. Finally, preliminary data suggests that PINK1-
phosphorylation of the Parkin Ubl domain may activate Parkin via alterations of 
autoinhibitory intramolecular interactions.  
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1 General Introduction 
1.1 Post-translational modification 
Post-translational modification is a process that occurs in all living organisms, ranging from 
bacteria, fungi and unicellular eukaryotes through to plants and complex multicellular 
animals. It is defined as the modification of proteins by the cleavage or formation of 
covalent bonds and despite the name, the classification encompasses modification of 
amino acids before, during and after their incorporation into a mature protein (Farriol-
Mathis et al, 2004). PTMs encompass a huge diversity of protein modifications, with one 
study on the relative abundance of PTMs in the human proteome analyzing a catalog of 
431 distinct modifications (Khoury et al, 2011). Two types of modification, 
phosphorylation and ubiquitylation, will be discussed in greater detail in Section 1.2.1 and 
Section 1.5.1 respectively. 
 
The general role of PTMs is to increase the complexity of the proteome, since a modified 
protein is chemically and often functionally distinct from its non-modified counterpart. In 
addition, the PTM status of a protein can vary independently of the level of expression of 
that protein, providing another layer of control above that of regulation of gene expression. 
It is estimated that from fewer than 25,000 human genes, around 1 million different 
protein molecules can be produced as a result of the diversity provided by PTMs in 
combination with alternative splicing (Farriol-Mathis et al, 2004). PTMs are known to 
influence or alter a number of aspects of protein biochemistry. They can control enzymatic 
activity; protein conformation and localization; and influence protein-protein interactions 
as well as controlling protein stability and targeting proteins for degradation.  
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PTMs can be added to a protein at any point during its life cycle and many, but not all 
PTMs, are reversible, with one enzyme carrying out the modification and another opposing 
enzyme undoing it. This reversibility of PTMs gives them a switch-like character and allows 
them to be dynamically regulated in response to a stimulus. This ability of PTMs to 
respond reversibly and rapidly to particular signals makes them a critical element of signal 
transduction cascades.  
 
Signal transduction is the general term for the mechanism by which cells, both unicellular 
and multicellular organisms, detect and respond appropriately to extracellular 
environmental stimuli. The key components of a signal transduction cascade include an 
activating signal, a receptor, a response relay and an output event (Figure 1.1). The 
activating signal binds to a receptor that spans the cell membrane and thereby contacts 
both the extracellular and intracellular environments. A change in the status of this 
receptor, for example a change in enzymatic activity, leads to the propagation of a signal 
through the cell by the sequential activation of a number of consecutive components. The 
cell achieves signal amplification at this stage in several ways. Protein kinase cascades can 
generate signal amplification, since the kinase activated at each step can phosphorylate and 
activate multiple copies of its substrate kinase that makes up the next step of the cascade. 
The generation of a small molecule known as a second messenger is an effective 
amplification technique since these molecules can diffuse rapidly in the cell to spread the 
signal and can be generated in large quantities to switch on many copies of a downstream 
component. The relayed signal ultimately induces a response from the cell, for example a 
change in gene expression or exocytosis and secretion of a substance from the cell surface.  
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Figure 1.1: Schematic illustration of a general signal transduction pathway.  
(L) The pathway is switched off and all components are dissociated. (R) The pathway is 
switched on by the binding of an extracellular signal (red) to the transmembrane receptors 
(blue). The signal propagates down the signal transduction cascade (green-orange), ending 
with the localization of an effector protein (purple) to the nucleus. This leads to a response 
from the cell, in this case the switching on of gene expression. 
 
To ensure the proper switch-like nature and rapid response of a signal transduction 
pathway, it is important that the signal can be switched off and the system swiftly reset 
following transmission of a message. For this reason, post-translational modification, 
particularly in the form of protein phosphorylation, forms a key part of any signal 
transduction cascade. These modifications are added enzymatically in a rapid and highly 
specific fashion and can be removed just as quickly by the opposing enzyme, allowing the 
fast transmission of discrete signals within the cell. A classic example of post-translational 
modification acting as a core component of a signal transduction cascade is seen in the 
MAP kinase (mitogen activated protein kinase) pathways (Morrison, 2012). This family of 
kinases includes members such as the ERKs (extracellular signal-regulated kinases) and 
JNKs (Jun amino-terminal kinases), which respond to diverse extracellular stimuli and 
regulate processes such as cell proliferation, differentiation and survival. Their signaling 
cascades typically consisting of an extracellular stimulus and cognate receptor, followed by 
a series of three protein kinases that sequentially phosphorylate and activate one another. 
The final kinase in the cascade then phosphorylates a range of substrates to bring about the 
appropriate response. 
Chapter 1 – General Introduction 
	  
	  
	   5 
1.2 Protein kinases and protein phosphorylation 
1.2.1 Protein phosphorylation 
Protein phosphorylation is the reversible modification of serine, threonine and tyrosine 
residues in a target protein by the addition of a phosphate group to the hydroxyl group of 
these amino acids, thus forming a phosphoester bond. Protein kinase activity was first 
observed in the 1950s with the identification of a liver enzyme that phosphorylated casein 
(Burnett & Kennedy, 1954) and subsequently with studies on glycogen metabolism that 
showed a phosphorylation/dephosphorylation cycle converted phosphorylase a to 
phosphorylase b and back again (Krebs & Fischer, 1956). Further historical discoveries in 
the field of protein phosphorylation are reviewed in (Cohen, 2002). It is now known that 
around 30% of the proteome is predicted to be subject to modification by protein 
phosphorylation, making this an important and ubiquitous method of regulating protein 
function (Kreegipuu et al, 1999). 
 
Protein phosphorylation is catalyzed by a family of 518 enzymes known as protein kinases, 
which transfer a phosphate group from the donor substrate adenosine triphosphate (ATP) 
onto a target protein. The reverse reaction is catalyzed by the protein phosphatase family 
(Figure 1.2A). Phosphorylation of a target protein can have a number of effects, many of 
which are as a direct consequence of the phosphate group possessing a double negative 
charge. Addition of such a charged group to a protein can lead to the formation of new 
ionic or hydrogen bond interactions in addition to creating attracting or repulsive 
electrostatic interactions (Johnson & Lewis, 2001). In this way, protein phosphorylation 
can mediate a large number of diverse effects upon its target proteins, broadly including: 
changes in conformation and/or enzymatic activity such as that seen in protein kinase 
activation loop phosphorylation; changes in protein-protein interactions such as binding to 
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regulatory partners or binding of enzymes to substrates; and changes in localisation, for 
example nuclear localisation of proteins upon phosphorylation (Figure 1.2B).   
 
Figure 1.2: Schematic of mechanism and effects of protein phosphorylation 
(A) The forward reaction is catalysed by a protein kinase and consumes ATP, yielding a 
phosphorylated substrate. The reverse dephosphorylation reaction is catalysed by a 
phosphatase and hydrolyses water. (B) Phosphorylation of a target protein can lead to 
changes in conformation and/or activity, changes in interactions, for example with 
substrates or regulatory partners, and changes in protein localization. 
 
A landmark study in 2002 classified all protein kinases in the human genome, known as the 
human “kinome”, according to their sequence similarity, firstly grouping them into either a 
superfamily of proteins containing a eukaryotic protein kinase (ePK) domain, or into a 
smaller superfamily of proteins containing an atypical protein kinase domain (aPK). These 
aPKs lack sequence similarity to the ePKs but are known to have protein kinase activity 
(Manning et al, 2002). The ePKs can mostly be further classified into one of seven 
subfamilies: TK (tyrosine kinase); TKL (tyrosine kinase-like); STE (containing the 
homologues of yeast Sterile 7, Sterile 11 and Sterile 20 kinases); CK1 (casein kinase 1); 
AGC (containing PKA, PKG and PKC families); CAMK (calcium/calmodulin-dependent 
protein kinases); and CMGC (containing the CDK, MAPK, GSK3 and CLK families). A 
phylogenetic tree of the ePK family was created to depict the evolutionary relationship 
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between the family members and to allow a visual representation of their grouping into the 
different subfamilies (Figure 1.3). 
 
Figure 1.3: The human kinome 
The ePKs can be classified into one of seven families: TK (tyrosine kinase); TKL (tyrosine 
kinase-like); STE (containing the homologues of yeast Sterile 7, Sterile 11 and Sterile 20 
kinases); CK1 (casein kinase 1); AGC (containing PKA, PKG and PKC families); CAMK 
(calcium/calmodulin-dependent protein kinases); and CMGC (containing the CDK, 
MAPK, GSK3 and CLK families). The kinase PINK1, of relevance to this thesis, is 
highlighted in a red oval. Adapted from Manning et al, 2002.  
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1.2.2 The structural basis of protein kinase activity 
The first structure of a protein kinase, that of cAMP-dependent protein kinase (PKA) 
revealed that the protein adopted a bilobal fold, with the smaller N-lobe consisting 
primarily of β-strands and the larger C-lobe mainly of α-helices. A flexible hinge region 
connected the two (Zheng et al, 1993). All protein kinases catalyse the same basic reaction, 
the transfer of a phosphoryl group onto a serine, threonine or tyrosine residue in a target 
protein (Adams, 2001). They also possess the same overall structural fold and a number of 
conserved amino acid motifs required for activity (Hanks & Hunter, 1995). These motifs 
are primarily involved in ATP binding and catalysis and are depicted in the schematic 
below along with a model of the crystal structure of PKA in the active state (Figure 1.4). 
PKA is one of the most well studied protein kinases and is used in this thesis as a model 
for the general protein kinase domain.  
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Figure 1.4: Conserved structural and sequence motifs of protein kinases 
(A) Secondary structure of PKA (α-helices: barrels; β-strands: arrows) showing conserved 
amino acid motifs (top) and the boundaries of the conserved kinase subdomains as defined 
by Hanks & Hunter (bottom). The N- and C-lobes and hinge region are also shown. (B) 
Crystal structure of PKA in the active state showing motifs involved in catalysis. Yellow: 
glycine-rich loop; orange: β3-αC salt bridge; pink: HRD catalytic motif; purple: DFG 
motif/N-terminal activation segment anchor; pale blue: activation segment; green: APE 
motif/C-terminal activation segment anchor. ATP is shown as turquoise/orange sticks. 
PDB ID: 1ATP. 
 
Protein kinases are dynamic enzymes, cycling between a fully active closed conformation 
and a fully inactive open conformation. Studies on the structure of PKA have revealed a 
number of discrete conformations in between these two opposing states, although it is 
uncertain if these intermediate structures represent partially active conformations that are 
steps on the way to full activation, or normal parts of the kinase catalytic cycle (Nolen et al, 
2004). As mentioned above, there are a number of conserved features common to all 
kinases that play a role in kinase activity. These will be discussed in greater detail, moving 
from N- to C-terminus within the kinase domain. Numbering is given according to PKA. 
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The glycine-rich loop motif is found in Subdomain I, in the loop between strands β1 and 
β2, starting with Gly50. The small glycine residues allow the loop to approach the ATP 
molecule and form hydrogen bonds from its peptide backbone atoms to the β-phosphate 
of ATP (Huse & Kuriyan, 2002). Hydrophobic side chains in this subdomain also 
contribute to the hydrophobic adenine-binding portion of the ATP binding pocket (Hanks 
& Hunter, 1995).  
An important ionic interaction occurs between a conserved lysine residue (Lys72) in the β3 
strand (Subdomain II) and a glutamic acid (Glu91) in the αC helix  (Subdomain III). Lys72 
forms a stabilising ionic interaction with the α- and β-phosphates of ATP and when the 
kinase is in the active conformation, forms a salt bridge with Glu91 (Huse & Kuriyan, 
2002). The conformation of αC relative to the rest of the kinase is flexible and often varies 
dependent on the activation state of the enzyme.  
The hinge region, made up of the β5 strand and the αD helix, connects the two lobes of 
the kinase domain and comprises Subdomain V. This region of the protein is flexible to 
allow for the movement of the two lobes relative to one another that occurs as the kinase 
moves from the active to the inactive state. The loop between strands β6 and β7 is referred 
to as the catalytic loop and is found in Subdomain VIB. It contains the catalytic base, an 
aspartic acid (Asp 166) found within the HRD motif.  
The activation segment spans Subdomains VII and VIII and is subdivided into several 
sections (Figure 1.5). The activation segment is a key structure for controlling the activation 
status of protein kinases, with many being regulated by an activating phosphorylation event 
within this region.  
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Figure 1.5: Schematic of the activation segment of 
protein kinases 
The same nomenclature for the different components 
of the activation segment is used throughout this thesis. 
Adapted from Nolen et al, 2004. 
 
 
The loop between strands β8 and β9 (Subdomain VII) is known as the magnesium-binding 
loop and contains the conserved DFG motif that defines the start of the activation 
segment. The structure of the DFG motif is highly similar in all kinases in the active state 
(Nolen et al, 2004). The DFG aspartic acid (Asp184) is involved in coordinating the 
magnesium ions that chelate the β- and γ-phosphates of ATP, helping to orient it correctly 
for catalysis (Adams, 2001). When the kinase is in the inactive state, Asp184 is positioned 
incorrectly and this interaction cannot take place. Furthermore, in PKA the DFG 
phenylalanine (F185) forms a hydrophobic interaction with the αC helix, disruption of 
which can perturb the conformation of this helix (Nolen et al, 2004).  
Subdomain VIII contains the activation loop and the P+1 loop. The APE motif found 
here marks the end of the activation segment, and as with the DFG motif, seems to adopt 
a similar conformation in all active kinases. The APE glutamic acid (Glu208) is generally 
conserved and forms a stabilising ionic bond with an arginine residue (Arg280) in 
Subdomain XI (Yang et al, 2012). The activation loop itself is variable in both sequence 
and structure, which reflects the diverse methods of regulation that are used to control the 
activity of different kinases via their activation segments. Many proteins are activated by 
phosphorylation within the activation segment, either by an upstream kinase or by 
autophosphorylation. Regulation of kinase activity will be discussed in more depth in 
Section 1.2.3. The P+1 loop is known to be involved in dictating the sequence specificity 
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of protein kinases, particularly with regards to the amino acids C-terminal to the site of 
phosphorylation (Ubersax & Ferrell, 2007).  The sequence and conformation of this region 
is therefore tailored according to the substrate specificity of each kinase. 
 
Finally, although they are not discrete amino acid motifs or linear regions, two structures 
known as the R- and C-spines also play an important role in kinase activity (Kornev et al, 
2006; Kornev et al, 2008). These spines were identified by computational studies and are 
made up of a number of amino acids spread throughout the primary sequence. They are 
separated in three-dimensional space in the inactive state, but come together and interact to 
form rigid structures that traverse the entire kinase domain upon entering the active 
conformation (Figure 1.6). 
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Figure 1.6: Crystal structure of active PKA showing R- and C-spines 
Spines are shown in sphere representation to illustrate the space occupied and each 
component is labelled. R-spine: raspberry; C-spine: purple; adenine ring of ATP: pink; αF 
helix: cream. PDB ID: 1ATP. 
 
The R-spine is made up of Leu96 from the αC helix, Leu106 from β4, Tyr 164 from the 
catalytic loop, Phe185 from the magnesium loop (DFG motif) and Asp220 from αF. Its 
assembly is linked to the conformation of the activation segment and with the αC helix 
(Kornev 2006). The C-spine consists of Leu227 and Met231 from the αF helix, Met128 
from αD, Leu127, Leu173 and Ile174 from β7, Val57 from β2 and Ala70 from β3. 
Critically, the adenine ring of ATP also contributes to the formation of this spine and its 
assembly is therefore linked to the binding of ATP to the kinase. Since the completed C-
spine extends throughout the kinase and traverses well into the N-lobe, binding of the 
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adenine moiety can be considered an important event that integrates the N-and C-lobes in 
preparation for catalysis.  
 
It is interesting to note that both the R- and C-spines contain amino acids that are located 
in the αF helix, with the R-spine originating from the N-terminus of the helix and the C-
spine from the C-terminus. In addition to providing support for these two structures, it has 
been shown that the αF helix forms a tight hydrophobic interaction with the αH helix that 
is presumed to aid in stabilising the hydrophobic core of the kinase. Furthermore, in PKA, 
interactions between the αF helix and the P+1 loop have been observed, along with more 
indirect interactions with the catalytic and activation loops. These are regions of the protein 
that play a key role in substrate recognition and are directly responsible for catalysis. The 
sum of these many interactions is that the αF helix is able to act as a central organising 
structure, coordinating separate inputs from activation segment and αC helix 
conformation, ATP binding, catalytic loop status and substrate binding. With this in mind, 
it becomes easy to understand how kinase activation can occur as an ordered multi-stage 
process where each step is sensitive to the occurrence of the others. This complex 
activation mechanism provides multiple levels of control to allow the precise activity of a 
given kinase to be finely tuned.  
 
1.2.3 Regulation of protein kinase activity 
Protein kinases play important roles in the regulation of almost every cellular process, 
including those such as cell division, survival, growth and metabolism and as a result it is 
not surprising that the presence of aberrant kinase activity has been linked to many human 
diseases (see Section 1.2.5 for more detail). The activity of protein kinases must therefore 
be kept tightly regulated both to avoid inappropriate activation and to ensure the enzyme 
responds only at the correct time to its physiological stimuli. 
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One of the most common regulatory mechanisms used to control the activity of many 
kinases is phosphorylation of the activation loop. This can be carried out either by a 
regulatory upstream kinase or as an activating autophosphorylation event. As a general rule, 
kinases with an arginine in the HRD motif, referred to as RD kinases, are regulated by 
activation loop phosphorylation and those without, referred to as non-RD kinases, are not. 
In RD kinases requiring phosphorylation, the arginine residue forms part of a basic pocket 
that captures the phosphorylated activation loop and holds it in the active conformation 
(Nolen et al, 2004). An example of this is seen in the structure of the Aurora-A spindle 
kinase in complex with a binding partner, in which Aurora-A is phosphorylated at residue 
Thr288 of the activation loop (Bayliss et al, 2003). This phosphorylated residue then forms 
an interaction with the HRD arginine (Arg255) and two other arginine residues, Arg180 
and Arg286, which form a basic pocket. The overall structure of the activation loop in this 
structure is highly similar to that of PKA in its active conformation. 
In RD kinases that are not phosphorylated, the basic pocket has been observed to bind 
anions, such as a sulphate ion in the case of GSK-3β (glycogen synthase kinase 3 beta), 
however this is not necessary for proper activation loop conformation (Bax et al, 2001), 
suggesting the activation loop is able to independently assume the conformation required 
for kinase activity. Other kinases, both RD and non-RD, make use of binding partners to 
position the activation loop. An example of this is the constitutively active CK2 (casein 
kinase 2), which uses interactions between its N-terminal extension and the activation loop 
to maintain the activation loop in the active conformation (Niefind et al, 1998). 
 
Regulation of kinase activity by phosphorylation is not just confined to phosphorylation 
events within the activation loop, however. Phosphorylation of GSK3 at its N-terminus 
(Ser9 in GSK3β, Ser21 in GSK3-α) has been shown to inhibit GSK3 activity and decrease 
the phosphorylation of glycogen synthase (Cross et al, 1995). The mechanism for this 
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inhibition was not understood until much later. GSK3 phosphorylates previously 
phosphorylated, or primed, substrates that then bind to a basic pocket analogous to the 
one used to bind phosphorylated activation loop residues in other kinases (ter Haar et al, 
2001). When the N-terminus of GSK3 is phosphorylated, it is able to occupy this basic 
substrate-binding site and prevent binding of the physiological substrate (Frame et al, 
2001). In this way, the phosphorylated N-terminus acts as an inhibitory pseudosubstrate. 
 
Another important mechanism for the regulation of kinase activity is by protein-protein 
interactions. These can occur either with another protein molecule, or with another 
segment of the same molecule such as a regulatory domain outside the kinase domain. A 
well-known example of regulation via a binding protein is the activation of the CDKs 
(cyclin-dependent kinases) by cyclin binding. In the inactive structure of human CDK2, the 
αC helix is rotated outwards and the salt bridge between this structure and the β3 strand is 
broken (De Bondt et al, 1993). However, upon cyclin binding (in this case Cyclin A) to the 
αC helix, it rotates inwards towards the ATP binding site. Lys33 from β3 and Glu51 from 
αC are then able to form an ionic interaction and Lys33 is correctly positioned to interact 
with and stabilise the ATP molecule. In addition, Cyclin A binds to the activation loop of 
CDK2, moving it away from where it was obscuring the peptide binding site and correctly 
positioning it for phosphorylation by its upstream kinase, which will in turn lead to 
maximal kinase activity (Jeffrey et al, 1995). The activation mechanism of CDK2 also 
provides an example of how several events required for kinase activation, in this case 
activation segment and αC helix conformation, can be linked and interdependent.  
 
A further interesting example of kinase regulation by binding partners is the regulation of 
the LKB1 kinase by the pseudokinase STRADα (Ste20-related adapter) and the scaffold 
protein MO25α (mouse protein-25) (Zeqiraj et al, 2009). Despite STRADα being a 
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pseudokinase, it is able to bind ATP and upon MO25α binding, adopt the canonical 
“active” kinase conformation. Interactions between MO25α and the LKB1 activation loop, 
αC and αI helices, along with interactions between STRADα and both the N- and C-lobes 
of LKB1, position LKB1 in the active conformation.   
 
CaMKII (Ca2+/calmodulin-dependent protein kinase II) is negatively regulated by a region 
C-terminal to its kinase domain. The structure of inactive CaMKII reveals that the 
regulatory segment, which contains the calmodulin-binding site, acts by blocking substrate 
binding. Interestingly, the activation loop is in an active conformation, although the N-lobe 
is rotated in an open conformation relative to the C-lobe (Rosenberg et al, 2005). This 
conformational change leads to a concomitant decrease in ATP binding affinity, mainly due 
to the loss of an interaction between residues in the αD helix and the ribose ring of ATP.  
Furthermore, interactions between the αF helix and the regulatory segment masks an 
autophosphorylation site within the regulatory segment that activates the enzyme in the 
absence of Ca2+ or calmodulin (Rosenberg et al, 2005). In this way, binding of the 
regulatory segment to CaMKII keeps multiple different checks upon its activity and 
ensures activation only occurs in the presence of the required stimulus.  
 
1.2.4 Mechanisms of substrate recognition in protein kinases 
Once a kinase has become activated, it needs to be able to discriminate between huge 
numbers of potential protein substrates. As previously mentioned, the basic reaction 
catalysed by a kinase is the phosphorylation of serine, threonine or tyrosine. It has been 
estimated that within a typical eukaryotic cell this provides a pool of around 700,000 
potentially phosphorylatable residues (Ubersax & Ferrell, 2007). Therefore it is imperative 
that additional mechanisms of specificity be employed to ensure that each kinase is only 
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able to phosphorylate these amino acids within the correct physiological target, with many 
kinases employing several different methods to ensure specificity.  
 
Protein kinases can generally be separated into those that phosphorylate serine and 
threonine residues and those that phosphorylate tyrosine residues. There are some 
exceptions, such as the DYRKs (dual-specificity tyrosine-regulated kinases), that are able to 
phosphorylate both serine/threonine and tyrosine residues (Aranda et al, 2011), although 
this is not common. To allow discrimination between serine/threonine and tyrosine 
residues, tyrosine kinases typically have a deeper catalytic cleft.  In this case, only tyrosine is 
large enough to reach close to the γ-phosphate of ATP and become phosphorylated 
(Ubersax & Ferrell, 2007). In addition, a conserved residue within the P+1 loop of the 
activation segment aids in dictating serine/threonine versus tyrosine specificity. In S/T 
kinases, this residue is often a serine or threonine that forms a hydrogen bond to the 
catalytic loop, whereas in tyrosine kinases, it is usually a proline that is able to form a 
stacking interaction with the tyrosine side chain and position it correctly (Nolen et al, 
2004). 
 
Important interactions for dictating substrate specificity occur between the substrate, 
typically around four amino acids on either side of the phosphorylation site, and the active 
site groove of the protein kinase. In some cases, a particular protein kinase will have a well-
defined consensus sequence for the residues surrounding the phosphorylation site that can 
even be used to predict its likely substrates. A well-known example of such a consensus 
motif is seen in PKB (protein kinase B), which phosphorylates substrates with the 
consensus sequence R-X-R-X-X-S/T-φ, where X is any amino acid and φ is a bulky 
hydrophobic residue (Alessi et al, 1996). PKB is part of the AGC family of protein kinases, 
which are known to display a general preference for basic substrates. For example, the 
Chapter 1 – General Introduction 
	  
	  
	   19 
consensus sequence for PKA, another AGC family member, is R-R/K-X-S/T (Kemp et al, 
1977). Since AGC kinases display similar substrate preferences, they often phosphorylate 
the same substrate proteins, such as GSK3, which is phosphorylated by multiple AGC 
family members (Frame & Cohen, 2001). This illustrates that although interactions around 
the active site can contribute significantly to kinase substrate specificity, they are limited in 
the degree of complexity of recognition they can confer.  
 
An additional level of substrate specificity can be conferred by interactions away from the 
active site, known as distal docking sites. These interactions can often increase the affinity 
of a kinase for its substrate and as a result make phosphorylation more efficient. The 
MAPKs (mitogen-activated protein kinases) provide a good example of the use of docking 
domains to provide substrate specificity. JNK2 possesses a small region near the active site 
that is responsible for binding to its substrate, c-Jun. In contrast, JNK1 does not possess 
this docking site and as a result phosphorylates c-Jun much less efficiently (Kallunki et al, 
1994).  
 
Finally, controlling the localisation of the kinase can control the phosphorylation of target 
proteins. PDK1 (phosphoinositide-dependent kinase 1) is a constitutively active kinase that 
is localised to the inner plasma membrane via binding of its PH (pleckstrin homology) 
domain to the second messenger PIP3 (Anderson et al, 1998). One of its substrates, PKB, 
also possesses a PH domain and is localised to the membrane by the same signal. Co-
localisation of these proteins on the membrane appears to be a key step for enabling the 
activation loop phosphorylation of PKB at Thr308 by PDK1 (Scheid et al, 2002). This co-
localisation was originally thought to be the main contributing factor to PKB activation, 
however it is now understood that prior phosphorylation of PKB at Ser473 by mTORC2 
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and the subsequent binding of this phosphorylated motif to the PIF pocket of PDK1 also 
plays a role (Najafov et al, 2012).  
 
1.2.5 Protein phosphorylation and human disease 
Aberrant protein phosphorylation is responsible for a large number of human diseases 
including cancer, autoimmune diseases and neurodegenerative disorders. In particular, 
inherited or sporadic mutations in protein kinases that lead to inactivation or inappropriate 
activation of the enzyme are a common cause of disease. A table of selected kinases and 
the disorder caused by their malfunction is presented below (Table 1.1). Much work has 
gone into understanding the pathways and mechanisms that lead to these diseases and as 
such, protein kinases are now a popular drug target. Extensive effort has gone towards 
developing potent and specific inhibitors against a plethora of different protein kinases. 
The first success with this approach came with the development of the inhibitor Imatinib 
(Gleevec), which targets the tyrosine kinase Bcr-Abl, a constitutively active fusion protein 
that causes the development of chronic myeloid leukaemia (Capdeville et al, 2002). Kinase 
inhibitors are now used to treat many other forms of cancer (Zhang et al, 2009) and have 
also been used with a moderate degree of success to treat autoimmune and inflammatory 
diseases, for example the JAK inhibitor tofacitinib, which has been approved in the United 
States for the treatment of rheumatoid arthritis (Patterson et al, 2014).  
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Table 1.1: Protein kinases mutated in human disease 
The symbol and full name of each kinase is listed along with the disease or disorder caused 
by mutations in each kinase. Adapted from Alessi & Zeqiraj, 2007. 
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1.3 Parkinson’s disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Its 
prevalence increases with age and it occurs in 1% of the population over the age of 60 (de 
Lau & Breteler, 2006). The overwhelming majority of cases (~95%) are idiopathic, 
however in a small number of cases (~5%), the disease can be traced to mutations in one 
of several known genes. These cases are referred to as familial PD to distinguish them from 
the more common idiopathic form. Diagnosis of PD is currently based upon the presence 
of clinical symptoms and signs and it is not possible to test for biomarkers prior to the 
development of the disease to give an indication of likelihood of future development 
(Jankovic, 2008). The only available therapies manage the symptoms of the disease and do 
not alter or prevent disease progression. Once the disease process has begun, it is currently 
irreversible (Rascol et al, 2003).  
 
1.3.1 Historical and landmark discoveries 
Parkinson’s disease was first formally described in 1817 by James Parkinson in his work 
“Essay on the Shaking Palsy”, where he described the subjects he observed as follows 
(Parkinson, 1817): 
 
“Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when 
supported; with a propensity to bend the trunk forward, and to pass from a walking to a running pace: the 
senses and intellects being uninjured” 
 
Further studies carried out by Charcot in 1872 refined the description of the disease, 
introducing the concept of bradykinesia as slowness in executing movement and being 
distinct from weakness caused by the tremor or rigidity also observed (Charcot, 1872). 
Charcot also re-named the disease Parkinson’s disease at this point, in recognition of its 
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original description. In 1912, Lewy discovered neuronal inclusions in the brains of 
Parkinson’s patients (Lewy, 1912), which later became known as Lewy bodies and are now 
a defining feature of Parkinson’s disease. The primary component of Lewy bodies was 
much later shown to be the protein α-synuclein, now known to be mutated in familial PD 
(Spillantini et al, 1998). Around the same time as Lewy, it was discovered that the 
substantia nigra was a major site of damage in PD, which was validated by a thorough 
pathological analysis of the lesions seen in the PD brain (Greenfield & Bosanquet, 1953). 
Loss of dopamine in the striatum of post-mortem PD brains was first observed in 1960 
(Ehringer & Hornykiewicz, 1960) and shortly after, administration of its precursor, L-
DOPA, was demonstrated to be an effective therapy for relief of the symptoms of PD 
(Cotzias et al, 1967). 
 
1.3.2 Clinical symptoms and pathology of Parkinson’s disease 
The clinical symptoms displayed by patients suffering from PD fall into two classes: motor 
and non-motor symptoms - with the motor symptoms of the disease being the most well 
known amongst laypersons, despite the non-motor symptoms being equally if not more 
debilitating. It is estimated that motor symptoms only start to manifest once 50-60% of 
dopaminergic neurons in the substantia nigra have been lost (Riederer & Wuketich, 1976), 
whereas certain non-motor symptoms can appear years before motor symptoms are 
detectable (Beitz, 2014).  
 
The major motor symptoms of PD include a resting tremor that often begins on one side 
of the body and progresses to the other side over time. This is the most common motor 
symptom, and has been found to occur in approximately 75% of PD patients (Hughes et 
al, 1993). Bradykinesia is also seen in many patients and is slowness of movement, 
including slowness of initiation, long gaps between successive elements of a movement and 
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difficulty performing two movements simultaneously (Berardelli et al, 2001). Patients also 
display rigidity, postural instability and freezing (Jankovic, 2008). 
 
The non-motor symptoms of PD can be broadly divided into cognitive and 
neurobehavioural symptoms, autonomic dysfunction and sleep and sensory dysfunction. 
Cognitive and neurobehavioural symptoms primarily include depression, anxiety, apathy 
and hallucinations. These disorders are thought to be present in up to 90% of PD patients 
(Aarsland et al, 2007). Autonomic dysfunctions seen in PD patients can include orthostatic 
hypotension (low blood pressure upon standing up), constipation, urinary difficulties, 
incontinence, sexual dysfunction, sialorrhea (excessive salivation), dysphagia (difficulty in 
swallowing) and sweating dysfunction (Jankovic, 2008). The sleep dysfunction seen in PD 
patients includes insomnia, excessive daytime sleepiness and REM sleep behavior disorder. 
REM sleep behavior disorder occurs in approximately one-third of PD patients and is 
known to be a risk factor for the development of PD (Postuma et al, 2013). Sensory 
dysfunctions include painful sensory symptoms and olfactory dysfunction, which is 
believed to be an early marker of the development of PD and is associated with an 
increased risk of developing the disease (Ponsen et al, 2004).   
 
The most pronounced pathological feature of PD is the loss of dopaminergic neurons 
within the substantia nigra pars compacta (Bernheimer et al, 1973), which subsequently 
leads to loss of dopamine in the striatum, a region of the brain that receives input from the 
substantia nigra. Both of these regions of the brain form part of a larger structure called the 
basal ganglia (Bergman & Deuschl, 2002). Examination of post-mortem PD patient brains 
reveals that surviving dopaminergic neurons commonly contain Lewy bodies (Spillantini et 
al, 1998). The mapping of the basal ganglia circuitry has provided some mechanistic 
understanding of how loss of dopaminergic neurons and the subsequent reduction in 
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striatal dopamine levels leads to the motor symptoms of PD, but the neural basis of the 
non-motor symptoms is still not well understood (Wichmann et al, 2011).  
 
1.3.3 Current therapies for Parkinson’s disease 
There are three main classes of treatment for patients suffering from PD, namely surgical 
interventions (Duker & Espay, 2013) and rehabilitation  (Hindle et al, 2013), which will not 
be discussed further, and finally pharmacological treatments.  
 
There are several classes of drugs that provide symptomatic relief for PD patients by 
increasing the levels of dopamine in the brain through various mechanisms, including 
promotion of dopamine synthesis, activation of neurotransmitter receptors in the brain, 
prolonging availability of dopamine in the brain, or prolonging the ability of other 
therapeutic drugs (Rascol et al, 2002). Treatment with the dopamine precursor L-DOPA 
remains one of the most potent forms of therapy for PD patients. L-DOPA, unlike 
dopamine itself, can cross the blood-brain barrier and once inside the brain is metabolised 
by DOPA decarboxylase to form dopamine. Unwanted metabolism of L-DOPA in the 
peripheral nervous system is blocked by taking a DOPA decarboxylase inhibitor in 
conjunction with L-DOPA. This restricts the conversion of L-DOPA and subsequently 
increases dopamine levels in the CNS (Katzenschlager & Lees, 2002). It should be noted 
that the existing therapies for PD focus on the motor symptoms of the disease and provide 
little relief for the non-motor symptoms, with few effective therapies being available for 
treatment of the latter set of symptoms (Rascol et al, 2002). 
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1.3.4 Genetics of Parkinson’s disease 
Although Parkinson’s disease is primarily a sporadic disorder, approximately 5% of PD 
cases have been shown to have a known genetic cause and it has also been hypothesized 
that the presence of certain genetic variations may contribute towards or confer 
susceptibility to development of the sporadic form of the disease (de Lau & Breteler, 2006). 
To date, eighteen chromosomal regions, or loci, have been suggested to have a link to PD 
through methods such as linkage analysis and genome-wide association studies. So far, only 
five of these regions have been unequivocally linked to monogenic forms of canonical PD 
with multiple mutations described in independent families (Klein & Westenberger, 2012); 
these genes are described in greater detail below. The situation with the remainder is more 
ambiguous. For some regions, the association between the locus and PD has not been 
replicated and is therefore unconfirmed. For others, the causative gene within the locus has 
not yet been identified, and for others, variations in the gene are risk factors and only 
confer susceptibility to PD (Klein & Westenberger, 2012). Each of these 18 loci and their 
status with regards to confirmation, causative gene (if known), inheritance and clinical 
features is listed below (Table 1.2). 
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Table 1.2: Genetic loci implicated in familial Parkinson’s disease 
The symbol of each locus is listed along with its location and whether or not the link 
between that locus and PD has been definitively confirmed. For each locus, the relevant 
gene (if known), mode of inheritance and details of the disorder caused is listed. Two genes 
of relevance to this thesis, PINK1 and Parkin, are highlighted. Adapted from Klein & 
Westenberger, 2012.  
 
LRRK2 (PARK8) mutations are the most common cause of autosomal dominant 
Parkinsonism (Paisan-Ruiz et al, 2004; Zimprich et al, 2004). The LRRK2 (Leucine-Rich 
Repeat Kinase 2) gene encodes for a large protein containing both a kinase domain and a 
GTPase domain in addition to multiple domains predicted to be involved in protein-
protein interactions. Many mutations in LRRK2 have been reported, with the most 
prevalent and well-studied being the G2019S mutation that increases kinase activity relative 
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to the wild-type protein (Jaleel et al, 2007; West et al, 2005). Little is known about the 
physiological function of LRRK2.  
 
The SNCA gene (PARK1/4) was the first gene to be linked to PD and encodes the protein 
α-synuclein (Polymeropoulos et al, 1997). Endogenous α-synuclein exists as a tetramer, 
with the monomers having a largely α-helical structure (Bartels et al, 2011). Aggregated α-
synuclein forms the primary component of the Lewy bodies that are observed in the 
surviving neurons of patients with PD (Spillantini et al, 1997). Several point mutations in 
the SNCA gene have been reported, some of which increase the aggregation propensity of 
the protein (Bussell & Eliezer, 2001)  More frequently reported are gene duplications and 
triplications, which have a gene dosage effect (Wales et al, 2013).  
 
Mutations in the Parkin gene (PARK2), first identified in 1998 (Kitada et al, 1998), are the 
most common cause of early-onset autosomal recessive Parkinsonism, with age of onset 
typically being between 30-40 years of age, but sometimes younger than 21 (referred to as 
juvenile PD). Over 100 mutations in Parkin have been reported (Klein & Westenberger, 
2012). The Parkin protein is a 465 amino acid ubiquitin E3 ligase belonging to the RBR 
family (Wenzel et al, 2011). The regulation, substrates and function of Parkin will be 
discussed in greater detail in Section 1.5. 
 
The PINK1 gene (PARK6) encodes a protein kinase (PTEN (phosphatase and tensin 
homologue)-induced kinase 1) of 581 amino acids. Mutations in the PINK1 gene were first 
identified in 2004 (Valente et al, 2004), and since then approximately 30 pathogenic 
mutations have been reported along with many more heterozygous variants of uncertain 
pathogenic significance (Appendix 1). Both point and truncating mutations have been 
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identified. PINK1, its substrates, regulation and function will be discussed in more detail in 
Section 1.4.  
 
Finally, mutations in the DJ-1 gene (PARK7) were first identified in 2003 (Bonifati et al, 
2003) and to date several additional point mutations have been identified. The L166P 
mutation is known to destabilize the protein, although the effect of the other mutations is 
less clear (Kahle et al, 2009). The DJ-1 protein is believed to act as an oxidative chaperone 
and is ubiquitously expressed.  
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1.4 PINK1 (PTEN-induced kinase 1) 
The gene encoding PINK1 (PTEN (phosphatase and tensin homologue)-induced kinase 1) 
was first identified in 2001 after it was discovered that its transcription was upregulated as a 
response to PTEN overexpression in endometrial cancer cells (Unoki & Nakamura, 2001). 
It was not until 2004 that PINK1 was linked to Parkinson’s disease, when homozygous 
mutations in PINK1 were found in patients with autosomal recessive early-onset 
Parkinson’s disease (Valente et al, 2004). A full list of PINK1 point mutations is provided 
in Appendix 1.  
 
The PINK1 gene is around 1.8 kb in length, consists of 8 exons and is found on 
Chromosome 1. The PINK1 protein is 581 amino acids in length. Initial Northern blot 
analysis of mRNA levels revealed that PINK1 is expressed ubiquitously in humans and is 
particularly abundant in the heart, skeletal muscle and testis (Unoki & Nakamura, 2001). A 
more detailed analysis of expression levels within the human brain revealed that PINK1 is 
expressed in neuronal cells, with higher levels seen in the substantia nigra, among other 
areas. In the same study it was shown that in brains from PD patients, PINK mRNA levels 
remained the same within the cerebellum and did not decrease in neurons of the substantia 
nigra (Blackinton et al, 2007).  
Patients harbouring PINK1 mutations generally have a strong and long-lasting response to 
Levodopa (L-DOPA) and have a lower prevalence of non-motor symptoms than sporadic 
PD patients (Puschmann, 2013). They may, however show psychiatric symptoms in 
addition to rigidity, lower limb dystonia (involuntary contractions) and hyperreflexia (over-
responsive reflexes). There is only a single report of a post-mortem brain from a PINK1 
patient showing Lewy body pathology (Samaranch et al, 2010). 
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1.4.1 Domain architecture of PINK1 
PINK1 is an unusual member of the protein kinase family; it does not fall into any of the 
known groupings in the human kinome tree and is found on a branch by itself, meaning 
there are no closely related or homologous kinases. The most closely related protein kinase 
is DMPK (myotonin-protein kinase), which shares only 31% sequence identity with 
PINK1. This lack of similarity to other kinases is due to a number of unusual features seen 
in this enzyme (Figure 1.7). At the N-terminus there is a mitochondrial targeting sequence 
and transmembrane domain - features not seen in any other member of the human 
kinome. This is followed by a moderately conserved stretch of amino acids that are 
predicted to form a disordered region. The kinase domain, found towards the C-terminus 
of the protein, contains three unusual insertions in its N-lobe (Cardona et al, 2011; Mills et 
al, 2008). The first, most N-terminal insertion is the longest and least conserved between 
species, the second and third are shorter and more highly conserved. Immediately 
following the kinase domain is a small, 68 amino acid domain that is predicted to be α-
helical in structure. The function of the N-lobe insertions and the C-terminal domain 
remains unclear, and it is these unique features that explain the lack of similarity between 
PINK1 and other protein kinases. 
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Figure 1.7: Domain architecture and multiple sequence alignment of PINK1 
(A) Domain structure of PINK1. MTS: mitochondrial targeting sequence; TM: 
transmemrane helix; Ins1-3; insertions in PINK1 kinase domain; CTD: C-terminal domain. 
(B) Multiple sequence alignment of PINK1 kinase domain against kinase domains of PKA, 
CaMKIα, CaMKIIγ, NEK4 and DMPK. Yellow: glycine-rich loop; orange: αC helix lysine; 
red: HRD catalytic motif; purple: DFG motif/N-terminal activation segment anchor; 
green: APE motif/C-terminal activation segment anchor. PINK1 kinase domain insertions 
are highlighted in dashed pink boxes and labelled.  
 
As previously discussed (Section 1.2.2), all active protein kinases possess several amino acid 
motifs required for catalysis and substrate binding, and are therefore a critical indicator of 
protein kinase function (Hanks & Hunter, 1995). To analyse the kinase domain of PINK1 
in more detail, a multiple sequence alignment of the human PINK1 kinase domain against 
the kinase domains of various other protein kinases was performed. Calcium/calmodulin-
dependent protein kinase 1 alpha subunit (CAMKIα, Uniprot ID: Q14012), 
Calcium/calmodulin-dependent protein kinase 2 gamma subunit (CAMKIIγ, Uniprot ID: 
Q13555), Never in mitosis A-related kinase 4 (NEK4, Uniprot ID: P51957) and Myotonin-
protein kinase (DMPK, Uniprot ID: Q09013) were identified as being the most similar to 
human PINK1 by BLAST search. In addition, cAMP-dependent protein kinase alpha 
subunit (PKAα, Uniprot ID: P17612) was included in the alignment since it is an extremely 
well studied kinase and much information relating its structure to its function is available. 
Alignment of the selected sequences was performed with MUSCLE (Edgar, 2004a; Edgar, 
2004b) and the resulting alignment was analysed and annotated using Jalview (Waterhouse 
et al, 2009).  
 
Inspection of this alignment reveals that all of the motifs that have been identified as 
critical for catalysis are conserved in PINK1 (Figure 1.7). Within the N-lobe these are the 
glycine-rich loop and the residues forming the conserved Arg-Glu salt bridge between β3 
and αC. Within the C-lobe, the HRD motif in the catalytic loop and the DFG and APE 
motifs that form the N- and C-terminal anchors of the activation segment respectively are 
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also conserved. Further analysis of this alignment confirms the three insertions in the N-
lobe of the PINK1 kinase domain are not observed in any of the other kinases analysed. 
The first of these insertions falls between the β2 and β3 strands, the second between the 
αC helix and the β4 strand, and the third and final one between the β4 and β5 strands. 
They are all similar in length, ranging from 23 to 28 amino acids long. Several other protein 
kinases contain insertions such as these, and they are often involved in regulation of kinase 
activity. HRI (heme-regulated α-subunit of eukaryotic initiation factor-2α (eIF-2α) kinase) 
contains an insertion in its N-lobe responsible for binding heme and downregulating its 
kinase activity (Rafie-Kolpin et al, 2000). A further interesting example of the function of 
insertions in protein kinases is seen in the CLKs (Cdc-like kinases). These function along 
with SRPK (SR (serine/arginine-rich) protein kinase) to phosphorylate the SR proteins that 
are involved in mRNA splicing. An insertion seen in the C-lobe of the CLKs blocks an 
interaction site in the αG helix that helps to determine substrate specificity in SRPK, 
thereby conferring a distinct and less rigid substrate specificity on the CLKs (Bullock et al, 
2009).  
 
1.4.2 Mitochondrial import and processing of PINK1 
PINK1 possesses a mitochondrial targeting sequence (MTS) and a transmembrane helix at 
its N-terminus and it was quickly confirmed after its discovery that PINK1 does indeed 
localise to the mitochondria (Valente et al, 2004). Mitochondria are double membrane-
bound organelles and possess both an inner and outer mitochondrial membrane, with the 
space in between the two being referred to as the intermembrane space (IMS) and the 
compartment contained inside the inner membrane as the matrix. Therefore, there are 
several possible orientations PINK1 could assume: bound to the inner membrane with the 
kinase domain facing the matrix; bound to the inner membrane and facing the IMS; bound 
to the outer membrane and facing the IMS; and finally bound to the outer membrane and 
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facing the cytoplasm. It is also possible that at different points in its lifespan, PINK1 could 
adopt one or more of these different orientations. Various reports have suggested PINK1 
localises to the inner membrane with the kinase domain facing the IMS (Muqit et al, 2006; 
Plun-Favreau et al, 2007; Pridgeon et al, 2007; Silvestri et al, 2005) although the most 
convincing data suggests that it is found on the outer membrane and faces the cytoplasm 
(Becker et al, 2012; Zhou et al, 2008).  
 
PINK1 is imported into the mitochondria via the TOM40/TIMM23 complexes in a 
manner dependent on the electrochemical potential across the inner mitochondrial 
membrane, or mitochondrial membrane potential (Greene et al, 2012). It appears that 
following import, PINK1 is initially cleaved by MPP (mitochondrial processing peptidase), 
which normally acts to remove the MTS from imported proteins (Greene et al, 2012), 
followed by further cleavage by the protease PARL (presenilin-associated rhomboid-like 
protein (Deas et al, 2011; Jin et al, 2010). The site of this cleavage has been mapped and 
occurs between Ala103 and Phe104, which are predicted to be near the middle of the 
transmembrane helix (Deas et al, 2011; Kondapalli et al, 2012). Once PINK1 has been 
cleaved, it is rapidly degraded by the N-end rule pathway (Yamano & Youle, 2013), 
whereby it becomes ubiquitylated and then degraded by the 26S proteasome (Lin & Kang, 
2008; Muqit et al, 2006). 
 
A critical discovery in the field was the finding that, in contrast to basal conditions, where 
PINK1 is constitutively imported, cleaved and degraded, under conditions where the 
mitochondrial membrane potential is lost, PINK1 is imported and then accumulates on the 
mitochondria (Lin & Kang, 2008). The compound CCCP (carbonyl cyanide m-
chlorophenyl hydrazone) acts as an ionophore and abolishes the proton gradient across the 
mitochondrial inner membrane. Treatment of cells with CCCP leads to mitochondrial 
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depolarisation and the subsequent stabilisation of PINK1 on the mitochondria (Matsuda et 
al, 2010; Narendra et al, 2010). This stabilisation is due to PINK1 cleavage by PARL being 
dependent on the presence of the mitochondrial membrane potential (Jin et al, 2010; 
Narendra et al, 2010). When mitochondria become depolarized, PARL cleavage is blocked 
and PINK1 subsequently accumulates on the mitochondrial outer membrane. 
 
1.4.3 PINK1 activity and function 
The link between PD and mitochondrial dysfunction was first established when it was 
discovered that the neurotoxin and mitochondrial Complex I inhibitor MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine), found in a contaminated batch of heroin, led to a 
Parkinsonian syndrome indistinguishable from idiopathic PD in the affected drug users 
(Langston et al, 1983). Studies on the post-mortem brains of PD patients have also shown 
a decrease in Complex I activity (Schapira et al, 1989). Mitochondria also play an important 
role in the regulation of Ca2+ homeostasis, with dysregulation of Ca2+ levels being 
implicated in several neurodegenerative disorders, including PD (Mattson, 2007). Since 
PINK1 is targetted to the mitochondria, it is not surprising that its biological role involves 
regulation of mitochondrial function.   
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Figure 1.8: Schematic of the mitochondrial electron transport chain 
I-IV: Complexes I-IV; Q: ubiquinone; Cyt c: cytochrome c. Blue lines show the flow of 
electrons, pink lines show the passage of protons. The relative charge (+/-) on either side 
of the inner membrane is also depicted. Adapted from Lehninger et al, 2008. 
 
It has been shown on a general level that PINK1 appears to be neuroprotective, with 
overexpression of PINK1 in neuronal cells leading to decreased susceptibility to apoptosis 
(Petit et al, 2005; Valente et al, 2004). Studies in PINK1 knockout mice and Drosophila have 
shown that loss of PINK1 impairs mitochondrial function, specifically mitochondrial 
respiration via a reduction in the activity of Complex I and subsequently reduced 
mitochondrial membrane potential (Gautier et al, 2008; Morais et al, 2009). Further work 
has shown that loss of PINK1 leads to loss of a phosphorylation site in the Complex I 
subunit NdufA10 that is required for the ubiquinone reductase activity of Complex I 
(Morais et al, 2014). This is corroborated by the discovery that in Drosophila, administration 
of Vitamin K2, which acts as an electron transporter and can substitute for ubiquinone, is 
able to rescue the phenotype of PINK1 null flies, presumably by bypassing the requirement 
for ubiquinone in the electron transport chain (Figure 1.8) (Vos et al, 2012). Studies in cell 
lines and neuronal cells have also shown that PINK1 regulates mitochondrial Ca2+/Na+ 
exchange and as a result, PINK1-deficient neurons have impaired Ca2+ handling ability, 
showing an elevated level of mitochondrial Ca2+ and are susceptible to mitochondrial Ca2+ 
overload after a rise in cytosolic Ca2+ (Gandhi et al, 2009). An increase in the level of 
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cellular reactive oxygen species (ROS) was observed in the same study. Similar data 
regarding the loss of mitochondrial membrane potential, increased ROS levels, defects in 
the electron transport chain and altered Ca2+ handling has been obtained from studies in 
fibroblasts of PD patients harbouring PINK1 mutations (Abramov et al, 2011). 
Interestingly, a study showing PINK1 is required for maintaining normal heart function 
also identified the same mitochondrial defects (Billia et al, 2011). 
 
Although it became apparent when the PINK1 gene was discovered that PINK1 was likely 
to possess protein kinase activity, it proved difficult to reliably detect and characterise this 
activity. Several studies describing the kinase activity of PINK1 emerged following its 
discovery, however they often reported conflicting data. Several studies claimed PD-linked 
point mutations decreased activity against a variety of substrates (Beilina et al, 2005; 
Pridgeon et al, 2007; Sim et al, 2006), however another study claimed they had no effect on 
activity (Silvestri et al, 2005). The same studies also claimed that C-terminal truncation of 
PINK1 either increased (Silvestri et al, 2005), decreased (Sim et al, 2006) or had no effect 
on kinase activity (Pridgeon et al, 2007). It was not possible to reproduce any of these 
findings in our own laboratory and furthermore, in our hands mammalian PINK1 did not 
exhibit detectable kinase activity. The lack of a suitable in vitro assay for PINK1 activity was 
a major obstacle in the field and severely hampered further understanding of the 
biochemical properties and function of PINK1.  
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1.5 PINK1 and Parkin 
1.5.1 Parkin 
The Parkin gene was first identified in 1998 after the mapping of partial deletions of the 
gene in patients with autosomal recessive early-onset PD (Kitada et al, 1998). Mutations in 
Parkin are the primary cause of autosomal recessive early onset PD where the age of onset 
is under 40, with Parkin mutations being responsible for around 50% of these cases 
(Lucking et al, 2000). The Parkin protein is 465 amino acids long with a molecular weight 
of 51 kDa and belongs to the ubiquitin E3 ligase family, which catalyse the final step in the 
ubiquitylation of substrate proteins. 
 
Ubiquitin is a small, 76 amino acid protein of 8.5 kDa and its attachment to target proteins 
is a reversible and highly complex form of post-translational modification. The 
ubiquitylation cycle is depicted below (Figure 1.9) and proceeds as follows: firstly, an E1 
ubiquitin-activating enzyme activates the ubiquitin molecule in an ATP-dependent step, 
followed by transfer to the catalytic cysteine of an E2 ubiquitin conjugating-enzyme. This 
step is referred to as “charging” of the E2 (Komander, 2009). Next, an E3 ligase mediates 
the transfer of ubiquitin from the E2 onto the substrate protein. The majority of E3 ligases 
belong one of two classes. The RING family, which act as adaptors, simply bring the E2 
and substrate into close proximity so ubiquitin transfer can occur. HECT E3 ligases on the 
other hand have a catalytic cysteine and accept ubiquitin from the E2, forming a thioester 
intermediate before conjugating it to the substrate (Metzger et al, 2012). Ubiquitylation of a 
protein is reversed by the action of deubiquitylating enzymes, or DUBs (Reyes-Turcu et al, 
2009). 
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Figure 1.9: The ubiquitylation cycle and mechanisms of ubiquitin E3 ligases 
(A) Ubiquitin is activated by an E1 enzyme in an ATP-dependent manner and is then 
passed on to an E2 enzyme. From here an E3 ligase mediates the transfer of the ubiquitin 
molecule to the substrate. Ubiquitin is removed from proteins by the action of DUBs 
(deubiquitylating enzymes). (B) (L) Mechanism of RING E3 ligases. These act as scaffolds, 
bringing the charged E2 and substrate into close proximity. Ubiquitin is then directly 
transferred from the E2 to the substrate. (R) Mechanism of HECT E3 ligases. These have 
a catalytic cysteine and accept ubiquitin from the E2 before transferring it on to the 
substrate.  
 
Ubiquitin is attached via its C-terminal glycine to lysine residues within the target protein. 
In addition to monoubiquitylation and multi-monoubiquitylation of substrates, 
polyubiquitin chains can be formed. Ubiquitin itself contains seven lysine residues and an 
N-terminal methionine to which additional ubiquitin molecules can be attached (Figure 
1.10). Depending on which lysine the ubiquitin is conjugated to, different chain topologies 
can be formed. Homotypic chains are the best studied and contain only one type of linkage 
(Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, Lys63-linked or linear (Met1) chains), whereas 
mixed, branched or forked ubiquitin chains are much less well understood (Komander, 
2009; Komander & Rape, 2012). It is apparent that with so many linkage combinations 
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available, a great number of different chain types could be generated and as such, 
ubiquitylation is an ideal system for specifying many diverse cellular signals. Ubiquitylation 
has been shown to play a role in many important cellular processes, but perhaps the most 
well-characterised example is the tagging of proteins for degradation by the proteasome 
using Lys48-linked ubiquitin chains (Finley, 2009). As with protein phosphorylation, 
defects in the ubiquitin system have been implicated in many human diseases (Popovic et 
al, 2014). 
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Figure 1.10: Different forms of ubiquitylation 
(A) Ubiquitin can be attached to proteins in several different ways. Monoubiquitylation is 
the attachment of a single ubiquitin that is not extended into a chain. Multi-mono 
ubiquitylation is the attachment of several ubiquitin molecules that are not extended. 
Homotypic polyubiquitylation is the attachment of a chain with a single linkage type. Mixed 
chains and branched chains contain more than one linkage type. (B) Structure of ubiquitin 
showing lysine residues and N-terminal methionine that can act as linkage points for the 
formation of different polyubiquitin chains. PDB ID: 1UBQ.  
 
Parkin is a multidomain protein containing an N-terminal Ubl (ubiquitin-like) domain, a 
RING0 domain followed by two RING (really interesting new gene) domains (RING1 and 
RING2) separated by an IBR domain (Figure 1.11). It is a member of the RBR (RING-In 
Between-RING) family of E3 ligases that act as RING-HECT hybrids (Wenzel et al, 2011). 
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This means that although Parkin contains RING domains, its mode of action is similar to 
that of a HECT E3 ligase. A key discovery in the understanding of Parkin’s biological 
function was the finding that Parkin exists in an autoinhibited conformation, similar to 
other RBR family members. This autoinhibition can be disrupted by the addition of an N-
terminal affinity tag. On the basis of this, it was proposed that the N-terminal Ubl domain 
was responsible for Parkin autoinhibition (Burchell et al, 2012; Chaugule et al, 2011).  
Further weight was added to this hypothesis when various crystal structures of Parkin, 
including a low-resolution structure of the full-length protein, were determined (Riley et al, 
2013; Spratt et al, 2013; Trempe et al, 2013; Wauer & Komander, 2013). In addition to an 
expected interaction with the Ubl domain, several other autoinhibitory interactions were 
revealed. The catalytic cysteine (Cys431), found in RING2, was occluded by an interaction 
with the RING0 domain and an interaction between the RING1 domain, the Ubl domain 
and a novel structural element designated the REP (regulatory element of Parkin) helix 
blocked what is predicted to be the E2 binding site. 
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Figure 1.11: Domain architecture and crystal structure of autoinhibited Parkin 
(A) Domain architecture of Parkin. Ubl: Ubiquitin-like domain; RING0: RING0 domain; 
RING1: Really Interesting New Gene domain 1; IBR: In-Between RING domain; REP: 
Regulatory Element of Parkin helix; RING2: Really Interesting New Gene domain 2. (B) 
Crystal structure of full-length Parkin. Colouring is the same as in (A). PDB ID: 4K95.  
 
1.5.2 The link between PINK1 and Parkin 
Several lines of evidence have suggested that PINK1 and Parkin may have a functional 
link. Patients with mutations in either PINK1 or Parkin tend to display a similar phenotype 
(Puschmann, 2013). Further substantiation for this idea came from genetic studies in 
Drosophila. The Drosophila PINK1 null mutant shows male sterility, a shortened lifespan and 
reduced ATP levels, poor climbing and flying ability, various muscle phenotypes including 
an altered wing posture, a crushed or indented thorax and degeneration of the indirect 
flight muscles and finally swollen and impaired mitochondria (Clark et al, 2006; Park et al, 
2006). These phenotypes are very similar to that of the Parkin null fly (Greene et al, 2003). 
It was demonstrated that PINK1 acts upstream of Parkin genetically since Parkin 
overexpression is able to rescue the PINK1 null phenotype, but not vice versa. In addition, 
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double knockout of the PINK1 and Parkin genes has a non-additive effect, due to epistatic 
interaction. This suggests the two genes act in the same genetic pathway, as opposed to 
acting in parallel pathways (Clark et al, 2006; Park et al, 2006). 
 
It was later shown that in addition to mitochondrial depolarisation leading to accumulation 
of PINK1, it also led to the recruitment of the normally cytosolic Parkin to the 
mitochondria. This recruitment of Parkin is dependent on the presence of PINK1 in the 
cell and overexpression of a non-cleavable form of PINK1 leads to recruitment of Parkin 
to the mitochondria in the absence of membrane depolarisation, suggesting PINK1 is both 
necessary and sufficient to recruit Parkin (Narendra et al, 2010).  In addition, the kinase 
activity of PINK1 is required for this recruitment, with both PD-linked and artificial 
mutations in PINK1 blocking the translocation of Parkin to the mitochondria, but not 
affecting accumulation of PINK1 on the mitochondria (Matsuda et al, 2010). 
 
The mechanism by which PINK1 recruits Parkin from the cytosol to the mitochondria is 
not yet clear, although it has been suggested that PINK1 autophosphorylation might play a 
role. PINK1 has been shown to autophosphorylate at Thr257 (Kondapalli et al, 2012) and 
further sites have been identified at Ser228 and Ser402 (Okatsu et al, 2012), although these 
sites were not identified conclusively. Alanine mutations of these two sites prevented 
recruitment of Parkin to the mitochondria after membrane depolarisation, however this 
finding has yet to be reproduced by independent laboratories.  
 
1.5.3 Regulation of Parkin by PINK1 
It has now been shown that PINK1 directly phosphorylates Parkin, confirming that 
PINK1 plays a key role in Parkin regulation. The PINK1 phosphorylation site in Parkin 
was mapped to residue Ser65, which is found in the N-terminal Ubl domain (Kondapalli et 
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al, 2012). As mentioned previously, this domain was believed to be responsible for Parkin 
autoinhibition and so an obvious hypothesis was that PINK1 phosphorylation would 
relieve this inhibition. This suggestion turned out to be correct; phosphorylation of PINK1 
leads to a marked increase the activity of the normally inactive Parkin (Kazlauskaite et al, 
2014a; Kondapalli et al, 2012). The mechanism by which Ser65 phosphorylation activates 
Parkin was not clear however, since examination of the full-length low-resolution structure 
of Parkin shows that Ser65 most likely not located at the interface between the RING1 
domain and the Ubl domain (Trempe et al, 2013). Parkin phosphorylation is also detectable 
in cells and occurs only 5 minutes after mitochondrial depolarisation takes place. This is in 
contrast to PINK1 autophosphorylation on Thr257, which only occurs around 40 minutes 
after the membrane potential is lost (Kondapalli et al, 2012). However, it appears that 
mutation of this phosphorylation site to alanine only partially prevents the translocation of 
Parkin to the mitochondria (Okatsu et al, 2012), suggesting that other factors may be 
regulating this process.  
 
It was later discovered that in addition to phosphorylating the Ubl domain of Parkin, 
PINK1 is also able to phosphorylate ubiquitin, also at Ser65, which is conserved between 
the Ubl domain and ubiquitin (Kane et al, 2014; Kazlauskaite et al, 2014b; Koyano et al, 
2014). This phosphorylation also occurs in cells in a manner dependent on depolarisation 
of the mitochondrial membrane potential (Kazlauskaite et al, 2014b). It appears that both 
Ubl domain and ubiquitin phosphorylation are required for Parkin activity, since each of 
them can activate Parkin to some degree but not to the same extent as both of them in 
combination. Likewise, only mutation of both proteins to alanine at Ser65 is able to 
completely abolish Parkin activation by PINK1 (Kazlauskaite et al, 2014b). However, the 
molecular mechanisms by which Parkin and ubiquitin phosphorylation activate the E3 
ligase activity of Parkin still remain unclear.  
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1.5.4 Function of the PINK1/Parkin pathway 
An accumulating body of evidence suggests that the PINK1/Parkin pathway plays a central 
role in mitochondrial quality control, specifically in the regulation of a process known as 
mitophagy. This is the selective destruction of damaged mitochondria by the process of 
autophagy. Before anything was known about PINK1 directly regulating Parkin, it was 
discovered that Parkin is selectively recruited to impaired mitochondria that have lost their 
membrane potential. Subsequently, these damaged mitochondria would be cleared from 
the cell by mitophagy (Narendra et al, 2008). Once it became clear that the trigger for 
Parkin recruitment was the accumulation of PINK1 on these damaged mitochondria, it 
was suggested that PINK1 acts as a sensor for mitochondrial impairment. The constitutive 
degradation of PINK1 ensures this signal is only present when the mitochondrial 
membrane potential is compromised; only under these circumstances can it accumulate and 
mark the mitochondria for Parkin-mediated destruction (Matsuda et al, 2010; Narendra et 
al, 2010; Ziviani et al, 2010).  
 
Once Parkin has been recruited to impaired mitochondria, a ubiquitylation signal can be 
observed (Matsuda et al, 2010). Different studies have shown conflicting results regarding 
the types of chains generated by mitochondrially-localised Parkin. One study reported 
Lys63 and Lys27-linked polyubiquitin chains (Geisler et al, 2010), whereas another reported 
Lys48, Lys63, Lys6 and Lys11-linked chains (Ordureau et al, 2014). In Drosophila, Parkin 
has been shown to ubiquitylate the protein Mitofusin, which promotes mitochondrial 
fusion (Poole et al, 2010; Ziviani et al, 2010). This Parkin substrate has also been detected 
in human cell lines, along with the ubiquitylation of Miro1, a mitochondrial GTPase 
implicated in mitochondrial trafficking (Sarraf et al, 2013). Miro1 is also a well-
characterised in vitro Parkin substrate (Kazlauskaite et al, 2014a). Many other candidate 
substrates have been proposed for Parkin, however the majority of these have not been 
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well characterised (Walden & Martinez-Torres, 2012). Furthermore, the mechanism by 
which the autophagy machinery is recruited to damaged mitochondria by the 
PINK1/Parkin pathway and the mechanism of mitochondrial clearance still remain 
unresolved. 
 
In addition to the role played in the removal of damaged mitochondria, it has also been 
suggested that the PINK1/Parkin pathway plays a role in the process of mitochondrial 
remodelling. Mitochondria are dynamic organelles that are transported within the cell and 
undergo fusion and fission events to increase or decrease the size of the mitochondria and 
to alter the structure of the mitochondrial network. Imbalances in mitochondrial dynamics 
have been linked to neurodegenerative diseases and the process appears to be essential for 
the health of the individual mitochondria themselves (Chan, 2006). Studies in Drosophila 
have shown that three proteins involved in mitochondrial remodelling, Drp1, OPA1 and 
Mfn2, interact genetically with PINK1 and Parkin. Specifically, an increase in Drp1 levels 
(GTPase, fission promoting) or a decrease in the levels of either OPA1 (dynamin-related 
GTPase, controls inner membrane fusion) or Mfn2 (transmembrane GTPase, controls 
outer membrane fusion) led to rescue of the PINK1 and Parkin null fly phenotypes (Park 
et al, 2009; Poole et al, 2008). However, in human cell lines the situation is reversed, with a 
decrease in Drp1 or an increase in OPA1 or Mfn2 rescuing PINK1 and Parkin loss of 
function. In the same study, knockdown of Parkin was also shown to lead to an increase in 
mitochondrial fission (Lutz et al, 2009). The precise roles played by PINK1 and Parkin in 
regulating mitochondrial morphology therefore remains unclear, and more work is 
necessary to dissect this pathway.  
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1.6 Project aims 
Although PINK1 was first discovered almost 15 years ago (Unoki & Nakamura, 2001) and 
was linked to Parkinson’s disease 10 years ago (Valente et al, 2004), at the start of this 
project (October 2010), little was known about the kinase PINK1 aside from the fact that 
its mutation leads to the development of early-onset PD. No well-validated substrates of 
PINK1 had been identified and there was a lack of a robust kinase assay for assessing its in 
vitro activity. The effects of PD-linked mutations on kinase activity and at a structural level 
were therefore unknown. In addition, it was known that PINK1 has several unusual 
features that make it distinct from other protein kinases, including three insertions in the 
N-lobe of the kinase domain and a small C-terminal domain, but the function of these 
features was not understood. Several years later it was discovered that PINK1 
phosphorylates another PD-linked protein, the ubiquitin E3 ligase Parkin. This 
phosphorylation, in combination with the phosphorylation of ubiquitin by PINK1, leads to 
an activation of Parkin E3 ligase activity. The mechanism by which this activation occurs, 
however, is still to be determined.  
 
The primary aim of this thesis was to utilise a more tractable PINK1 homologue from the 
insect species Tribolium castaneum (TcPINK1) and employ a joint structural and biochemical 
approach in order to gain insight into some of the following questions regarding PINK1 
that were unsolved at the time: 
 
• What is the substrate specificity of PINK1 and what factors dictate this? 
• What is the function and requirement for the C-terminal domain and kinase 
domain insertions? 
• What are the biochemical and structural effects of Parkinson’s disease-linked 
PINK1 mutations? 
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• What are the molecular mechanisms by which the dual PINK1 phosphorylation of 
the Parkin Ubl domain and ubiquitin lead to activation of Parkin? 
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2 Materials and methods 
2.1 Reagents 
2.1.1 Bacterial strains 
The following bacterial strains were used in this thesis: BL21 (DE3) RIL CodonPlus from 
Stratagene (La Jolla, CA) for recombinant protein expression and EcAR7, kindly provided 
by Dr. Natasha Pirman and Dr. Jesse Rinehart (Yale University) for production of 
phosphorylated proteins. 
2.1.2 Cloning and DNA constructs 
All mutagenesis was carried out using the QuikChange site-directed-mutagenesis method 
(Stratagene, Santa Clara, CA) with KOD polymerase (Novagen, Merck, Whitehouse 
Station, NJ). All DNA constructs were verified by DNA sequencing, which was performed 
by The Sequencing Service (School of Life Sciences, University of Dundee) using 
DYEnamic ET terminator chemistry (Amersham Biosciences, GE Healthcare, Little 
Chalfont, UK) on Applied Biosystems automated DNA sequencers (Foster City, CA). 
cDNA for Tribolium castaneum PINK1 and Pediculus humanus corporis PINK1 were 
synthesized by GenScript USA (Piscataway, NJ). 
 
Bacterial expression vectors used in this thesis were: pMal4c with a PreScission cleavage 
site after the MBP affinity tag; pGEX-6P-1, with a PreScission protease site following the 
GST tag; and pET6His-SUMO with a SENP1 cleavage site following the 6-His-SUMO 
affinity tag. Table 2.1 lists all DNA constructs used in this thesis. All constructs were 
generated by Dr. Mark Peggie and Dr. Maria Deak, with the exception of GST-Parkin 1-
76, generated by Dr. Thomas Macartney, and His-SUMO-Parkin 1-465, generated by Dr. 
Rachel Toth.  
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Table 2.1: DNA constructs used in this thesis.  
 
2.1.3 Protein expression and purification 
Isopropyl-β-D-1-thiogalactoside (IPTG, dioxane free), ampicillin sodium (Amp), 
kanamycin monosulphate (Kan), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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(HEPES) and dithiothreitol (DTT) were from ForMedium (Norfolk, UK). Tris base, 
glycerol, D-(+)-sucrose and sodium chloride were from VWR (Radnor, PA). D-(+)-
maltose monohydrate, β-mercaptoethanol, ethylene diamine tetraacetic acid (EDTA), 
ethylene glycol tetraacetic acid (EGTA), O-phospho-L-serine (SEP), D-(+)-glucose, 
imidazole, Triton™ X-100, phenylmethanesulphonyl fluoride (PMSF), benzamidine, and 
lysozyme from chicken egg white were from Sigma-Aldrich (Poole, UK). Brij® 35 was 
from Merck Millipore (Billerica, MA). Amylose resin was from New England Biolabs 
(Ipwitch, MA). Nickel resin and GST resin were provided by the DSTT (University of 
Dundee). cOmplete protease inhibitor cocktail tablets were from Roche (Lewes, UK). 
VivaSpin centrifuge concentrators of all sizes were from Sartorius Stedim (Gottingen, 
Germany), Slide-A-Lyzer dialysis cassettes and SnakeSkin dialysis tubing of all sizes and 
Tris (2-carboxyethyl)phosphine hydrochloride (TCEP) were from Thermo Scientific 
(Essex, UK). EconoPac disposable columns were from BioRad (Herts, UK). GST- and 
MBP-PreScission protease and His-SENP1 were produced by the DSTT (University of 
Dundee). 
2.1.4 Protein analysis 
40% (w/v) 29:1 Acrylamide: Bis-Acrylamide solution was from Flowgen Bioscience 
(Nottingham, UK). Ammonium persulphate (APS), N,N,N′,N′-Tetramethylethane-1,2-
diamine (TEMED), sodium dodecyl sulphate (SDS), bovine serum albumin (BSA) and 
Immobilon PVDF membrane (pore size 0.45µm) were from Sigma-Aldrich (Poole, UK). 
Precision Plus Protein unstained standards were from BioRad (Herts, UK). Coomassie 
(Bradford) protein assay kits were from Thermo Scientific (Essex, UK). InstantBlue 
Coomassie stain was from Expedeon (San Diego, CA). 3MM paper was from Whatman 
(Maidstone, UK). Photographic developer (LX24) and liquid fixer (FX40) were from 
Kodak (Liverpool, UK). X-ray films were from Konica Corporation (Japan). Enhanced 
chemiluminescence (ECL) kit was from GE Healthcare (Piscataway, NJ).  
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2.1.5 Antibodies 
Sheep polyclonal antibodies (Table 2.2) were produced in-house by the Division of Signal 
Transduction Therapy (DSTT, University of Dundee). Antisera were raised in sheep by 
Diagnostics Scotland (Lanarkshire, UK). All in-house antibodies were affinity purified on 
CH-Sepharose covalently coupled to the corresponding antigen. The commercial anti-
phosphotyrosine 4G10 antibody was from Merck Millipore (Billerica, MA). 
 
 
Table 2.2: Antibodies used in this thesis 
 
2.1.6 Lysine methylation 
Borane dimethylamine complex (ABC) and 37% formaldehyde solution were from Sigma-
Aldrich (Poole, UK). 
2.1.7 Protein crystallisation 
The Crystal Screen 1 and 2, Natrix, MembFac, Index 1 and 2, PEG/Ion, Salt Rx and 
Additive screens were from Hampton Research (Aliso Viejo, CA). The ProPlex 1 and 2, 
JCSG, PACT Premier, Morpheus, MemStart, MemSys and MemPlus screens were from 
Molecular Dimensions (Suffolk, UK). The Protein Complex screen, adenosine 5’-
triphosphate disodium salt hydrate (ATP), adenosine 5’-diphosphate (ADP), adenosine 5′-
(β, γ-imido) triphosphate lithium salt hydrate (AMP-PNP), magnesium chloride and 2-
methyl-2,4-pentanediol/hexylene glycol (MPD) were from Sigma-Aldrich (Poole, UK).  
Chapter 2 – Materials and methods 
	  
	  
 57 
2.1.8 Kinase assays 
[γ-32P] ATP was from PerkinElmer (Waltham, MA) P81 paper was from Whatman 
(Maidstone, UK), bovine myelin basic protein and casein were from Sigma (St. Louis, MO). 
Bovine histone H1 was from Abcam (Cambridge, UK). PINKtide and its derivatives were 
synthesized by GL Biochem (Shanghai, China). Other substrate peptides were provided by 
the DSTT (University of Dundee).  
 
2.2 Equipment 
Bacterial incubators were from Infors (Reigate, UK). All centrifuges, rotors and centrifuge 
tubes were from Beckmann Coulter (Brea, CA). The digital sonicator was from Branson 
(Danbury, CT). AKTA protein purification systems, Superdex 200 26/60, Mono Q 5/50 
GL and 5 ml Hi-Trap columns were from GE Healthcare (Piscataway, NJ). The pH meters 
and electrodes were from Horiba (Kyoto, Japan). Power packs for electrophoresis, Trans-
Blot cells, Model 583 vacuum gel drier and GelAir Dryer were from BioRad (Herts, UK). 
Mini gel tank electrophoresis systems were from Atto (Tokyo, Japan). The LiCOR Odyssey 
infrared imaging system was from LiCOR biosciences (Cambridge, UK). X-omat 
autoradiography cassettes with intensifying screens were from Kodak (Liverpool, UK). The 
Konica automatic film processor was from Konica Corporation (Tokyo, Japan). The 
scintillation counter (Tri-Carb 2800 TR) was from Perkin- Elmer (Waltham, MA). The 96-
well Versamax plate reader was from Molecular Devices (Wokingham, UK). The 
NanoDrop was from Thermo Scientific (Essex, UK). The BioPhotometer 
spectrophotometer and Thermomixer IP shakers were from Eppendorf (Hamburg, 
Germany). The Mosquito crystallography robot and consumables were from TTP Lab 
Tech (Herts, UK). MRC 96 well crystallisation plates were from Molecular Dimensions 
(Suffolk, UK). The in-house X-ray generator was from Rigaku (Tokyo, Japan). The LC-MS 
machine was from the Agilent 1200 Infinity series (Santa Clara, CA).  
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2.3 General buffers & solutions 
2.3.1 Bacterial growth media 
Luria Bertani (LB) media and plates and Terrific broth (TB) and SOC media were kindly 
supplied by the Media Kitchen (University of Dundee).  
 
LB media:  10.0 g bacto-tryptone, 5.0 g bacto-yeast extract, 10.0 g NaCl, 950 ml ddH2O 
and was adjusted to pH 7.0 with NaOH. The media was adjusted to 1 L using ddH2O after 
autoclaving for 20 minutes at 2 bar.  
TB media:  12.0 g bacto-tryptone, 24.0 g bacto-yeast extract, 4.0 ml glycerol and 900 ml 
ddH20. One hundred ml of a sterile 0.17M KH2PO4 and 0.72M K2HPO4 solution was 
added after autoclaving for 20 minutes at 2 bar.  
SOC media:  contained 2.0 g bacto-tryptone, 0.5 g bacto-yeast extract, 0.2 ml of 5 M NaCl, 
0.25 ml of 1 M KCl, 1.0 ml of 1 M MgCl2, 1.0 ml of 1 M MgSO4, 2.0 ml of 1 M glucose, 90 
ml ddH20. The media was adjusted to 100 ml using ddH2O after autoclaving for 20 minutes 
at 2 bar.  
 
The following extra components were added as necessary: the antibiotics ampicillin (Amp) 
to a final concentration of 50 µg/ml from a 100 mg/ml stock and kanamycin (Kan) to 
25µg/ml from a 50 mg/ml stock, glucose (Glu) to 0.08% (w/v) from a 20% (w/v) stock, 
and O-phospho-L-serine (SEP) to 2 mM from an 125 mM, pH 6.8 stock.   
2.3.2 Buffers for preparation of competent EcAR7 cells 
Prepared buffers were sterile filtered and stored and used at 4°C. 
TFB1 buf fer :  100 mM RbCl, 50 mM MnCl2, 30 mM potassium acetate, 10 mM CaCl2, 
15% (v/v) glycerol, adjusted to pH 5.8 with dilute acetic acid 
Chapter 2 – Materials and methods 
	  
	  
 59 
TFB2 buf fer :  10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15% (v/v) glycerol, adjusted to 
pH 6.8 
2.3.3 SDS-PAGE stock solutions 
The following stock solutions were used for preparation of SDS-polyacrylamide gels: 1.5 M 
Tris-HCl (pH 8.6), 2 M Tris-HCl (pH 6.8), 10% (w/v) SDS, a 40% acrylamide solution 
containing bis-acrylamide at 29:1, TEMED solution and a 10% (w/v) APS solution stored 
at -20°C. 
Tris-Glyc ine running buf fer :  25 mM Tris-HCl (pH 8.3), 192 mM glycine, 0.1% (w/v) 
SDS.  
5X sample buf f er :  250 mM Tris-HCl (pH 6.8), 5% SDS, 5% (v/v) β-mercaptoethanol, 
32.5% (v/v) glycerol, 0.05% bromophenol blue. 
2.3.4 Buffers for Western blotting 
Tris-Glyc ine transfer  buf f er :  48 mM Tris-HCl (pH 8.3), 39 mM glycine, 20% (v/v) 
methanol.  
TBST buf fer :  50 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.1% (v/v) Tween-20. 
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2.4 Gel pouring 
SDS-PAGE was used to separate proteins for analysis according to their molecular weight. 
Gels were prepared with varying concentrations of acrylamide as necessary. Recipes for 
one gel at various concentrations are provided below (Table 2.3).  
 
 
Table 2.3: Recipes for a single SDS-PAGE gel at various acrylamide percentages 
 
The components of the separating gel were first mixed thoroughly, poured into assembled 
glass plates and covered with a thin layer of isopropanol. The gels were left to polymerise 
at RT for 15 min. The isopropanol layer was then removed and the top surface of the gel 
washed with water. The stacking gel components were mixed and poured on top of the 
separating gel, followed by insertion of a 12-well comb. The stacking gel was left to 
polymerise for 20 min at RT, and completed gels were used immediately or stored at 4°C.  
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2.5 Buffers for protein purification 
2.5.1 Buffers for purification of MBP-TcPINK1 (kinase assays) 
Lysis  buf fer :  50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
5%(v/v) glycerol, 1%(v/v) Triton X-100, 0.1% (v/ v) β-mercaptoethanol, 1 mM 
benzamidine, 0.1 mM PMSF. 
High sal t  wash buf f er :  50 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.1 mM EGTA, 5% 
(v/v) glycerol, 0.03% (v/v) Brij-35, 0.1% (v/v) β-mercaptoethanol, 1 mM benzamidine, 0.1 
mM PMSF.  
Equil ibrat ion buf fer :  50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 mM EGTA, 5% (v/v) 
glycerol, 0.03% (v/v) Brij-35, 0.1% (v/v) β-mercaptoethanol, 1 mM benzamidine, 0.1 mM 
PMSF.  
Elution buf fer :  50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 mM EGTA, 5% (v/v) 
glycerol, 0.03% (v/v) Brij-35, 0.1% (v/v) β-mercaptoethanol, 1 mM benzamidine, 0.1 mM 
PMSF, 12 mM maltose.  
Storage buf f er :  50 mM Tris pH 7.5, 150 mM NaCl, 0.27 M sucrose, 0.03% (v/v) Brij-35, 
0.1% (v/v) β-mercaptoethanol 
2.5.2 Buffers for purification of His-SUMO TcPINK1 (crystallization) 
Lysis  buf fer :  50 mM Tris-HCl pH 9.0, 350 mM NaCl, 20 mM imidazole, 5% (v/v) 
glycerol, 0.1% (v/v) β-mercaptoethanol, 0.1 mM PMSF, 1 mM benzamidine. 
High sal t  wash buf f er :  50 mM Tris-HCl pH 9.0, 500 mM NaCl, 20 mM imidazole, 5% 
(v/v) glycerol, 0.1% (v/v) β-mercaptoethanol 
Elution buf fer :  50 mM Tris-HCl pH 9.0, 350 mM NaCl, 200 mM imidazole, 5% (v/v) 
glycerol, 0.1% (v/v) β-mercaptoethanol 
Ion exchange buf f er  A:  50 mM Tris-HCl pH 9.0, 5% (v/v) glycerol, 0.1% (v/v) β-
mercaptoethanol, filtered using a 0.2 µm filter, then degassed. 
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Ion exchange buf f er  B:  50 mM Tris-HCl pH 9.0, 1 M NaCl, 5% (v/v) glycerol, 0.1% (v/v) 
β-mercaptoethanol filtered using a 0.2 µm filter, then degassed. 
Tag c l eavage buf f er :  50 mM Tris-HCl pH 9.0, 350 mM NaCl, 5% (v/v) glycerol, 0.1% 
(v/v) β-mercaptoethanol 
Gel f i l t rat ion buf f er :  50 mM Tris-HCl pH 9.0, 350 mM NaCl, 5% (v/v) glycerol, 10 mM 
DTT, filtered using a 0.2 µm filter, then degassed. 
2.5.3 Buffers for purification of the His-SUMO-Ubl domain  
Lysis  buf fer :  50 mM Tris pH 7.5, 500 mM NaCl, 25 mM imidazole, 5% (v/v) glycerol, 
0.1% (v/v) β-mercaptoethanol, 0.1 mM PMSF, 1 mM benzamidine 
Wash buf fer :  50 mM Tris pH 7.5, 500 mM NaCl, 25 mM imidazole, 5% (v/v) glycerol, 
0.1% (v/v) β-mercaptoethanol 
Elution buf fer :  50 mM Tris pH 7.5, 200 mM NaCl, 5% (v/v) glycerol, 200 mM imidazole, 
0.1% (v/v) β-mercaptoethanol 
Dialys is  buf f er :  50 mM Tris pH 7.5, 200 mM NaCl, 5% (v/v) glycerol, 0.1% (v/v) β-
mercaptoethanol 
Ion exchange buf f er  A (cat ion and anion exchange) :   50 mM HEPES pH 7.0, 5% (v/v) 
glycerol, 0.1% (v/v) β-mercaptoethanol, filtered using a 0.2 µm filter, then degassed 
Ion exchange buf f er  B (cat ion and anion exchange) :  50 mM HEPES pH 7.0, 1M NaCl, 
5% (v/v) glycerol, 0.1% (v/v) β-mercaptoethanol, filtered using a 0.2 µm filter, then 
degassed 
2.5.4 Buffers for purification of the GST-pS65-Ubl domain  
Lysis  buf fer :  50 mM Tris pH 7.5, 500 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 10% 
(v/v) glycerol, 5 mM DTT, 1 mg/ml lysozyme, 50 mM NaF, 1 mM NaVO4, 1x 50 ml 
Roche Protease inhibitor tablet  
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Wash Buf fer :  50 mM Tris pH 7.5, 500 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 10% 
(v/v) glycerol, 5 mM DTT, 50 mM NaF, 1 mM NaVO4 
 
2.6 Molecular biology methods 
2.6.1 Preparation of competent EcAR7 cells 
Competent EcAR7 cells were provided by Charles Williams and Dr. Natasha Pirman (Yale 
University). A 30 ml culture of LB + glucose was inoculated with EcAR7 cells and grown 
overnight at 30°C, 230 rpm. The next day, the culture was diluted to 500 ml with LB + 
glucose and grown at 30°C, 230 rpm until OD600 = 0.6. The cells were then spun down at 
4000 rpm, 10 min, 4 °C and the pellet re-suspended in 150 ml TFB1 buffer and incubated 
on ice for 15 min. The cells were then spun down again as before, the pellet re-suspended 
in 15 ml TFB2 buffer and then incubated on ice for 30 min. The cells were then aliquoted 
and stored at -80°C.  
2.6.2 Bacterial transformation 
Competent BL21 CodonPlus E. coli cells were provided by the Division of Signal 
Transduction Therapy (University of Dundee). For each transformation, 100 µl of bacteria 
were incubated with approximately 10 ng of plasmid DNA and incubated on ice for 10 
min. Cells were then heat shocked at 42°C for 1 min, incubated on ice for a further 15 min, 
then plated onto LB agar plates containing the appropriate antibiotic for selection. The 
plates were then incubated overnight at 37°C. 
 
Competent EcAR7 E.coli cells were provided by either Dr. Natasha Pirman (Yale 
University) or Charles Williams (University of Dundee). For each transformation, 200-300 
ng of both the required plasmid and the OTS plasmid were added to 100 µl of cells. The 
cells were incubated on ice for 30 min, heat shocked for 40 sec at 42 °C, then incubated on 
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ice for 2 min. 700 µl of SOC media was added and the cells incubated at 30 °C, 230 rpm 
for at least 2 h. 10 µl and 100 µl of recovered cells were plated onto LB + Glc, 2x Amp, 
Kan plates. The remaining cell mixture was spun down at 4000 g, 2 min, and all but 100 µl 
of the supernatant was removed. This remaining 100 µl was also plated onto the same 
plates. All three plates were then incubated for 2 days at 30°. 
2.6.3 Preparation of glycerol stocks 
For BL21 CodonPlus cells, single colonies transformed with the required plasmid were 
picked from an agar plate and used to inoculate 5 ml of LB + Amp. The culture was grown 
overnight at 37°C with shaking, and the next day 500 µl of culture was added to 500 µl of 
autoclaved sterile glycerol and thoroughly mixed. The resulting glycerol stocks were then 
stored at -80°C. 
 
2.7 Expression and purification of recombinant proteins 
2.7.1 Expression of TcPINK1 in BL21 CodonPlus E. coli strain 
All forms of MBP and His-SUMO tagged TcPINK1, including all mutants and truncations, 
were expressed as N-terminal fusions in E. coli BL21 CodonPlus cells. For each litre of 
expression culture, a 10 ml starter culture of TB + Amp was inoculated with a single 
transformed colony or cells from a glycerol stock and grown overnight at 37°C with 
shaking. The next day, TB + Amp expression media was inoculated 1:100 (v/v) with starter 
culture, then grown at 37 °C, 180 rpm. When OD600 = 0.3 was reached the cells were 
cooled to 16 °C, 180 rpm, then induced with 250 µM IPTG at OD600 = 0.5 and grown for 
a further 16-18 h.  
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2.7.2 Expression of His-SUMO-Ubl in BL21 CodonPlus E. co l i  strain 
For each litre of expression culture, a 10 ml starter culture of LB + Amp was inoculated 
with a single transformed colony or cells from a glycerol stock and grown overnight at 
37°C with shaking. The next day, LB + Amp expression media was inoculated 1:100 (v/v) 
with the starter culture, then grown at 37 °C, 180 rpm. When OD600 = 0.3 was reached they 
were cooled to 15 °C, 180 rpm, then induced with 25 µM IPTG at OD600 = 0.5 and grown 
for a further 16-18 h.  
2.7.3 Expression of GST Sep65-Ubl in EcAR7 E. co l i  strain 
In the morning, for each 500 ml of final expression culture, 10 ml of LB + Glc, 2x Amp, 
Kan starter pre-culture was inoculated with 5 colonies from an agar plate and grown at 
30°C, 230 rpm. In the evening, this starter pre-culture was diluted into 100 ml of LB + 
Glc, 2x Amp, Kan to form a larger starter culture, which was then grown overnight at 
30°C, 230 rpm. The next day, the OD600 of the starter culture was measured and it was 
used to inoculate 500 ml of LB + Glc, 2x Amp, Kan, SEP to an OD600 of 0.15. The cells 
were then grown at 30°, 200 rpm until OD600 reached 0.8, at which point they were 
induced with 1 mM IPTG, and the temperature reduced to 20°C. The cells were then 
grown overnight.  
2.7.4 Purification of MBP TcPINK1 
Cells were harvested by centrifugation at 3290 g, 15 min, 4 °C and the pellet re-suspended 
in Lysis buffer to a volume of 40 ml per cell pellet. The cell suspension was lysed by 
sonication (14x 10 s pulses alternating with 10 s cooling time, with amplitude of 45%) and 
the resulting lysate centrifuged at 30,000 g, 30 min, 4 °C.  The clarified lysate was incubated 
for 1.5 h at 4 °C in a 50 ml Falcon tube on a rotating platform, with amylose resin (2 ml 
50:50 slurry per litre of culture) pre-washed with Lysis buffer. The resin in each tube was 
then washed with 5x 50 ml Wash buffer and 1x 40 ml Equilibration buffer. All resin was 
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then pooled by washing into an Econo-Pac disposable column using more Equilibration 
buffer. Elution buffer was then added and protein was collected in 1 ml fractions. Protein 
purity and quantity were assessed by SDS-PAGE analysis and Bradford assay respectively. 
Proteins were dialysed into Storage buffer and frozen at -80 °C for later use.  
2.7.5 Purification of His-SUMO TcPINK1 
Cells were harvested by centrifugation at 3290 g, 15 min, 4 °C and the pellet re-suspended 
in Lysis buffer to a volume of 40 ml per cell pellet. The cell suspension was lysed by 
sonication (14x 10 s pulses alternating with 10 s cooling time, with amplitude of 45%) and 
the lysate centrifuged at 30,000 g, 30 min, 4 °C. The clarified lysate was then incubated for 
1.5 h at 4 °C in a 50 ml Falcon tube on a rotating platform with Ni-NTA resin (1 ml 50:50 
slurry per litre of culture) pre-washed with Lysis buffer. The resin was centrifuged and the 
supernatant poured off, and then all resin was pooled in an Econo-Pac disposable column 
and washed with Wash buffer until flow-through A280 <0.05. Elution buffer was then 
added and protein was collected in 5 ml fractions. Purity and quantity of eluted protein was 
analysed by SDS-PAGE and Bradford assay respectively.  
 
Protein-containing fractions were pooled and diluted 3.5-fold in Ion exchange buffer A to 
lower the salt concentration. Diluted protein was loaded manually with a syringe onto a 
pre-washed 5 ml Hi-Trap Q FF anion exchange column at a rate of 5 ml/min. The column 
was then attached to an AKTA Purifier and washed in Buffer A for 10 column volumes 
(CV) to remove unbound protein. Bound protein was eluted by increasing the 
concentration of Ion exchange buffer B, producing a gradient of increasing salt 
concentration from 0-500 mM over 10 CV, followed by a step to 1M NaCl for 6 CV. 
Eluted protein was collected in 1.5 ml fractions, and peak fractions analysed by SDS-
PAGE.  
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Peak fractions were pooled together and then diluted to 0.25 mg/ml in Tag cleavage 
buffer. SENP1 protease was then added in a 1:25 (w/w) ratio to cleave off the His-SUMO 
tag, and the mixture was incubated for 16-18 h on a rolling platform at 4 °C. The cleaved 
mixture was then incubated twice with Ni-NTA resin (100 µl 50:50 slurry per mg of 
uncleaved protein), pre-washed with Tag cleavage buffer. Incubations were for 1 h at 4 °C. 
 
The resulting TcPINK1 solution was concentrated to 5 ml using a spin concentrator, 
centrifuged at 14,000 g, 15 min, 4 °C and filtered through a 0.2 µm filter to remove 
aggregates. The protein was loaded through a 5ml loop onto a Superdex 200 26/60 column 
attached to an AKTA Prime and pre-equilibrated in Gel filtration buffer. Protein was 
eluted with Gel filtration buffer at 2 ml/min and 3 ml fractions were collected. Protein 
purity was analysed by SDS-PAGE. 
2.7.6 Purification of His-SUMO Ubl domain 
Cells were harvested by centrifugation at 3290 g, 15 min, 4 °C and each cell pellet re-
suspended in Lysis buffer to 15 ml. The cell suspension was lysed by sonication (14x 10 s 
pulses alternating with 10 s cooling time, with amplitude of 45%) and the lysate centrifuged 
at 30,000 g, 30 min, 4 °C. Clarified lysate was then incubated for 45 min at 4 °C in a 50 ml 
Falcon tube on a rotating platform with Ni-NTA resin (0.6 ml 50:50 slurry per litre of 
culture) pre-washed with lysis buffer. The resin was centrifuged and the supernatant 
discarded, then transferred into an Econo-Pac disposable column and washed with Wash 
buffer until flow-through A280 <0.05. Elution buffer was added and protein was collected 
in 5 ml fractions. Protein purity and quantity was analysed by SDS-PAGE and Bradford 
assay respectively.  
 
Protein-containing fractions were pooled and cleaved overnight at 4°C with 1:10 SENP1 
whilst dialysing into Dialysis buffer. The cleaved mixture was then incubated with Ni-NTA 
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resin pre-washed with Tag cleavage buffer (for 12 L culture, twice with 2 ml 50:50 slurry, 
once with 1 ml 50:50 slurry). Incubations were for 45 min at 4 °C. The resulting protein 
solution was dialysed overnight at 4°C into Ion exchange buffer A. 
 
Dialysed protein was manually loaded with a syringe onto a 5 ml Hi-Trap CM FF cation 
exchange column at a rate of 5 ml/min. The column was attached to an AKTA Purifier 
and the column washed in Buffer A for 10 column volumes (CV) to remove unbound 
protein. Bound protein was eluted by increasing the concentration of Ion exchange buffer 
B, producing a gradient of increasing salt concentration from 0-500 mM over 10 CV, 
followed by a step to 1M NaCl for 6 CV. Eluted protein was collected in 1.5 ml fractions. 
2.7.7 Phosphorylation of Ubl domain with TcPINK1 and purification of Ser65-
phospho Ubl domain 
After purification by cation exchange, the Ubl phosphorylation reaction was set up as 
follows in a final volume of 500 µl: MBP-TcPINK1 128-570 and Ubl domain were at 0.2 
mg/ml, ATP at 0.1 mM, and MgCl2 at 10 mM in 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 
1 mM DTT. Reactions were incubated in a ThermoMixer at 16°C for 2h. The reaction was 
terminated by passing the mixture through a 30 kDa molecular weight cutoff (MWCO) 
spin concentrator to separate TcPINK1 from the Ubl domain. The Ubl domain was 
collected from the flow-through, buffer exchanged into Ion exchange buffer A and then 
concentrated to 4 ml using a 3 kDa MWCO spin concentrator.  
 
The protein was loaded using a 4 ml loop onto a pre-washed 1 ml Mono Q 5/50 GL 
column attached to an AKTA Explorer. The column was then washed with Ion exchange 
buffer A until the UV baseline returned to zero to remove unbound protein. Bound 
protein was then eluted with a gradient of Ion exchange buffer B to 50% over 40 CV. One 
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ml fractions were collected throughout the run and subsequently analysed by SDS-PAGE 
and Western blotting to assess the presence of phosphorylated protein.  
2.7.8 Purification of GST Sep65-Ubl  
Cells were harvested by centrifugation at 4000 g, 20 min, 4°C. The resulting cell pellet was 
re-suspended in 30 ml of the used media and centrifuged again. This pellet was frozen at -
80°C to be stored for later use or defrosted immediately to aid with cell lysis. Cell pellets to 
be thawed were incubated in a water bath at 37°C for around 30 s and then placed on ice. 
Thawed pellets were re-suspended in 10 ml of Lysis buffer and incubated on ice for 30 min 
to allow the lysozyme to digest the cell wall. Cells were lysed by sonication with 20 cycles at 
55 Amps, with 5 s on time and 40 s off time for each cycle.  
 
Lysates were centrifuged at 20,000 g, 15, min, 4 °C and the resulting supernatant was 
incubated with glutathione resin prewashed in lysis buffer (400 µl 50:50 slurry per 500 ml 
culture) for 1 h at 4°C. The resin was then centrifuged at 500 g, 5 min and the supernatant 
removed, followed by washing with Wash buffer until the A280 <0.05. GST-Prescission 
protease was then added and the resin incubated overnight at 4°C. The next day, the 
supernatant was collected and remaining cleaved Sep65-Ubl was washed from the resin 
using Wash buffer.  
 
2.8 Lysine methylation of protein preparations 
Lysine methylation of TcPINK1 was carried out according to (Walter et al, 2006), with 
slight modifications. TcPINK1 purified by anion exchange and with the His-SUMO tag 
cleaved off was diluted to below 0.1 mg/ml in Tag cleavage buffer. Twenty microlitres of 
freshly prepared 1 M dimethylamine-borane complex (ABC) and 40 µl of 1 M 
formaldehyde were added per 1 ml of protein solution, which was then incubated at 4°C 
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on a platform roller for 2 h. Then, another 20 µl ABC and 40 µl formaldehyde per 1 ml of 
solution was added and incubated for a further 2 h. Following a final addition of 10 µl 
ABC per 1 ml of solution, the reaction was then incubated overnight at 4°C. The 
methylated protein solution was centrifuged at 4000 rpm, 15 min, 4°C to remove any 
aggregated protein before gel filtration as described in Section 2.7.5. 
 
2.9 Analysis and of protein preparations 
2.9.1 SDS-PAGE analysis 
Protein samples were prepared in 1X SDS sample buffer and heated to 90 °C for 2 min. 
Gels were loaded into an Atto tank filled with running buffer and 20 µl of each sample was 
loaded onto the gel along with Precision Plus protein standard, which contains markers 
with the following apparent molecular weights: 250, 150, 100, 75, 50, 37, 25, 20, 15 and 10 
kDa. Electrophoresis was carried out at 180 V for 90 min, after which gels were either 
Coomassie stained with InstantBlue stain for 1 h followed by de-staining with water or 
used for Western blotting. 
2.9.2 Determination of protein concentration 
For rough estimation of protein concentration, for example prior to SDS-PAGE analysis, 
the Bradford assay was employed (Bradford, 1976). Ten microlitres of protein sample was 
mixed with 200 µl of Bradford reagent in a 96-well plate. BSA standards at concentrations 
of 0.1, 0.25, 0.5 and 1.0 mg/ml were used to produce a standard curve and water was used 
as a blank. The absorbance at 595 nm was measured using a plate reader and the standard 
curve was used to determine sample concentration. Samples were measured in duplicate 
and highly concentrated samples were diluted in water before measurement.  
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For accurate determination of the concentration of highly pure protein samples, the 
absorbance at 280 nm was measured (A280). The theoretical extinction coefficients (ε) were 
calculated using the ExPASY ProtParam tool (http://web.expasy.org/protparam/) and are 
listed below in Table 2.4. Samples were diluted as required in either buffer or water in a 
cuvette with a 1 cm path length and either buffer or water was used as a blank. The 
concentration of the protein sample was determined using the following formula: 
 
Concentration (mg/ml) = (A280/ε) x MW (Da) x Dilution factor 
 
 
Table 2.4: Extinction coefficients used for accurately calculating concentrations of 
proteins in this thesis 
 
To accurately determine the concentration of less pure proteins, the Li-Cor Odyssey 
system was used. Approximately 1 µg of protein sample, and 1µl of BSA standards at 
0.125, 0.25, 0.5 and 1.0 mg/ml were run on an SDS-PAGE gel, and the de-stained gel was 
scanned by the Li-Cor scanner at 700 nm. The intensity of each band was quantified using 
the Odyssey software, allowing measurement of the intensity of only the band of interest in 
a less pure protein sample. A standard curve was constructed using the BSA standards and 
the concentration of the protein of interest could then be determined.  
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2.9.3 Immunoblotting 
After separation of proteins by SDS-PAGE, gels were assembled into BioRad transfer 
apparatus. Prior to assembly, the nylon sponge pads and Whatman 3mm filter papers were 
soaked in transfer buffer, and the PVDF membrane was activated by soaking in methanol. 
The completed transfer assembly was then loaded into a BioRad Mini Trans-blot 
electrophoretic transfer tank, which was then filled with transfer buffer and an ice pack. 
Proteins were transferred from the gel to the membrane at 100 V for 1.5 h. 
 
Membranes were blocked for 30 min in TBST buffer containing 5 % (w/v) BSA and 
incubated overnight at 4°C with the appropriate primary antibody. Membranes were then 
washed 3 times for 5 min with TBST, incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies for 1 h at RT and washed another 3 times with TBST. In-
house primary antibodies were used at 1 µg/ml in 5% BSA in TBST with the addition of 
10 µg/ml of dephospho peptide for phospho-specific antibodies. Secondary antibodies 
were used at a 1:2500 dilution in 5% BSA in TBST. 
 
Finally, membranes were incubated with enhanced chemiluminescence reagent (ECL) and 
exposed to X-ray film for the required length of time. Films were developed using a 
Konica automatic developer. 
2.9.4 MALDI-TOF analysis 
Matrix-assisted laser desorption/ionisation and time of flight (MALDI-TOF) analysis of 
lysine methylated TcPINK1 and Ser65-phosphorylated Ubl domain was performed by Dr. 
Stella Ritorto (University of Dundee).  
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2.10 Protein crystallography 
2.10.1 Crystallisation theory and experimental setup 
A full discussion of the theory behind protein crystallography will not be presented here, 
however the reader is directed to the following book for further information: 
“Crystallography Made Crystal Clear” (Rhodes, 2006).  
 
All crystallisation experiments described in this thesis were carried out in the sitting drop 
format (Figure 2.1). This consists of a reservoir solution and a platform, on which sits a 
drop of protein solution mixed with a small quantity of the reservoir solution (typically in a 
1:1 ratio) and additive solutions, if required. The setup is sealed and equilibration occurs 
between the reservoir solution and the crystal drop. As this occurs, the concentration of 
components in the drop increases until supersaturation occurs. In the ideal situation, at this 
stage, nucleation occurs and crystals begin to grow. As more protein molecules enter the 
growing crystals, the overall concentration of components in the drop decreases and 
nucleation ceases. The crystals will continue to grow, increasing in size but not number. 
Many less desirable variations on this situation are possible, including too many nucleation 
events occurring and too many small crystals forming, crystals growing that are twinned or 
stuck together, or the protein precipitating, or crystals failing to grow entirely. 
 
 
 
Figure 2.1: Schematic showing setup used for crystallization screening 
A drop of protein solution is mixed with reservoir solution and the setup is sealed. 
Equilibration occurs between the drop and the reservoir solution, leading to an increase in 
the concentration of the drop and crystal growth.  
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2.10.2 Sample preparation 
Protein solutions after gel filtration were concentrated to between 1 and 5 mg/ml, 
depending on the construct using Vivaspin 500 centrifugal concentrators, with 
centrifugation at 13,000 g, 4°C until the required concentration was obtained. Following 
concentration, proteins were prepared for crystallisation trials by centrifugation at 14,000 g, 
15 min, 4°C to pellet any aggregated or insoluble material. If required, the protein was then 
incubated in the presence of a ligand. ADP, ATP and AMP-PNP (plus MgCl2) were added 
at a 5-fold molar excess and the protein solution then incubated on ice for 30 min.  
2.10.3 Setting up of crystal trays 
Crystallisation screens were set up in sitting drop format (Figure 2.1) using 96-well MRC 
plates, either manually or with a Mosquito crystallisation robot. The reservoir volume for 
all screens was 50 µl. For screens set up manually, the drop size was 2 µl (1 µl protein + 1 
µl reservoir solution). For screens set up with the Mosquito, the drop size was 1 µl (0.5 µl 
protein + 0.5 µl reservoir solution). During setup, the protein solution was either kept on 
ice (manual setup) or in a chilled reservoir (Mosquito) to avoid precipitation of the 
concentrated protein. For all screens, 1 µl β-mercaptoethanol was added to the reservoir as 
a final step to help improve crystal size and growth. For additive screening, additives were 
added at 1:10 of the final drop volume, so 0.1 µl for manual screens and 0.05 µl for those 
set up with the Mosquito. Finished trays were sealed with Crystal Clear tape, incubated in a 
temperature controlled room set at 18°C and checked regularly for crystal growth. 
 
2.10.4 Crystal handling and diffraction experiments 
Protein crystals were harvested from the mother liquor prior to a diffraction experiment 
using CryoLoops of the appropriate size. Crystals were submerged in a cryoprotectant 
solution, typically the mother liquor + 20% MPD, for a few seconds before freezing in 
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liquid nitrogen. Cryoprotectants were tested before use to ensure that a high enough 
concentration to prevent ice formation had been selected. Frozen crystals were either 
transferred to the storage dewar on the home X-ray generator or into a travel dewar for 
transport. Diffraction experiments were carried out at the European Synchrotron Radiation 
Facility (ESRF) in Grenoble, France, at the Diamond Light Source in Oxfordshire, UK and 
on the Rigaku generator at Dundee University.  
 
2.11 Kinase assays 
2.11.1 Assays with phosphorylation measured by autoradiography 
For assays using recombinant proteins where phosphorylation was detected by 
autoradiography, the following method was used. Reactions were set up in a final volume 
of 40 µl, using 1 µg of enzyme, either 2 µg or 2 µM of the appropriate substrate and [γ-32P] 
ATP at 0.1 mM in 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 10 mM MgCl2, and 2 mM 
DTT. Assays were incubated at 30°C, 1200 rpm for the indicated time, usually 30 min, 
followed by termination by the addition of SDS sample buffer. Reactions were then 
resolved by SDS-PAGE. The de-stained gel was then either dried in a GelAir Dryer or a 
Model 583 vacuum gel dryer. The dried gel was then exposed to ultra sensitive X-ray film 
for several hours or until an appropriate level of signal had developed. Where necessary, 
for further quantification the appropriate bands were cut out of the dried gel and the 
incorporation of [γ-32P] into each band was measured by Cerenkov counting.  
2.11.2 Assays with phosphorylation measured by scintillation counting 
For assays where phosphorylation was detected by scintillation counting, reactions were set 
up in a final volume of 50 µl, with 1 µg of enzyme, 5 µg of substrate for protein substrates 
and 1mM of peptide substrates (unless otherwise indicated) and 0.1 mM [γ-32P] ATP, also 
in 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 10 mM MgCl2, and 2 mM DTT. Assays were 
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normally incubated at 30°C, 1200 rpm for the required time and then terminated by 
spotting onto P81 paper squares and washing in 50 mM phosphoric acid. Assays set up in 
96-well format (PINKtide kinetics analysis) were incubated at 30°C with no shaking and 
terminated by addition of 20 µl 0.1 M EDTA, followed by spotting of 50 µl of this solution 
onto P81 paper and washing in 50 mM orthophosphoric acid. P81 papers were washed 
twice in fresh orthophosphoric acid for 30 min before being thoroughly dried. 
Incorporation of radioactivity into the substrate was then detected by Cerenkov counting.  
One unit of TcPINK1 activity was defined as the amount of enzyme that catalysed the 
incorporation of 1 nmol of ATP into a given substrate. Km and Vmax values were 
determined by analysing the phosphorylation of PINKtide and its variants at various 
concentrations. Km and Vmax values were calculated using the GraphPad Prism program. 
 
2.12 AlphaScreen assays 
AlphaScreen assays were set up in 384-well plates with a final reaction volume of 20 µl. 
GST-Ubl (1-76) was added at 0.3 µM and ΔUbl Parkin-biotin was added at 0.1 μM. Plates 
were sealed with an adhesive seal and incubated at RT for 60 min to allow protein binding 
to occur. Acceptor (glutathione-coated) and donor (streptavidin-coated) beads were added 
to a final concentration of 20 μg/ml each. Plates were then centrifuged at 500 g for 5 min, 
followed by horizontal shaking at 100 rpm for 5 min and incubation for 60 min at RT in 
the dark. As before, plates were sealed during this period with an adhesive seal to prevent 
evaporation. After incubation, plates were read with an EnVision Multilabel plate reader 
and data was collected.  
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3 Analysis of the biochemical properties of an active PINK1 
orthologue from the species Tribo l ium cas taneum : 
3.1 Introduction: 
The link between the PINK1 (PTEN (phosphatase and tensin homologue)-induced kinase) 
gene and Parkinson’s disease (PD) was first reported in 2004 after two families with 
autosomal recessive PD were found to harbour PINK1 mutations (Valente et al, 2004). 
Since then, many additional PINK1 mutations have been described in patients with familial 
PD. Whilst these mutations occur throughout the entire coding sequence of the PINK1 
gene, the majority are found within the region encoding the kinase domain (Mills et al, 
2008). There has therefore been a strong motivation to understand the biological function 
of PINK1 and how it is disrupted by PD-linked mutations. However, despite nearly a 
decade of research, relatively little progress has been made, in large part due to difficulties 
in assessing the enzymatic activity of PINK1 in vitro. In our laboratory and many others, it 
has been found that human PINK1 exhibits very low in vitro kinase activity and therefore 
no robust, reliable assay for its activity has been developed. This in turn has hampered 
efforts to identify genuine PINK1 substrates and regulators and to understand how its 
function may be altered by PD-linked mutations. 
 
It has been suggested that PINK1 may be an inactive pseudokinase with a function not 
dependent on catalytic activity, however bioinformatics analysis of the sequence of human 
PINK1 reveals that PINK1 contains all of the conserved amino acid motifs found in active 
protein kinases that are necessary for catalysis (Hanks & Hunter, 1995), (Sim et al, 2012). 
In addition, this hypothesis conflicts with data showing that Drosophila melanogaster PINK1 
null mutants have a severe phenotype that can be rescued by re-introduction of wild-type 
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but not kinase-inactive PINK1 (Kim et al, 2008). This provides an indication that, at least 
in Drosophila, the kinase activity of PINK1 is important for its biological function. 
 
In order to overcome these difficulties in studying the catalytic properties of human 
PINK1 in vitro, I sought to identify orthologues of PINK1 in non-mammalian species that 
might display detectable in vitro activity and subsequently to characterise them as a potential 
surrogate model for the kinase activity of human PINK1. Such a model could subsequently 
be used to further understand its biological function and how it might be impacted by PD-
linked mutations. Bioinformatics analysis in the form of a BLAST search and analysis of 
multiple sequence alignments suggested PINK1 orthologues from the species Tribolium 
castaneum (TcPINK1) and Pediculus humanus corporis (PhcPINK1) as potential candidates for 
further investigation. Both of these PINK1 orthologues also appear to be more tractable 
candidates than human PINK1 with regards to crystallisation screening, which will aid in 
future work determining the crystal structure of PINK1. 
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3.2 Identification and validation of TcPINK1 and PhcPINK1 as bona fide 
PINK1 orthologues 
3.2.1 Bioinformatics identification of two insect PINK1 orthologues, Tribol ium 
castaneum  PINK1 and Pediculus humanus corporis  PINK1, lacking the non-
conserved first kinase domain insertion: 
To identify putative non-mammalian PINK1 orthologues that might possess detectable in 
vitro activity, a BLAST search was performed using the full amino acid sequence of human 
PINK1. Orthologous protein sequences from a diverse range of species were selected and 
used as the input for a multiple sequence alignment, performed with MUSCLE (Edgar, 
2004a; Edgar, 2004b). The resulting alignment was viewed, edited and annotated using 
Jalview (Waterhouse et al, 2009). Incomplete sequences were removed from the alignment, 
leaving a total of PINK1 sequences from 18 different species including human in the final 
version (Figure 3.1). The criteria for identification of potential candidates for enzymatic 
characterisation was to look for orthologues with variations in the N-lobe insertions, since 
similar insertions have been shown to act as regulatory features in other protein kinases. 
Inspection of the alignment revealed that PINK1 orthologues from the species Tribolium 
castaneum (red flour beetle) and Pediculus humanus corporis (human body louse) completely 
lacked the first, longest insertion in the kinase domain. These two proteins were chosen as 
potential candidates for further analysis. Interestingly, this insertion is highly variable in 
both length and conservation between different species, whereas the second and third 
insertions are far less variable (Figure 3.1). 
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Figure 3.1: Multiple sequence alignment of PINK1 
Full-length human PINK1 was aligned against PINK1 orthologues from other species 
identified by BLAST search. Alignment performed with MUSCLE and annotated with 
Jalview. The mitochondrial targeting sequence is highlighted inside a purple dashed box 
and the transmembrane helix inside a pink dashed box. The start and finish of the kinase 
domain are highlighted with red arrows. Within the kinase domain, the first variable 
insertion is highlighted in a green dashed box, and second and third insertions are 
highlighted inside orange dashed boxes. Amino acid motifs critical for catalysis are 
highlighted as follows – yellow: glycine rich loop; orange: LAIK motif lysine; dark red: 
HRD catalytic motif; purple: DFG motif/N-terminal activation loop anchor; green: APE 
motif/C-terminal activation loop anchor.  
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3.2.2 Complementation of PINK1 null Drosophila melanogaster phenotypes with 
Tribolium castaneum PINK1 and Pediculus humanus corporis PINK1 
Subsequently it was critical to address whether or not the two proteins identified in the 
bioinformatics search, Tribolium castaneum PINK1 (TcPINK1) and Pediculus humanus corporis 
PINK1 (PhcPINK1) were genuine PINK1 orthologues, since the only information 
available at the time was their amino acid sequence. This was done in collaboration with 
Joe Pogson & Professor Alex Whitworth (University of Sheffield), who determined 
whether TcPINK1 and PhcPINK1 were able rescue the phenotype of a PINK1 null 
Drosophila model. PINK1 null flies display several quantifiable phenotypes (Clark et al, 
2006; Park et al, 2006) and for this experiment locomotion defects, namely flight and 
climbing ability and the presence of thoracic indentations were assessed. Multiple 
transgenic lines bearing TcPINK1 or PhcPINK1 under the control of the inducible 
GAL4/UAS system were generated and then combined into a PINK1 mutant background 
and found to rescue the flight and climbing defects as well as the appearance of thoracic 
indentations that are attributed to loss of PINK1. Each of these phenotypes was rescued to 
wild type levels by expression of both TcPINK1 and PhcPINK1, indicating that both of 
these proteins are likely to be genuine, functional orthologues of human PINK1 (Figure 
3.2). 
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Figure 3.2: Analysis of T. castaneum  and P. humanus corporis  PINK1 function in 
v ivo   
Performed by Joe Pogson & Alex Whitworth. (A) Averaged data of PINK1 null Drosophila 
phenotype rescued by overexpression of Tribolium castaneum PINK1 (TcPINK1) or Pediculus 
humanus corporis PINK1 (PhcPINK1). Flight and climbing ability, and presence of thoracic 
indentations were quantified. Genotypes are - control: PINK1B9/+, mutant: PINK1B9/Y; 
da-GAL4/+, mutant rescue: PINK1B9/Y; da-GAL4/+, UAS-Tb.PINK12a/+ or 
PINK1B9/Y; da-GAL4/+, UAS- Phc.PINK11/+. Data are presented as mean ± SEM. 
(B) Raw data for each of the five fly lines analysed with TcPINK1 overexpression and 
each of the 8 lines analysed with PhcPINK1 overexpression. Analysis and genotypes are 
same as in (A).  
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3.3 Comparison of in v i tro  activity of insect PINK1 homologues and human 
PINK1 
3.3.1 In vi tro  kinase activity of Tribol ium castaneum  PINK1 and Pediculus 
humanus corpor is  PINK1 against generic kinase substrates 
After validating that TcPINK1 and PhcPINK1 were genuine orthologues of human 
PINK1, it was next necessary to assess whether they possessed detectable in vitro kinase 
activity. To do this, MBP-tagged full-length wild type and kinase inactive forms of 
TcPINK1 (aa 1-570) and PhcPINK1 (aa 1-575) were recombinantly expressed in Escherichia 
coli. Kinase inactive mutations used as controls were D359A and D357A for TcPINK1 and 
PhcPINK1 respectively. Proteins were incubated in the presence of [γ32P] ATP and one of 
three generic kinase substrates: myelin basic protein, histone H1 or casein. Assays were 
resolved by SDS-PAGE and incorporation of [γ32P] ATP into substrates was detected by 
autoradiography. This revealed that both TcPINK1 and PhcPINK1 displayed detectable in 
vitro kinase activity, with a preference for myelin basic protein as a substrate (Figure 3.3). 
Histone H1 was phosphorylated to a lesser extent and casein was only phosphorylated in 
trace amounts. TcPINK1 appeared to be significantly more active than PhcPINK1, and 
interestingly, a band corresponding to autophosphorylation was observed with both 
kinases and was absent in the kinase inactive controls (Figure 3.3).  
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Figure 3.3: Activity of TcPINK1 and PhcPINK1 against generic kinase substrates 
Full-length wild type TcPINK1 (1-570), kinase inactive TcPINK1 (D359A), wild type 
PhcPINK1 (1-575) and kinase inactive (D357A) were tested against myelin basic protein, 
histone H1 and casein. The indicated enzymes (1 µg) were incubated in the presence of the 
indicated substrate (2 µM) and [γ32P] ATP for 30 min. Assays were terminated by addition 
of loading buffer and separated by SDS-PAGE. Proteins were detected by Coomassie 
staining (upper panel) and incorporation of [γ32P] ATP was detected by autoradiography 
(lower panel). Similar results were obtained in two experiments carried out in duplicate. 
Fine dividing lines indicate that reactions were resolved on separate gels and grouped in the 
final figure. Abbreviations: M/MBP, myelin basic protein; H/H1, histone H1; C, casein. 
 
 
3.3.2 Insect PINK1 orthologues display detectable in v i tro  activity against generic 
substrates in comparison to human PINK1 
Subsequently, the activity of the newly identified active insect orthologues was compared to 
that of human PINK1 (hPINK1), expressed in both E. coli and Sf9 cells. Although we were 
unable to detect hPINK1 kinase activity in our lab, there were several reports in the 
literature showing activity of hPINK1 both towards substrates (Kim et al, 2008; Pridgeon 
et al, 2007), by measuring autophosphorylation (Beilina et al, 2005; Silvestri et al, 2005) and 
when expressed in Sf9 cells  (Sim et al, 2006). TcPINK1 and PhcPINK1 had been initially 
selected for analysis since they lacked the first insertion in the kinase domain. In contrast, 
the PINK1 orthologue from another insect species, Drosophila melanogaster PINK1 
(DmPINK1), possesses a very long first insertion of approximately 90 amino acids, 
compared to around 30 in hPINK1. We therefore chose to include DmPINK1 in this 
experiment to provide further information on the role of the first insertion in regulation of 
PINK1 kinase activity.  
 
Full-length MBP-tagged forms of TcPINK1 (1-570), PhcPINK1 (1-575) and DmPINK1 
(1-721), both wild type and kinase inactive (D359A, D357A and D501A respectively) were 
compared to N-terminally truncated hPINK1, since it was not possible to express full-
length hPINK1 in E. coli. Wild type and kinase inactive (D384A) MBP-tagged hPINK1 was 
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expressed in E. coli (aa 123-581) and Sf9 cells (aa 125-581). These enzymes were incubated 
in the presence of myelin basic protein, the preferred substrate for TcPINK1 and 
PhcPINK1, and [γ32P] ATP, and phosphorylation of myelin basic protein was detected by 
scintillation counting. This revealed that hPINK1 expressed in either E. coli or Sf9 cells 
displayed no detectable kinase activity, in contrast to previous reports in the literature, and 
DmPINK1 displayed activity against myelin basic protein, albeit considerably weaker than 
the most active kinase, TcPINK1 (Figure 3.4).  
 
 
Figure 3.4: Activity of insect PINK1 homologues and human PINK1 against myelin 
basic protein 
Wild type N-terminally truncated human PINK1 (125-581) expressed in E. coli and Sf9 
cells, full-length D. melanogaster PINK1 (DmPINK1, 1-721), T. castaneum PINK1 
(TcPINK1, 1-570) and P. humanus corporis PINK1 (PhcPINK1, 1-575) and corresponding 
kinase inactive mutants (HsPINK1-D384A, DmPINK1-D501A, TcPINK1-D359A, 
PhcPINK1-D357A) were tested against myelin basic protein. The indicated enzymes (1 µg) 
were incubated in the presence of 5 µg myelin basic protein and [γ32P] ATP for 30 min. 
Reactions were terminated by spotting on P81 paper, washing in phosphoric acid and 
quantifying phosphorylation of myelin basic protein. The results are presented as ± SD for 
a representative experiment undertaken in duplicate (upper panel). In the lower panel 
representative Coomassie stained gels showing the relative amounts of PINK1 enzyme 
used for each assay are shown. Fine dividing lines indicate that reactions were resolved on 
separate gels and grouped in the final figure. 
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To ensure that the lack of detectable hPINK1 activity was not due to myelin basic protein 
being a poor substrate for this enzyme, E. coli and Sf9-expressed hPINK1 was again 
assayed in parallel with TcPINK1 and PhcPINK1 against histone H1 and casein in 
addition to myelin basic protein. Full-length MBP-tagged forms of TcPINK1 (1-570) and 
PhcPINK1 (1-575), both wild type and kinase inactive (D359A and D357A respectively) 
were used along with N-terminally truncated MBP-tagged hPINK1 expressed in E. coli (aa 
123-581) and Sf9 cells (aa 125-581), both wild type and kinase inactive (D384A) forms. 
These proteins were incubated with the indicated substrates in the presence of [γ32P] ATP, 
and incorporation of [γ32P] was detected by autoradiography. In this case, hPINK1, 
expressed in both E. coli and Sf9 cells again did not display detectable in vitro activity against 
any of the substrates utilized, suggesting the lack of kinase activity is not dependent on the 
substrate used (Figure 3.5). 
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Figure 3.5: Activity of insect PINK1 orthologues and human PINK1 against generic 
kinase substrates 
Comparison of activity of full length TcPINK1 (1-570) and PhcPINK1 (1-575) with N- 
terminal truncations of hPINK1 expressed in both E. coli (aa 123-581) and Sf9 cells (aa 
125-581). The indicated enzymes (1 µg) were incubated in the presence of the indicated 
substrate (2 µM) and [γ32P] ATP for 30 min. Assays were terminated by addition of loading 
buffer and separated by SDS-PAGE. Proteins were detected by Coomassie staining (upper 
panel) and incorporation of [γ32P] ATP was detected by autoradiography (lower panel). 
Similar results were obtained in two experiments carried out in duplicate. Fine dividing 
lines indicate that reactions were resolved on separate gels and grouped in the final figure. 
Abbreviations: M/MBP, myelin basic protein; H/H1, histone H1; C, casein. 
 
3.3.3 Deletion of the non-conserved insertion 1 in human PINK1 does not impart 
in v i tro  kinase activity 
Since a major difference at the primary sequence level between the active TcPINK1 and 
the inactive hPINK1 was the first kinase domain insertion, we hypothesized that this 
insertion, which is present in hPINK1 and absent in TcPINK1, might play an 
autoinhibitory role, thus regulating PINK1 catalytic activity. To test this idea, an artificial 
deletion of the first insertion (aa 184-212) in hPINK1 was designed. This protein was 
expressed in E. coli and tested for catalytic activity against myelin basic protein. 
Incorporation of [γ32P] ATP was measured by scintillation counting. The results clearly 
show that deletion of the first insertion of hPINK1 is not sufficient to impart in vitro kinase 
activity, since this protein, like wild type hPINK1, displays no detectable phosphorylation 
of myelin basic protein (Figure 3.6).  
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Figure 3.6: Analysis of the effect of first kinase domain insertion on human PINK1 
activity 
(A) Activity of wild type and kinase inactive (D384A) hPINK1 (123-581) was compared to 
ΔIns1 hPINK1 (123-581 Δ184-212) wild type and kinase inactive, Tribolium castaneum 
PINK1 (TcPINK1) wild type and kinase inactive (D359A), and Pediculus humanus corporis 
PINK1 (PhcPINK1) wild type and kinase inactive (D357A). Enzymes (1 µg) were 
incubated with myelin basic protein (5 µg) and [γ32P] ATP for 30 min. Assays were 
terminated by spotting on P81 paper and phosphorylation was quantified by scintillation 
counting.  Results are presented as ± SD for a representative experiment undertaken in 
triplicate (upper panel). Coomassie stained gels showing the relative amounts of PINK1 
enzyme used for each assay are shown (lower panel). Fine dividing lines indicate that 
reactions were resolved on separate gels and grouped in the final figure. (B) Schematic of 
the protein constructs used in (A).  
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3.4 Deletion of the PINK1 C-terminal domain leads to a loss of kinase 
activity 
To further probe the factors necessary for the catalytic activity of PINK1, the contribution 
of each domain of the protein to the catalytic activity of TcPINK1 was analysed. From this 
point, all further studies were carried out with TcPINK1, since it was the most active of 
the identified insect orthologues. PINK1 contains several major regions: the N-terminal 
region of the protein, comprising the mitochondrial targeting sequence and transmembrane 
helix, followed by the disordered region, the kinase domain and finally the small C-terminal 
domain (Figure 3.7A). Constructs were designed comprising truncations of each of these 
regions: construct aa 128-570 lacked the mitochondrial targeting sequence and 
transmembrane helix; construct aa 155-570 lacked all regions N-terminal to the kinase 
domain; and construct aa 155-486 lacked all N-terminal regions and the C-terminal domain 
(Figure 3.7A). These proteins were expressed in E. coli and their activity was assessed by 
incubation with myelin basic protein and [γ32P] ATP. Incorporation of [γ32P] into the 
substrate was detected by autoradiography. This experiment demonstrated that all regions 
of the protein N-terminal to the kinase domain were dispensable for kinase activity, since 
both the truncations from aa 128 and 155 were still active, although a slight loss of activity 
was seen when the entire N-terminal region, from aa 155, was deleted (Figure 3.7B). In 
contrast, the isolated kinase domain (aa 155-486) exhibited a complete loss of myelin basic 
protein phosphorylation, suggesting that the C-terminal domain is essential for kinase 
activity. Interestingly, all active constructs still displayed a detectable level of 
autophosphorylation, which was reduced in a fashion mirroring substrate phosphorylation 
in the less active N-terminal truncations (Figure 3.7B).  
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Figure 3.7: Analysis of requirement for each domain of TcPINK1 for kinase activity 
(A) Schematic of protein constructs utilised in this experiment. (B) Assessment of kinase 
activity of wild type or kinase inactive (D359A) full-length (1-570), N-terminal truncation 
(128-570 & 155-570) and N- & C-terminal truncation mutants (155-486) of TcPINK1. The 
indicated forms of TcPINK1 (1 µg) were incubated in the presence (+) or absence (-) of 
myelin basic protein (2 µM) and [γ32P] ATP for 30 min. Reactions were terminated by the 
addition of SDS sample buffer and separated by SDS- PAGE. Gels were analysed by 
Coomassie staining (upper panel) and incorporation of [γ32P] ATP was detected by 
autoradiography (lower panel). Fine dividing lines indicate that reactions were resolved on 
separate gels and grouped in the final figure.  
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3.5 Analysis of TcPINK1 autophosphorylation 
3.5.1 Tribol ium castaneum  PINK1 is able to autophosphorylate on both 
serine/threonine and tyrosine residues within the kinase domain 
Autophosphorylation is a widespread mechanism of both kinase activation and regulation 
of kinase activity, and since PINK1 autophosphorylation had been observed in several 
prior experiments, autophosphorylation sites in TcPINK1 were mapped and it was 
determined whether any of them were required for kinase activity. To do this, full-length 
wild type TcPINK1 was analysed using a Thermo-Electron LTQ-Orbitrap mass 
spectrometer (performed by Dr. David Campbell). This analysis revealed multiple putative 
autophosphorylation sites. TcPINK1 appears to autophosphorylate on serine and 
threonine residues, but also strikingly on some tyrosine residues, which is unexpected since 
PINK1 belongs to the serine/threonine kinase family. For the majority of the identified 
phosphopeptides it was not possible to distinguish the exact phosphorylation site, since 
there were several adjacent or nearby residues that could potentially be phosphorylated 
(Table 3.1). Tyr439 and Thr 186 were identified unambiguously, but the other peptides 
contained clusters of several residues that could become phosphorylated. Each of the 
putative sites was assessed for conservation between TcPINK1 and hPINK1. Many of the 
identified sites are not conserved between TcPINK1 and hPINK1, and so were not 
considered for further analysis. Ten possible sites, found in four distinct peptides, are 
conserved between TcPINK1 and hPINK1 and these are highlighted in Table 3.1.  
Chapter 3 – Analysis of the biochemical properties of an active PINK1 orthologue from 
the species Tribolium castaneum 
	  
	  
 96 
 
Table 3.1: Putative autophosphorylation sites identified in TcPINK1 
Phospho-site mapping performed by Dr. David Campbell. The sequence of each identified 
phosphopeptide is shown with potential phosphorylation sites highlighted in red and the 
residue numbers of potential phospho-sites are listed. The conservation of the identified 
sites between TcPINK1 and hPINK1 is depicted as follows: ✔, residue conserved in 
hPINK1; ✖, residue not conserved in hPINK1; ~, residue substituted with another 
phosphorylatable amino acid in hPINK1. The theoretical (m) and observed (m/z) masses 
of each peptide are also listed.  
 
To assess the relative importance of the identified potential sites, non-phosphorylatable 
alanine and phenylalanine mutants in full-length MBP-tagged TcPINK1 were designed for 
each of the serine/threonine and tyrosine sites respectively, including a double alanine 
mutant for residues Ser205 and Ser207 (Figure 3.8A). Ser205 is the only fully conserved 
residue that is not a tyrosine, and was therefore considered likely to be significant for 
potential regulation of PINK1 kinase activity. These mutants were expressed in E. coli and 
their ability to phosphorylate myelin basic protein in the presence of [γ32P] ATP was 
assessed by autoradiography. No strong effect on kinase activity was seen with mutation of 
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any residue, with the exception of the S205A and S205/S207A single and double mutants, 
which led to an approximately 75% reduction in kinase activity relative to the wild type 
protein (Figure 3.8B). This suggests that Ser205 is most likely to be the phosphorylation 
site on this peptide, and may be important for regulating the kinase activity of PINK1. 
However, further mass spectrometry analysis using additional techniques such as ETD 
(Electron Transfer Dissociation) would be required to confirm that Ser205 is indeed 
phosphorylated and that the observed loss of activity is not due to an alternative 
explanation, such as destabilization of the protein due to the introduction of an alanine 
mutation. 
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Figure 3.8: Effect of autophosphorylation site mutants on TcPINK1 kinase activity 
(A) Schematic of location of autophosphorylation sites in TcPINK1. (B) The indicated 
mutants (1 µg) of full-length TcPINK1 (1-570) were incubated with myelin basic protein (5 
µg) in the presence of [γ32P] ATP for 30 min. Reactions were terminated by spotting on 
P81 paper and incorporation of [γ32P] was detected by scintillation counting. Results are 
presented as ± SD for a representative experiment undertaken in triplicate (upper panel). 
Coomassie stained gels showing the relative amounts of PINK1 enzyme used for each 
assay are shown (lower panel).  
 
3.5.2 Tribol ium castaneum  PINK1 can tyrosine phosphorylate itself but not the 
substrate myelin basic protein 
Although PINK1 belongs to the serine/threonine kinase family, several potential tyrosine 
autophosphorylation sites were identified in the phosphopeptide mapping experiment. To 
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further investigate this unexpected finding, and to determine whether TcPINK1 was 
additionally capable of tyrosine phosphorylating substrates other than itself, the tyrosine 
kinase activity of full-length wild type and kinase inactive (D359A) TcPINK1 against both 
itself and myelin basic protein was tested (performed by Dr. Miratul Muqit). Incorporation 
of [γ32P] ATP was measured by autoradiography and phosphorylation of tyrosine residues 
by immunoblotting with an anti-phosphotyrosine antibody (4G10) (Figure 3.9). This 
revealed that PINK1 is able to tyrosine autophosphorylate itself but is unable to 
phosphorylate tyrosine residues on the substrate myelin basic protein. Further experiments 
would be necessary to determine the exact residues modified, and it is unclear whether 
tyrosine autophosphorylation is a unique feature of TcPINK1 under in vitro conditions or 
whether it has broader relevance to PINK1 in general.  
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Figure 3.9: Analysis of tyrosine autophosphorylation of TcPINK1  
Performed by Dr. Miratul Muqit. Full-length wild type and kinase-inactive (D359A) 
TcPINK1 (1 µg) was incubated with myelin basic protein (MBP, 5 µg) in the presence or 
absence of [γ-32P] ATP. Reactions were terminated by addition of SDS sample buffer and 
analysed by SDS-PAGE (lower panel). Incorporation of [γ-32P] was assessed by 
autoradiography (top panel). Tyrosine autophosphorylation of enzymes and substrates was 
detected by blotting with an anti-phospho tyrosine antibody (4G10, middle panel).  
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3.6 Substrate specificity of TcPINK1 
3.6.1 Determination of the optimal peptide substrate, PINKtide, for Tribol ium 
castaneum  PINK1 using a positional scanning peptide library 
One of the major mechanisms by which protein kinases identify and interact with their 
correct physiological substrates is through recognition of a consensus amino acid sequence 
surrounding the site of phosphorylation. Since it has previously not been possible to detect 
the in vitro kinase activity of PINK1, there was nothing known about its potential modes of 
substrate recognition and whether it displays a preference for a particular amino acid 
consensus sequence. To address this lack of information, it was decided to carry out a 
positional scanning peptide library assay - a technique for assessing kinase substrate 
specificity (Hutti et al, 2004). This approach utilises libraries of degenerate peptides with a 
central serine/threonine amino acid as the phospho-acceptor, a single fixed amino acid at 
an additional position and randomized amino acids at each other position from -5 to +4 
surrounding the phosphorylation site. The phosphorylation of each of these library 
mixtures by the kinase of interest is assessed, and the strength of phosphorylation reveals 
the effect of each amino acid at each position in the peptide upon phosphorylation. Using 
this technique, it is possible to assess the enzymes preference for each amino acid, 
including phospho-threonine and phospho-tyrosine at each position surrounding the 
phosphorylation site in an unbiased fashion.  
 
Screening of TcPINK1 against the peptide libraries was carried out as follows (performed 
by Dr. Mike Begley and Professor Lewis Cantley, Harvard Medical School). Wild type and 
kinase inactive (D359A) TcPINK1 was incubated with these peptide libraries in the 
presence of [γ32P] ATP. The relative phosphorylation of each peptide was measured by 
spotting the biotin-coupled peptides onto a streptavidin membrane, and incorporation of 
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[γ32P] was detected by phosphoimaging. This experiment revealed that TcPINK1 has a 
preference for tryptophan at the -5 position, followed by isoleucine at -4, then a strong 
preference for phospho-tyrosine at -3, and a weak preference for arginine at -2 and -1. The 
strongest preference was for proline at the +1 position, then again followed by a weak 
preference for arginine at positions +2 to +4 (Figure 3.10). In total this suggests the 
optimal peptide substrate for PINK1 would be WIpYRRS/TPRRR, where the phospho-
acceptor is indicated in bold. Key determinants of TcPINK1 substrate specificity at the 
peptide level might be the -5 tryptophan, -3 phosphotyrosine and +1 proline in 
combination with a general preference for a basic peptide (Figure 3.10). The discovery of 
this sequence allowed the design of an optimal peptide substrate for PINK1, which was 
designated PINKtide. Its sequence is as follows, with the addition of N-terminal lysine 
residues to aid solubility: KKWIpYRRSPRRR. 
 
A weighted matrix based on the intensity of phosphorylation at each position in the 
peptide scanning library (Figure 3.10) was also generated (Appendix 2). This matrix can be 
used to search the Scansite database (scansite.mit.edu) to return a list of proteins containing 
the input phosphorylation consensus sequence and that are ranked in order of how closely 
they conform to the consensus. Searching the database with this matrix did not find any 
proteins that precisely conformed to the PINKtide sequence, and returned mostly serine 
and arginine rich proteins such as splicing factors (Appendix 2).  
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Figure 3.10: Determination of optimal peptide substrate sequence for TcPINK1 
Performed by Dr. Mike Begley and Professor Lewis Cantley (Harvard Medical School). 
Full-length (1-570) wild type (left panel) and kinase inactive (D359A, right panel) 
TcPINK1 was used to screen a positional scanning peptide library of 198 sets of 
biotinylated peptides. Reaction products were bound to a streptavidin-coated membrane, 
washed and visualised by phosphoimaging. Small red dots indicate the residues selected for 
the PINKtide peptide sequence. 
 
 
3.6.2 Kinetics analysis of PINKtide mutants reveals a +1 proline is essential for 
phosphorylation by Tribol ium castaneum  PINK1 
After the elaboration of the PINKtide sequence, it was next important to assess which 
features of the peptide were critical for its phosphorylation by TcPINK1. Three residues 
were selected as being most likely to contribute to PINK1 specificity towards PINKtide: 
the -5 tryptophan, -3 phospho-tyrosine and +1 proline. Peptides varying at each of these 
positions were designed. The -5 position was varied to another large and two small 
hydrophobic residues (F, L and A) and a positive and negatively charged residue (K and E). 
The -3 phospho-tyrosine was changed to tyrosine and phenylalanine, phospho- and 
dephospho-serine and threonine, plus lysine and glutamic acid. Finally, the +1 proline was 
changed to the same five residues as the -5 position. This choice of alternative residues 
covers the spectrum of large and small hydrophobic residues, charged residues and in the 
case of the -3 position, alternative phospho and de-phospho amino acids. Additionally, a 
version of PINKtide containing tyrosine at the phosphorylation site was included, giving a 
total of 20 peptides including the original PINKtide.  
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The ability of full-length MBP-tagged wild type TcPINK1 to phosphorylate each of these 
new peptides was tested and compared to the phosphorylation of the original PINKtide 
sequence. This analysis revealed that there was no strong effect upon activity due to 
variation of residues at the -5 and -3 position, as assessed by variation in the Km and Vmax 
values. However, variation of the +1 proline to any other amino acid tested led to a 
complete loss of the ability of TcPINK1 to phosphorylate the peptide (Figure 3.11). This 
demonstrates that the +1 proline is an essential determinant of selectivity for TcPINK1 
and suggests that this kinase may possess strong +1 proline-directed activity. In agreement 
with previous data (Figure 3.9), TcPINK1 was not able to phosphorylate PINKtide with a 
central tyrosine residue, confirming that it does not possess the ability to carry out tyrosine 
phosphorylation of non-self substrates. 
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Figure 3.11: Analysis of kinetics of PINKtide phosphorylation 
 (A) Schematic of PINKtide sequence with -5 (orange), -3 (purple) and +1 (green) 
positions depicted. (B) Kinetic values of phosphorylation of PINKtide and indicated 
variants by full length (1-570) TcPINK1. Residues that were changed relative to PINKtide 
are indicated in bold. Km and Vmax values were derived by nonlinear regression analysis as 
described in Materials and methods. ND denotes that a particular peptide was 
phosphorylated poorly and kinetic values were not determinable. Similar results were 
obtained in at least 2 experiments. (C) Kinetics of phosphorylation of mutants of 
PINKtide at the 0, +1, -3 and -5 positions by full-length TcPINK1 (1-570). Enzyme was at 
1 µg, peptides were at 1µM, 3µM, 10 µM, 30 µM, 100 µM, 300 µM and 1 mM. Reactions 
were incubated for 30 min in the presence of [γ-32P] ATP. Graphs are colour-coded to 
match the illustrated PINKtide sequence in (A).  
 
3.6.3 Tribol ium castaneum  PINK1 is not able to phosphorylate the peptide 
substrates of a diverse array of other protein kinases 
To further confirm that PINKtide was a specific substrate for PINK1, we decided to test 
the ability of TcPINK1 to phosphorylate a diverse selection of peptide substrates that had 
been previously described for other protein kinases. The substrate peptides selected 
corresponded to kinases from all families of the kinome except the STE family, ensuring 
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that the selected peptides represented the preferred substrates of a wide range of kinases. 
Full-length MBP-tagged TcPINK1 was used to phosphorylate each of these peptides in 
parallel with PINKtide and incorporation of [γ32P] ATP was detected by scintillation 
counting. None of the substrate peptides were phosphorylated to a significant extent 
compared to PINKtide, with weak phosphorylation of the NEK2a and PKB peptide 
substrates observed (Figure 3.12). This data confirms that PINKtide is the optimal and 
strongly preferred substrate of TcPINK1. 
 
Figure 3.12: Analysis of specificity of TcPINK1 for PINKtide 
Full-length TcPINK1 (1-570, 1 µg) was incubated with the indicated substrate peptides (1 
mM) for 30 min. Reactions were terminated by spotting onto P81 paper and incorporation 
of [γ32P] ATP was quantified by scintillation counting. Similar results were obtained in two 
separate experiments carried out in duplicate; data is presented as average values ± SD. 
Names of peptides or the kinases for which they are a substrate are indicated, the site of 
phosphorylation is coloured red in each sequence. 
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3.6.4 PINKtide is an optimal substrate for Tribol ium castaneum  PINK1 only 
In addition to demonstrating that PINKtide is a highly specific and optimal substrate for 
TcPINK1, it would be interesting to test whether it is a general substrate for other insect 
PINK1 orthologues, and further to this, whether it is a substrate for human PINK1. The 
activity of TcPINK1 against PINKtide was measured in parallel with the activity of 
PhcPINK1, DmPINK1 and hPINK1, expressed in both Sf9 cells and E. coli. Incorporation 
of [γ32P] ATP was measured by scintillation counting. This experiment demonstrated that 
TcPINK1 strongly phosphorylated PINKtide, but in contrast, both PhcPINK1 and 
DmPINK1 phosphorylated PINKtide at a much lower level (Figure 3.13). This suggests 
that PINKtide is an optimized substrate for TcPINK1 only, as opposed to all insect PINK 
orthologues. hPINK1 expressed in both Sf9 cells and E. coli did not show any activity 
against PINKtide (Figure 3.13). 
 
Figure 3.13: Phosphorylation of PINKtide by different PINK1 species 
1 µg of wild type N-terminally truncated human PINK1 (125-581) expressed in E. coli and 
Sf9 cells, full-length Drosophila PINK1 (dPINK1, 1-721), T. castaneum PINK1 (TcPINK1, 1-
570) and P. humanus corporis PINK1 (PhcPINK1, 1-575) and corresponding kinase inactive 
mutants (HsPINK1-D384A, dPINK1-D501A, TcPINK1-D359A, PhcPINK1-D357A), 
were incubated as indicated with PINKtide (1 mM) and [γ-32P] ATP for 30 min. Reactions 
were terminated by spotting onto P81 paper and incorporation of [γ32P] ATP was 
quantified by scintillation counting (upper panel). Amounts of proteins used in the assay 
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are depicted in the lower panel. Fine dividing lines indicate that proteins were resolved on 
separate gels and grouped in the final figure. 
 
3.6.5 Tribol ium castaneum  PINK1 cannot phosphorylate putative PINK1 
substrates previously described in the literature 
Several putative PINK1 substrates have been described in the literature, however previous 
work in our lab to try and reproduce this data has been unsuccessful due to the lack of 
detectable in vitro activity displayed by human PINK1. Now that an active model of PINK1 
is available, it was possible to revisit these findings. The reported substrates chosen for 
analysis were: TRAP1, a mitochondrial chaperone protein that has been suggested as an 
interacting partner and direct substrate of PINK1 (Pridgeon et al, 2007); and Omi/HtrA2, 
a mitochondrial serine protease that was reported to be phosphorylated in a PINK1-
dependent manner (Plun-Favreau et al, 2007). Each of these proteins was incubated in the 
presence of [γ32P] ATP with full-length wild type or kinase inactive (D359A) TcPINK1, 
PhcPINK1 (kinase inactive: D357A), DmPINK1 (kinase inactive: D501A) and human 
PINK1 expressed in either E. coli (aa 123-581) or Sf9 cells (aa 125-581), (kinase inactive: 
D384A). Substrate phosphorylation was detected by autoradiography. No phosphorylation 
of any substrate by any of the tested kinases was detected, suggesting that may not be 
genuine PINK1 substrates (Figure 3.14).  
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Figure 3.14: Phosphorylation of putative PINK1 substrates/interactors reported in 
the literature 
1 µg of wild type N-terminally truncated human PINK1 (125-581) expressed in E. coli and 
Sf9 cells, full-length Drosophila PINK1 (dPINK1, 1-721), T. castaneum PINK1 (TcPINK1, 1-
570) and P. humanus corporis PINK1 (PhcPINK1, 1-575) and corresponding kinase inactive 
mutants (HsPINK1-D384A, dPINK1-D501A, TcPINK1-D359A, PhcPINK1-D357A), 
were incubated as indicated with GST- TRAP1 or GST-Omi (2 µg) and [γ32P] ATP for 30 
min. Assays were terminated by addition of loading buffer and separated by SDS-PAGE. 
Proteins were detected by Coomassie staining (upper panel) and incorporation of [γ32P] 
ATP was detected by autoradiography (lower panel). Fine dividing lines indicate that 
reactions were resolved on separate gels and grouped in the final figure. 
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3.6.6 Tribol ium castaneum  PINK1 can phosphorylate Parkin but not a peptide 
containing the Parkin phosphorylation site 
Further work in our lab utilizing TcPINK1 revealed that the ubiquitin E3 ligase Parkin, 
also linked genetically to Parkinson’s disease, is a substrate for PINK1 (Kondapalli et al, 
2012). The mapping of the PINK1 phosphorylation site in Parkin to residue Ser65 revealed 
an amino acid sequence of surrounding residues quite different to the previously 
established consensus sequence for TcPINK1 as seen in PINKtide. This raised the 
question as to whether TcPINK1 would be able to phosphorylate a peptide comprising the 
phosphorylation site in Parkin. To address this, a peptide was designed with the sequence 
RDLDQQSIVHIVQR (phospho-acceptor site is highlighted and in bold) and its ability to 
be phosphorylated by TcPINK1 was examined. This experiment revealed that the Parkin 
peptide could not be phosphorylated at all by TcPINK1, in comparison to PINKtide, 
which was robustly phosphorylated (Figure 3.15). This suggests that the interactions that 
govern Parkin phosphorylation by PINK1 are not mediated solely through the canonical 
kinase substrate-binding groove, and instead may include interactions distal from the active 
site. 
 
 
 
Chapter 3 – Analysis of the biochemical properties of an active PINK1 orthologue from 
the species Tribolium castaneum 
	  
	  
 111 
 
Figure 3.15: Phosphorylation of PINKtide and Parkin serine 65 peptide by 
TcPINK1 
Full-length MBP-tagged TcPINK1 (1 µg) was incubated in the presence of PINKtide or 
Parkin peptide at the indicated concentrations and [γ32P] ATP for 30 min. Reactions were 
terminated by spotting onto P81 paper, and quantified by scintillation counting. 
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3.7 Application of TcPINK1 activity assay to characterise PD-linked 
mutations and a novel in v ivo  PINK1 knockout model 
3.7.1 Parkinson’s disease-linked mutations in PINK1 lead to a loss of catalytic 
activity of Tribol ium castaneum  PINK1 
Since 2004, when the first PD-linked missense mutation in PINK1 was described, many 
other mutations have been identified (Appendix 1). However, due to the lack of a suitable 
in vitro assay for PINK1 activity it has not been possible to test the effect of these 
mutations on the kinase activity of PINK1. We therefore chose to use the active TcPINK1 
as a model to analyse for the first time the effects of PD-linked mutations on PINK1 
kinase activity. A subset of the disease mutants comprising only those described as 
homozygous or compound heterozygous point mutations in patients were selected (Table 
3.2). Due to the recessive nature of PINK1 mutations, these were likely to be genuine 
disease-causing mutations, as opposed to the heterozygous variants whose pathogenicity is 
less certain. From this list, only the mutations where the original, wild type residue was 
conserved between human PINK1 and TcPINK1 were selected, resulting in a final total of 
fourteen missense mutations to be analysed. In addition, three C-terminally truncating 
nonsense mutations were selected for analysis (Table 3.2).  
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Table 3.2: PD-linked PINK1 mutations conserved in TcPINK1 
The genotype of the patient in which each mutation was identified is listed as follows: 
HOM, homozygous; CH, compound heterozygous. The conservation and equivalent 
residue in TcPINK1 is listed, followed by the location of each mutated residue in 
TcPINK1. For mutations within the kinase domain, the secondary structure element or 
conserved motif in which each mutation is found is noted.  
 
Each of the missense mutants were expressed in E. coli as full-length MBP-tagged proteins, 
and their ability to phosphorylate PINKtide in the presence of [γ32P] ATP was determined 
by scintillation counting. All of the point mutations falling within the kinase domain led to 
a complete loss of kinase activity, with the exception of the G309D mutation that reduced 
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activity by about 90% when assessing activity using PINKtide. One mutation tested that 
fell outside the kinase domain, C125G, led to a more modest reduction in activity, reducing 
it to about 40% of the wild type levels (Figure 3.16). A similar trend was seen when using 
myelin basic protein as a substrate although the impact of C125G on phosphorylation was 
more modest (Appendix 3).  
 
Figure 3.16: Effect of PD-linked missense mutations on TcPINK1 kinase activity 
(A) Schematic showing location of point mutations in TcPINK1. Numbering is according 
to residue numbers in human PINK1. (B) Full-length MBP-tagged TcPINK1 enzymes 
containing point mutations (1 µg) were incubated in presence of PINKtide (1 mM) and 
[γ32P] ATP for 30 min. Reactions were terminated by spotting onto P81 paper, and 
quantified by scintillation counting. The results are presented as ± SD for three 
experiments undertaken in duplicate (upper panel). In the lower panel, representative 
Coomassie stained gels showing the relative amounts of PINK1 enzyme used for each 
assay are shown.  
 
Each of the C-terminally truncating mutants were also expressed in E. coli as MBP fusion 
proteins and their activity against PINKtide was tested. All of the truncating nonsense 
mutations tested led to a total loss of kinase activity (Figure 3.17), which is in agreement 
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with the previous experiment showing that removal of the C-terminal domain of the 
protein leads to abrogation of kinase activity (Section Error! Reference source not 
found.). A similar result was observed when the activity of these mutants was tested 
against myelin basic protein (Appendix 3). The fact that all of the tested mutations led to at 
least some decrease in kinase activity and in most cases led to a dramatic loss of activity is 
also in accordance with the genetic information regarding the mode of action of PINK1 
mutations.  
 
Figure 3.17: Effect of PD-linked nonsense mutations on TcPINK1 kinase activity 
(A) Schematic showing location of mutations in TcPINK1. Numbering is according to 
residue numbers in human PINK1. (B) Full-length MBP-tagged TcPINK1 enzymes 
containing point mutations (1 µg) were incubated in presence of PINKtide (1 mM) and 
[γ32P] ATP for 30 min. Reactions were terminated by spotting onto P81 paper, and 
quantified by scintillation counting. The results are presented as ± SD for three 
experiments undertaken in duplicate (upper panel). In the lower panel, representative 
Coomassie stained gels showing the relative amounts of PINK1 enzyme used for each 
assay are shown.  
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3.7.2 Analysis of a novel Zebrafish PINK1 knockout using TcPINK1 as a model 
for PINK1 activity 
Several well-characterised models for the loss of PINK1 seen in familial PD patients have 
been previously described, including the PINK1 knockout mouse and the PINK1 null 
Drosophila, and these have both provided insight into the biological functions of PINK1. 
However, these model systems are not without their limitations. The PINK1 knockout 
mouse does not show the loss of dopaminergic neurons or the decrease in striatal 
dopamine levels that are seen in PD patients (Kitada et al, 2007). Although the PINK1 null 
fly shows loss of dopaminergic neurons, mitochondrial dysfunction and muscular defects 
(Clark et al, 2006; Park et al, 2006), Drosophila are invertebrates and they are evolutionarily 
distant from humans, meaning studies carried out with fly models may not be relevant to 
human PD. There is therefore significant interest in the development of novel in vivo 
PINK1 models. Danio rerio (Zebrafish) is an ideal intermediate between the fly and the 
mouse, since Zebrafish are vertebrates and the PINK1 knockout Zebrafish shows a 
neurodegenerative and mitochondrial phenotype.  
 
Genetic studies in Zebrafish are commonly carried out using morpholino knockout 
technology, however this has the disadvantage of only inducing a very short-term 
knockdown, meaning it is not possible to conduct studies in the adult organism. 
Morpholinos may also produce off-target effects and their use in the PINK1 field has 
generated conflicting data. Studies in the Bandmann laboratory (University of Sheffield) 
had generated by mutagenesis a stable Zebrafish line carrying a premature stop codon in 
the pink1 gene, leading to truncation of the protein at amino acid 431. In order to use this 
line as a genetic model for studying the effects of loss of PINK1 function, it was necessary 
to demonstrate that the identified truncating mutation led to a loss of kinase activity. To do 
this, full-length wild-type Zebrafish PINK1 (ZfPINK1) and the Y431X mutant were 
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expressed as MBP fusions in E. coli. The ability of wild type ZfPINK1 and the Y431X 
mutant to phosphorylate myelin basic protein in the presence of [γ32P] ATP was assessed. 
Incorporation of  [γ32P] was detected by autoradiography and quantified by scintillation 
counting (Figure 3.18). This revealed that wild type ZfPINK1 does not display detectable 
in vitro kinase activity against myelin basic protein. A similar result was obtained when the 
Ubl domain of Parkin was used as a substrate (Appendix 4).  
 
Figure 3.18: In vi tro  activity of Zebrafish PINK1 
Full-length MBP-tagged wild type, kinase inactive (D372A) ZfPINK1, Y431X mutant and 
TcPINK1 wild type and kinase inactive (D359A) (1µg) were incubated in the presence of 
[γ32P] ATP and MBP (2 µM) for 30 min at 30°C. Assays were terminated by addition of 
loading buffer and separated by SDS-PAGE. Proteins were detected by Coomassie staining 
(upper panel) and incorporation of [γ32P] ATP was detected by autoradiography (lower 
panel). Fine dividing lines indicate that reactions were resolved on separate gels and 
grouped in the final figure. Phosphorylation was quantified by scintillation counting of 
excised gel bands.  
 
Chapter 3 – Analysis of the biochemical properties of an active PINK1 orthologue from 
the species Tribolium castaneum 
	  
	  
 118 
It was therefore necessary to assess the effect of the Y431X mutation of PINK1 kinase 
activity by another method, since ZfPINK1 was not active in vitro. The equivalent mutation 
to Y431X in TcPINK1 (Y419X) was therefore introduced and expressed as an MBP fusion 
protein in E. coli. The activity of this mutant against myelin basic protein was then 
compared to that of full-length wild type TcPINK1. Incorporation of [γ32P] into the 
substrate was measured by autoradiography and quantified by scintillation counting. This 
showed that, compared to the wild type protein, the Y419X mutation completely abolished 
the kinase activity of TcPINK1 against myelin basic protein (Figure 3.19). A similar result 
was obtained when the Ubl domain of Parkin was used as a substrate (Appendix 4). It is 
therefore possible to conclude that the Y431X mutation of PINK1 seen in the newly 
characterised Zebrafish model leads to a loss of kinase activity and that this provides a 
genuine model of PINK1 deficiency in vivo.  
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Figure 3.19: Effect of Y419X mutation on TcPINK1 activity 
Full-length MBP-tagged wild type and kinase inactive (D359A) TcPINK1 and Y419X 
mutant (1µg) were incubated in the presence of [γ32P] ATP and MBP (2 µM) for 30 min at 
30°C. Assays were terminated by addition of loading buffer and separated by SDS-PAGE. 
Proteins were detected by Coomassie staining (upper panel) and incorporation of [γ32P] 
ATP was detected by autoradiography (lower panel). Fine dividing lines indicate that 
reactions were resolved on separate gels and grouped in the final figure. Phosphorylation 
was quantified by scintillation counting of excised gel bands.  
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3.8 Discussion 
Although the gene encoding PINK1 was first linked to early-onset Parkinson’s disease in 
2004, little progress in terms of biochemical understanding had been made in the field 
since then, in large part due to the lack of a suitable and robust in vitro assay for mammalian 
PINK1 kinase activity. Several human PINK1 assays based on autophosphorylation 
(Beilina et al, 2005; Silvestri et al, 2005) and a number of putative substrates and interacting 
partners had been reported over the years, namely the mitochondrial chaperone TRAP1 
(Pridgeon et al, 2007) and the serine protease Omi/HtrA2 (Plun-Favreau et al, 2007), but 
this work has not been reproducible in our lab. The inability to study the catalytic activity 
of this enzyme led to a dearth of information on its potential substrates, mechanisms of 
regulation, and innate catalytic properties. To address this problem, I developed a novel 
assay for PINK1 activity by utilizing the PINK1 orthologue from the species Tribolium 
castaneum (TcPINK1). This approach has been validated by demonstrating that when 
TcPINK1 is overexpressed in PINK1 null Drosophila, the phenotype of these flies is fully 
rescued to the same levels as observed in a wild type fly (Figure 3.2). This system had 
previously been used to demonstrate a genetic interaction between PINK1 and Parkin 
(Clark et al, 2006; Park et al, 2006). In addition, only wild type and not kinase inactive 
PINK1 can rescue this phenotype (Kim et al, 2008), showing the importance of PINK1 
kinase activity for its function. The Drosophila system is therefore a robust and well-
validated system for assessing PINK1 function in vivo. 
 
3.8.1 Why do insect PINK1 orthologues display detectable in v i tro  activity when 
human PINK1 does not? 
Initially, the kinase activity of two insect PINK1 orthologues, TcPINK1 and PhcPINK1 
was tested against a panel of generic kinase substrates, revealing both possessed detectable 
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kinase activity and a preference for the substrate myelin basic protein (Figure 3.3). An 
immediate question raised by these experiments is why are insect PINK1 orthologues 
active in vitro when hPINK1 is not?  
 
It is possible that hPINK1 requires chaperones not found in E. coli to fold correctly and 
hence be active, whereas TcPINK1 is able to fold correctly in the absence of additional 
chaperones. In addition, hPINK1 may require post-translational modifications that are not 
conserved in TcPINK1 for activation of its kinase activity that may not be possible in the 
E. coli cell. To try and address these issues, Sf9 cells were utilised. These insect expression 
cells have a chaperone system more closely related to that found in humans and may 
possess necessary upstream kinases for expressing active enzymes. In spite of this, hPINK1 
expressed in Sf9 cells did not display detectable kinase activity (Figure 3.4 & Figure 3.5). So 
far, no upstream enzymes carrying out post-translational modifications of PINK1 have 
been identified despite extensive searching, so it is unlikely this is the reason for the lack of 
hPINK1 activity.  
 
PINK1 in cells is anchored in the mitochondrial outer membrane by its transmembrane 
helix. Since transmembrane proteins are often not stable when removed from their 
membrane environment, hPINK1 may not be stable when it is not anchored to the 
mitochondria. It is not possible to express full-length hPINK1 in E. coli, so instead a 
truncated construct (aa 123-581) was used. Since this construct does not possess the 
mitochondrial targeting sequence (MTS) and transmembrane helix, it is possible that this 
construct is stable even in the absence of mitochondrial localization. In addition, multiple 
constructs of TcPINK1, including the full-length protein containing both the predicted 
MTS and transmembrane helix, are stable on overexpression and display detectable kinase 
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activity (Figure 3.7), suggesting that lack of mitochondrial localization and any subsequent 
stabilizing effect may not be the cause of the lack of detectable hPINK1 activity.  
 
An immediately obvious difference at the sequence level between the active TcPINK1 and 
the inactive hPINK1 is the presence or absence of the first kinase domain insertion. If this 
were acting as an autoinhibitory feature of hPINK1 and was not conserved in TcPINK1 
and PhcPINK1, this might explain why TcPINK1 and PhcPINK1 are constitutively active 
whereas hPINK1 is not. However, we were unable to validate this hypothesis, since 
deletion of the first insertion in hPINK1 does not restore its kinase activity (Figure 3.6). In 
addition, testing of the activity of DmPINK1, which has a significantly longer first 
insertion than hPINK1, showed that this orthologue is also active in vitro (Figure 3.4), 
clearly demonstrating there is no correlation between the presence or absence of this 
insertion and kinase activity.  
 
A critical factor determining whether or not an enzymatic activity can be assessed in vitro is 
the presence of a specific substrate. There are examples of protein kinases that can only 
phosphorylate a single substrate, for example the kinase PKR and its substrate eIF2α (Dar 
et al, 2005), illustrating the importance of using the correct substrate when attempting to 
measure kinase activity. TcPINK1 displays detectable kinase activity against a variety of 
generic substrates (Figure 3.3) and more specific substrates such as PINKtide (Figure 3.13), 
whereas hPINK1 did not appear to display in vitro kinase activity against any of these 
substrates (Figure 3.4, Figure 3.5 & Figure 3.13). However, once a specific substrate, the 
E3 ligase Parkin, was identified, very low-level in vitro activity of immunoprecipitated 
hPINK1 could be detected (Kondapalli et al, 2012). This activity is considerably weaker 
than that displayed by TcPINK1, and it now raises the question as to why this is the case. 
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One important difference that has been observed between TcPINK1 and hPINK1 is in 
their responsiveness to CCCP-induced depolarization of the mitochondrial membrane. 
TcPINK1, which shows strong in vitro activity, has been found in our lab to be 
constitutively active when overexpressed in mammalian cells and this activity is not altered 
by CCCP stimulation (Hazel Rooney, unpublished data). hPINK1, on the other hand, 
under overexpression conditions shows only very weak in vitro activity after CCCP 
stimulation (Kondapalli et al, 2012). Under basal conditions, hPINK1 is constitutively 
degraded, but when cells are treated with CCCP, the mitochondrial proton gradient is 
abolished and the mitochondria becomes depolarized, subsequently leading to the 
stabilization of PINK1 on the mitochondria (Matsuda et al, 2010). 
 
 
Figure 3.20: Schematic of PINK1 activation by mitochondrial depolarization 
(L) In healthy mitochondria, PINK1 is imported then subsequently cleaved by the 
mitochondrial integral membrane protease PARL then subsequently degraded by the 
proteasome. (R) Upon mitochondrial depolarization, for example with the ionophore 
CCCP, PARL activity is lost and PINK1 is able to accumulate on the mitochondrial 
surface. It also then autophosphorylates and forms a complex with proteins such as VDAC 
and the TOM complex. 
 
After CCCP stimulation, hPINK1 has been shown to form a complex on the outer 
mitochondrial membrane with a number of other outer mitochondrial membrane (OMM) 
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proteins, namely the TOM (translocase of the outer membrane) complex (Lazarou et al, 
2012) and VDAC2 (voltage-dependent anion-selective channel protein 2) (Chandana 
Kondapalli, unpublished data). It is not known whether this complex is conserved in 
Tribolium castaneum and whether TcPINK1 forms the same interactions. However, it is clear 
that when hPINK1 is expressed in E. coli, no mitochondria are present and in Sf9 cells this 
complex may either not be conserved or will not form due a lack of mitochondrial 
depolarization. Therefore hPINK1 is unable to interact with these potentially stabilising 
interacting partners when overexpressed in these two systems. In contrast, these CCCP-
dependent interactions do not seem necessary for the activity of TcPINK1.  
 
A further change induced by CCCP stimulation and following mitochondrial depolarization 
is the appearance of autophosphorylation sites on hPINK1 (Kondapalli et al, 2012; Okatsu 
et al, 2012).  The role of these autophosphorylation events is currently not clear, and the 
best-characterised site, Thr257, is not detectable until a considerable time after substrate 
phosphorylation is detected, as judged by Parkin Ser65 phosphorylation (Kondapalli et al, 
2012). This suggests that autophosphorylation is not essential for initial activation of 
PINK1 kinase activity, and may instead be involved in maintenance of activity or reaching 
maximal activation. TcPINK1, on the other hand, is able to autophosphorylate in vitro, in 
the absence of CCCP stimulation (Table 3.1 & Figure 3.8). 
 
It seems most likely that hPINK1 displays a very low level of basal activity directed 
towards specific substrates and therefore appeared inactive in vitro until the correct 
substrate was identified. In vivo, its activity is facilitated and maintained by a number of 
factors, such as interacting partners and autophosphorylation, that only occur upon CCCP 
stimulation and will therefore not be present in recombinant overexpression systems such 
as E. coli and Sf9 cells. TcPINK1 and the other insect kinases on the other hand, do not 
Chapter 3 – Analysis of the biochemical properties of an active PINK1 orthologue from 
the species Tribolium castaneum 
	  
	  
 125 
appear to be subject to such complex regulation, presumably due to evolutionary 
differences between humans and insects, and as such display robust in vitro activity that is 
not modulated by the effects of CCCP.  
 
3.8.2 Requirement of the C-terminal domain for kinase activity 
Using the newly established assay for PINK1 activity, it was possible to analyse the 
requirement of each domain of the protein for kinase activity. This experiment revealed 
that only truncation of the C-terminal domain had any effect on TcPINK1 kinase activity, 
abolishing it completely (Figure 3.7). This suggests that the MTS and transmembrane helix 
are dispensable for the activity of PINK1, at least in vitro, where localization will not affect 
access to substrates. In contrast, the C-terminal domain appears to be essential.  
 
It is common for protein kinases to have regions outside the kinase domain that have an 
impact on kinase activity, for example CaMKI, which has an autoinhibitory C-terminal 
domain (Goldberg et al, 1996), and PKA, whose C-terminal extension is important for 
maintaining the kinase in its active conformation (Batkin et al, 2000). Very little is known 
about the PINK1 C-terminal domain except that is it predicted to be α-helical in nature. 
Inspection of the sequence of PINK1 (Figure 3.1) shows that there appears to be no linker 
region between the end of the kinase domain C-lobe and the start of the C-terminal 
domain. This, combined with the C-terminal domain’s hydrophobicity and probable α-
helical nature, suggests that it may form an extension of the primarily α-helical C-lobe and 
that its removal may destabilize the protein by exposing the hydrophobic core, leading to a 
loss of kinase activity. Knowledge of the structure of PINK1 would confirm whether or 
not this hypothesis is correct and may shed light on whether or not this domain plays a role 
in regulation of kinase activity. 
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3.8.3 Mechanisms and significance of TcPINK1 tyrosine autophosphorylation 
It was observed that TcPINK1 appears to undergo autophosphorylation (Figure 3.3, 
Figure 3.5 & Figure 3.7). To analyse this, autophosphorylation sites in the protein were 
mapped. The only site that could be conclusively pinpointed was residue Tyr439 (Table 
3.1). This was unexpected as PINK1 is predicted to belong to the serine/threonine kinase 
family. Anti-phosphotyrosine Western blotting confirmed that TcPINK1 is able to tyrosine 
autophosphorylate, but cannot tyrosine phosphorylate the substrate myelin basic protein 
(Figure 3.9).  
 
An example of a protein kinase family that can both tyrosine autophosphorylate and 
phosphorylate substrates on serine/threonine residues is the DYRK (dual specificity 
tyrosine-phosphorylation regulated kinase) family. These proteins have been shown to 
tyrosine autophosphorylate co-translationally and after translation as a mature protein 
(Walte et al, 2013). The data regarding overexpressed TcPINK1 suggests that it becomes 
tyrosine autophosphorylated whilst it is inside the E. coli cell, since this 
autophosphorylation is visible by Western blotting before further incubation with ATP 
(Figure 3.9). However, further experiments would need to be done to determine whether 
or not this is a co-translational event. Furthermore, it is unclear whether this tyrosine 
autophosphorylation is relevant to hPINK1, since no tyrosine autophosphorylation sites 
have been observed on the human protein (Chandana Kondapalli and Miratul Muqit, 
unpublished data).  
 
With regards to the mechanism by which TcPINK1 undergoes tyrosine 
autophosphorylation, a key determinant of specificity for serine/threonine versus tyrosine 
kinases is a single amino acid in a region of the activation segment known as the P+1 loop 
(Nolen et al, 2004). In serine/threonine kinases, this residue is a serine or a threonine, and 
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in tyrosine kinases, it is a proline essential for interacting with the phospho-acceptor 
tyrosine residue. In dual-specificity kinases, for example in the DYRKs, it is a serine 
(Aranda et al, 2011). In TcPINK1, and in PINK1 from all other species, this amino acid is 
a conserved asparagine (Figure 3.1). The significance of this for PINK1 substrate selectivity 
is not clear, and further experiments would be necessary to define how this amino acid 
contributes to substrate selectivity, for example mutagenesis to either serine/threonine or 
proline and analysis of the effect on tyrosine/serine/threonine autophosphorylation. In 
addition, the crystal structure of TcPINK1 in complex with its substrates might aid in 
defining the contribution of this region to serine/threonine versus tyrosine substrate 
selectivity. 
 
3.8.4 Autophosphorylation in TcPINK1 and hPINK1 
Several putative autophosphorylation sites were identified on each peptide found in the 
site-mapping experiment with the exception of the peptide containing Tyr439. A 
mutagenesis study revealed that only mutation of Ser205 to alanine and a double mutation 
of Ser205 and Ser207 led to any disruption of kinase activity, in both cases reducing it to 
about ¼ of the wild-type activity (Figure 3.8). Based on these findings, it is most likely that 
Ser205, located in the loop between the β3 sheet and the αC helix, is a relevant 
autophosphorylation site and that it may play a role in regulating PINK1 activity. However, 
further studies leading to more conclusive mapping of potential site would be needed in 
future.  
 
The equivalent residue in hPINK1, Ser228, was identified by mass spectrometry and 
mutagenesis as being autophosphorylated in a manner dependent on mitochondrial 
depolarization (Okatsu et al, 2012). The authors suggest that this site is necessary for 
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recruitment of the PINK1 substrate Parkin to the mitochondria and did not examine the 
effect of mutating this residue on PINK1 activity. In addition, the authors identified 
another site by mutagenesis, Ser402, located in the activation loop of human PINK1. They 
propose a structural model of hPINK1 and suggest that the two sites, Ser228 and Ser402, 
are located very close together (Okatsu et al, 2012). However, our lab has never observed 
any evidence of Ser402 phosphorylation despite conducting multiple experiments searching 
specifically for activation loop phosphorylation (Miratul Muqit, unpublished data). The 
best-characterised PINK1 autophosphorylation site is Thr257 (Kondapalli et al, 2012), 
substituted to a glutamic acid in TcPINK1. Since this site is not required for activation of 
human PINK1, it indicates that there is a discrepancy between the autophosphorylation 
observed in hPINK1 and TcPINK1. 
 
3.8.5 Mechanisms of substrate specificity  
Since at the time of this work there was a lack of information on substrates of PINK1 and 
it was not possible to reproduce any of the reported substrates in the literature (Figure 
3.14), we sought to investigate the substrate specificity of PINK1 at the peptide level. 
There are well known examples of protein kinases that have a strict amino acid consensus 
sequence for phosphorylation, for example PKB and PKA (Pearce et al, 2010), where it is 
possible to predict their potential substrates by searching for this amino acid motif in other 
proteins. Although this approach will not allow identification of all substrates and may 
result in false positives, having such knowledge for PINK1 would aid greatly in the search 
for its substrates.  
 
To this end, we carried out a positional scanning peptide library assay to determine the 
optimal peptide substrate for TcPINK1, resulting in the design of the peptide 
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KKWIpYRRSPRRR, designated PINKtide (Figure 3.10). Kinetics analysis of variants of 
PINKtide revealed that in agreement with previous data (Figure 3.9), TcPINK1 was not 
able to phosphorylate a peptide with tyrosine at the phospho-acceptor site and was able to 
phosphorylate serine and threonine equally well. Otherwise, with regards to levels of 
phosphorylation, only variation of the +1 position (proline) position had a strong effect; 
mutation of this residue led to a complete loss of phosphorylation of the peptide (Figure 
3.11).  
 
Several other protein kinase families are well known to demonstrate +1 proline-directed 
activity, including the CDKs (Brown et al, 1999) and MAPKs (Pelech, 1995). The structure 
of CDK2 in complex with a peptide substrate has been determined (Brown et al, 1999), 
which reveals the mechanism of +1 proline-directed specificity in this enzyme. Part of the 
activation loop adopts an unusual conformation that results in the lack of a hydrogen bond 
acceptor at this site, thus blocking the binding of any amino acid but proline, which is not 
able to form this hydrogen bond and can bind comfortably. Without knowledge of the 
crystal structure of PINK1, it is not possible to say if a similar mechanism exists or to 
speculate on which residues in the protein may be determining its specificity for peptides 
with a +1 proline.  
 
Finally, to confirm that PINKtide is truly a specific substrate for TcPINK1, we tested the 
ability of TcPINK1 to phosphorylate a panel of different peptide substrates for kinases 
from a wide range of different kinome families. As expected, TcPINK1 was not able to 
phosphorylate any other peptide to a significant degree, confirming its specificity for 
PINKtide (Figure 3.12). Included in the peptide panel was the substrate for the DYRK 
kinases, Woodtide, which also contains a +1 proline (Woods et al, 2001). Interestingly, 
despite TcPINK1 displaying a marked preference for substrates with a +1 proline, it was 
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not able to phosphorylate Woodtide, indicating that a +1 proline is necessary but not 
sufficient for TcPINK1 phosphorylation (Figure 3.12). Attempts to use the PINKtide 
sequence to search for putative PINK1 substrates using a weighted matrix to search the 
Scansite database were not successful and did not return any promising candidate 
substrates (Appendix 2).  
 
3.8.6 Substrate specificity at the peptide versus the protein level 
The discovery of TcPINK1 also allowed the subsequent discovery of the first well-
validated PINK1 substrate, the ubiquitin E3 ligase Parkin (Kondapalli et al, 2012). This 
facilitated detailed studies into how Parkin is activated by PINK1 phosphorylation 
(Kazlauskaite et al, 2014a) and played a part in the later discovery of another PINK1 
substrate and Parkin activator, ubiquitin (Kane et al, 2014; Kazlauskaite et al, 2014b; 
Koyano et al, 2014). Upon discovery of the PINK1 phosphorylation site in Parkin, it 
became apparent that the amino acid sequence surrounding the site of modification 
(RDLDQQSIVHIVQR) in no way resembled the PINKtide sequence previously described 
as being the optimal substrate for TcPINK1 (KKWIpYRRSPRRR). The +1 proline that 
had been shown to be critical for PINK1 phosphorylation was absent, and the peptide was 
slightly acidic. The ability of TcPINK1 to phosphorylate this peptide was tested, and no 
phosphorylation was detected (Figure 3.15). Since TcPINK1 is able to phosphorylate the 
intact Ubl domain, this strongly suggests that TcPINK1 is able to phosphorylate protein 
substrates on a residue with a flanking sequence strongly different from that of its optimal 
peptide substrate. 
 
Recognition of substrates in the region directly surrounding the site of phosphorylation is 
mediated by the amino acids forming the active site groove of a protein kinase. However, 
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this is not the only method used by kinases to identify their substrates. Many protein 
kinases form additional interactions with the substrate using regions of the protein away 
from the active site cleft (reviewed in (Ubersax & Ferrell, 2007)), An example of such a 
distal interaction is the DEF sites on MAP kinases. This family of kinases has an 
overlapping substrate specificity at the peptide level, but unique specificities for binding 
partners at their DEF sites allows them to phosphorylate only their precise targets 
(Sheridan et al, 2008). In addition, binding of a substrate at the DEF site increases their 
affinity for the substrate dramatically when compared to an isolated peptide, allowing for 
more efficient phosphorylation.  
 
A further instance of distal sites contributing to kinase specificity is provided by protein 
kinase B (PKB). PKB possesses a strong consensus sequence including a preference for a  
-5 arginine, which is absent in one of its substrates, ATP citrate lyase (Berwick et al, 2002). 
Despite this, PKB is still able to efficiently phosphorylate this protein in vivo. In addition, 
the kinase DYRK1A is able to phosphorylate substrates that conform precisely, partially or 
not at all to its optimal peptide consensus sequence (Soundararajan et al, 2013), giving 
another illustration of the flexibility of substrate recognition by protein kinases. Examples 
such as this suggest a mechanism for how TcPINK1 may be able to display highly differing 
substrate preferences at the peptide and whole protein level. Further studies would be 
necessary to identify regions on TcPINK1 that may required for binding and efficient 
phosphorylation of Parkin and ubiquitin. Furthemore, knowledge of the three-dimensional 
structure of TcPINK1 would shed light on the interactions formed in the peptide binding 
groove and how this region might contribute to substrate specificity.  
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3.8.7 Effects of Parkinson’s disease-linked mutations on kinase activity 
Finally, the effect of Parkinson’s disease (PD) linked mutations on PINK1 kinase activity 
was tested. To date there has been no thorough analysis of the effect of disease mutations 
on PINK1 catalytic activity and so this was an important question to address. A panel of 
mutations that were present as homozygous or compound heterozygous mutations in 
patients and where the wild type residue was conserved between hPINK1 and TcPINK1 
was selected (Table 3.2). These mutations were introduced into full-length TcPINK1 and 
the kinase activity of the resulting mutant enzymes was tested. In addition, the effects of 
three C-terminally truncating mutations were tested. More truncating mutations have been 
described, but these truncate the protein within the kinase domain and so would clearly 
lead to a loss of activity.  
 
The results of these experiments showed that all point mutations falling inside the kinase 
domain completely abolished or severely reduced kinase activity (Figure 3.16).  The most 
active mutant within the kinase domain is G309D, which displayed around 10% of the 
wild-type activity against PINKtide. Interestingly, the sole mutation outside of the kinase 
domain, C125G, only reduced kinase activity against PINKtide to just under half of wild 
type levels. This suggests that this mutation affects PINK1 function in a way distinct from 
directly interfering with catalysis. It has been shown in single-pass transmembrane proteins 
that the region of the protein close to the membrane on the cytoplasmic side, know as the 
juxtamembrane region, is often a disordered region that is enriched for protein-protein 
interaction motifs (Stavropoulos et al, 2012). The region of PINK1 between the 
transmembrane helix and kinase domain, where Cys125 is located, is predicted to be 
disordered and may be a binding site for interacting partners. If this is the case, mutation of 
this residue could well lead to a loss of interactions with a regulatory partner or substrate 
and the subsequent manifestation of PD. Alternatively, since this site is close to the 
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transmembrane helix, mutations could lead to defective mitochondrial import or 
processing, since PINK1 is known to undergo several proteolytic cleavage events upon 
mitochondrial import, notably by the proteases PARL (Deas et al, 2011) and MPP (Greene 
et al, 2012).  
 
Each of the C-terminally truncating mutations tested also led to a complete loss of kinase 
activity relative to the wild-type protein (Figure 3.17), which is in agreement with previous 
data (Figure 3.7) showing that a construct lacking the C-terminal domain has no in vitro 
kinase activity. All of the data regarding point mutations and truncating mutations leading 
to a general decrease in kinase activity is supported by the genetic evidence linking PINK1 
to PD, which shows that both copies of the pink1 gene must be mutated before the patient 
develops a disease phenotype, suggesting mutations are loss-of-function mutations.  
 
Various other studies have analysed the effect of PD-linked PINK1 mutations on several 
different parameters and have led to findings that are in agreement with our results. A 
study on PINK1 autophosphorylation (Okatsu et al, 2012) examined the effect of 
mutations upon PINK1 autophosphorylation and found that mutations outside the kinase 
domain did not affect autophosphorylation, whereas mutations inside the kinase domain 
led to a loss of autophosphorylation, with the exception of the G309D mutation that only 
reduced it slightly. An additional study on PINK1 activators also confirmed that the 
G309D mutation displays reduced but still detectable activity (Hertz et al, 2013). Studies in 
Drosophila provided further evidence for the effect of PINK1 mutations in the kinase 
domain, demonstrating that PINK1 mutants cannot rescue the PINK1 null phenotype 
(Song et al, 2013). These studies provide further evidence to consolidate our findings. 
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3.9 Conclusion 
To conclude, the discovery of TcPINK1 has provided the PINK1 field with a valuable 
tool. It has facilitated the identification of several PINK1 substrates, greater understanding 
of PINK1 autophosphorylation, and regulation of its substrate the E3 ligase Parkin, and 
has generally advanced understanding of PINK1 biology. In addition, it has provided 
insight into its basic catalytic properties, most importantly the effect of Parkinson’s disease-
linked mutations on PINK1 kinase activity. 
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4 Crystallisation of a PINK1 orthologue from the insect 
species Tribo l ium cas taneum  
4.1 Introduction 
At the start of this project, there was no crystal structure available for PINK1. Although 
the crystal structures of multiple members of the protein kinase family have been 
determined over the years, revealing a highly conserved general architecture of the protein 
kinase fold, PINK1 possesses a number of unusual features which make its structure of 
particular interest. The domain architecture of PINK1 is depicted below (Figure 4.1). 
PINK1 is the only kinase to be targeted to the mitochondria via a mitochondrial targeting 
sequence (MTS) and anchored there by a transmembrane domain. The transmembrane 
domain is predicted to be α-helical and to extend from residues 94-110. Within the kinase 
domain itself, PINK1 possesses three insertions in its N-lobe between the conserved 
secondary structure elements that make up the protein kinase fold. The first is between the 
β2 and β3 strands, the second between the αC helix and the β4 strand, and the third falls 
between the β4 and β5 strands. The function and orientation of these insertions with 
respect to the rest of the kinase domain is unknown. Finally, PINK1 has a C-terminal 
domain, again of unknown function, but which has been shown to be essential for kinase 
activity (Section Error! Reference source not found.). This domain consists of 
approximately 70 amino acids and is predicted to be α-helical in nature. Knowledge of the 
crystal structure of PINK1 might shed light on the nature of some of these features and 
might hint towards their potential roles in PINK1 function.  
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Figure 4.1: Schematic of human PINK1 and TcPINK1 domain architecture.  
MTS: mitochondrial targeting sequence; TM: transmembrane helix; Ins1-3: kinase domain 
insertions 1-3; CTD: C-terminal domain.  
	  
Furthermore, due to the lack of a PINK1 structure, there is no molecular explanation for 
the effects of Parkinson’s disease-linked mutations upon PINK1. Confirmed disease-
causing homozygous and compound heterozygous mutations have been found throughout 
the protein but mainly fall within the kinase domain. Several studies have attempted to 
categorise PD-linked mutations based upon their likely effect on protein stability and 
activity (Cardona et al, 2011; Sim et al, 2012), however without knowledge of the PINK1 
crystal structure, it is not possible to offer a definitive explanation for the observed effects 
on kinase activity (Section 3.7.1).  
 
In order to address these questions, I undertook the structural characterisation, by 
macromolecular crystallography, of a more tractable homologue of human PINK 
(hPINK1) from the species Tribolium castaneum (TcPINK1). TcPINK1 was chosen for this 
purpose since it expresses readily in E. coli and with a higher yield and purity than human 
PINK1. Previous work has demonstrated that TcPINK1 is a functional orthologue of 
hPINK1 (Section 3.2) and therefore any findings made from the crystal structure of 
TcPINK1 ought to be possible to translate to hPINK1. 
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4.2 Optimisation of purification conditions for TcPINK1 
4.2.1 Selection of the optimal affinity tag for purification of TcPINK1 
Previous work with TcPINK1 (Chapter 3) had been carried out using a maltose binding 
protein (MBP) tag, since it can help to solubilise unstable proteins. It was decided to test 
the expression of a construct comprising the kinase domain, C-terminal domain and N-
terminal region of TcPINK1 with alternative affinity tags to determine which tag and 
purification system gave the best yield and purity for crystallography purposes. Wild type 
and kinase inactive (D359A) TcPINK1 128-570 were expressed on a small scale in E. coli 
BL21-CodonPlus cells with either a 6-His, GST or MBP affinity tag. The resulting 
recombinant proteins were affinity purified with their respective affinity resins (6-His: Ni-
NTA resin; GST: glutathione resin; MBP: amylose resin) and the results were analysed by 
SDS-PAGE (Figure 4.2). This showed that His-tagged TcPINK1 appeared to express to a 
high level and purity compared to the GST and MBP tags. In addition, the His-tag has the 
advantage that it is a small tag and so it may not be essential to remove it before beginning 
crystallisation trials. Furthermore, the nickel affinity purification system is very versatile and 
can easily yield protein of high purity. 
 
Figure 4.2: Comparison of TcPINK1 expression with different affinity tags 
MBP: maltose binding protein; GST-glutathione-S-transferase; His: hexahistidine. B: 
recombinant protein bound to affinity beads; P: insoluble pellet fraction; FT: flow-through 
not bound to affinity resin. 
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4.2.2 Large-scale expression of His-tagged TcPINK1 128-570 (D359A) 
Expression of kinase inactive His-TcPINK1 128-570 (D359A) was carried out on a large 
scale in E. coli BL21 CodonPlus cells and the resulting protein was affinity purified using 
nickel resin. The protein was then subjected to anion exchange purification. The 
chromatogram showed a very poor UV280 profile with a single extremely broad and low 
peak (Figure 4.3A). SDS-PAGE analysis showed that TcPINK1 was present throughout 
the peak and the contaminants present in the input sample had not been removed (Figure 
4.3B).  This suggests that the protein may not be stable under the low salt conditions 
required for binding of the protein to the ion exchange column. 
 
Figure 4.3: His-TcPINK1 128-570 (D359A) expression and purification 
(A) Chromatogram of SourceQ anion exchange chromatography. Blue trace: UV280 
absorbance; green trace: Buffer B gradient. (B) SDS-PAGE analysis of anion exchange 
chromatography. Input: protein before purification.  
 
4.2.3 Optimisation of the buffer conditions used for purification of His-tagged 
TcPINK1 
Since His-tagged TcPINK1 had performed poorly in previous purification attempts, it was 
decided to try and optimise the buffer conditions used for nickel affinity chromatography 
to promote protein stability and purity. A single large culture was split and used for 
multiple nickel affinity purifications carried out at a range of pH values, from pH 5.0 to 
10.0. All buffers utilised throughout the protocol were adjusted to the required pH. SDS-
PAGE analysis of the protein eluted from the nickel resin revealed that recombinant 
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protein was only obtained at pH values above 7.0 and that the yield decreased above pH 
9.0 (Figure 4.4A). Separate analysis of the eluted protein showed that the purity was highest 
at pH 9.0 (Figure 4.4B). In addition, the salt concentration of the buffers used was 
optimised. As before, multiple nickel affinity purifications were carried out in which the 
salt concentration of the buffers was varied from 75 mM to 750 mM. The eluted protein 
was subjected to centrifugal concentration and the maximum concentration reached before 
the protein began to precipitate was measured (Figure 4.4C). This showed that the highest 
TcPINK1 concentration was obtained using buffers containing 350 mM NaCl. As a result 
the composition of the buffers used to purify TcPINK1 were changed where necessary to 
pH 9.0 and 350 mM NaCl. 
 
Figure 4.4: Optimisation of nickel affinity purification protocol to maximise His-
TcPINK1 purity and stability 
(A) SDS-PAGE analysis of nickel affinity purification from pH 5.0-10.0. P: insoluble pellet 
fraction; FT: flow-through not bound to nickel resin; E1-2: eluted recombinant His-
TcPINK1. (B) SDS-PAGE analysis of concentrated eluted TcPINK1 purified at pH 7.0-
9.0. (C) Graph showing maximal protein concentration (mg/ml) obtained while 
concentrating eluted TcPINK1 at salt concentrations from 75 to 750 mM. 
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4.2.4 Optimised large-scale purification of His-tagged TcPINK1 128-570 (D359A) 
His-TcPINK1 128-570 (D359A) was overexpressed on a large scale in E. coli BL21-
CodonPlus cells and the resulting protein was purified using buffers with the previously 
determined optimal pH and salt concentration. The eluted protein was then further 
purified by anion exchange. The chromatogram showed a large asymmetrical peak (Figure 
4.5A) and SDS-PAGE showed that the entire peak contained TcPINK1 with visible 
contaminants (Figure 4.5B). This suggested that despite optimisation of the buffers used 
for the purification, the protein is still not stable.   
 
Figure 4.5: Purification of His-TcPINK1 128-570 (D359A) using optimised 
purification protocol 
(A) Chromatogram of SourceQ anion exchange purification of TcPINK1. Blue trace: 
UV280 absorbance; green trace: Buffer B gradient. (B) SDS-PAGE analysis of TcPINK1 
eluted from anion exchange column. Input: protein sample before anion exchange. 
  
Chapter 4 – Crystallisation of a PINK1 orthologue from the insect species Tribolium 
castaneum 
	  
	  
 142 
4.3 Purification and crystallisation trials of TcPINK1 
4.3.1 Test expressions of TcPINK1 with the His-SUMO tag system: Constructs 
with N-terminal boundaries between residues 128 and 165 
Since attempts to express and purify TcPINK1 using a His-tag had been unsuccessful due 
to protein instability, it was decided to utilise the His-SUMO tag system, which comprises 
the small ubiquitin-like protein SUMO with an N-terminal 6-His tag (Lee et al, 2008). This 
enables purification using the nickel affinity chromatography method and provides the 
benefits of a solubilising tag through the SUMO moiety. Furthermore, the tag can easily be 
removed in a sequence-independent manner by cleavage with the highly efficient protease 
SENP1, which recognises the three-dimensional structure of SUMO and cleaves 
immediately after the C-terminus of the SUMO molecule. Since both the cleaved SUMO 
tag and the protease have a His-tag, they can easily be removed after cleavage by incubation 
with nickel resin (Figure 4.6).  
 
Figure 4.6: Schematic of His-SUMO tag cleavage by the SENP1 protease 
The His-SUMO tag is fused directly to the target protein with no protease recognition 
sequence necessary. SENP1 recognises the three-dimensional structure of the SUMO 
moiety and cleaves directly C-terminal to it. The His-tagged SENP and the His-SUMO 
moiety can then be removed by incubation with nickel resin, leaving the target protein in 
the supernatant.  
 
In addition, a range of new kinase inactive constructs was designed for expression with the 
His-SUMO tag. The N-terminal start sites of the constructs ranged from aa 128 to aa 165, 
(Figure 4.7A). A test expression of these constructs was carried out in E. coli BL21 
CodonPlus cells. The protein was purified by nickel affinity chromatography and the 
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results were analysed by SDS-PAGE (Figure 4.7B & C). From the initial test expression it 
appeared that each of the constructs expressed to similar levels and with a similar purity. It 
was decided not to do any further work on the 128-570 construct, since previous studies 
with this construct and other tags had not been successful (Section 4.2). Large-scale 
expressions and purifications were carried out systematically for the remaining construct. 
Based on the results of these purifications (Appendix 5), no further work was done on the 
constructs starting at amino acids 138, 148 or 165. The 155-570 was chosen for further 
optimisation.  
 
Figure 4.7: Test expression of TcPINK1 (D359A) constructs with His-SUMO tag 
(A) Schematic of TcPINK1 domain architecture showing the domain boundaries of the 
new constructs. MTS: mitochondrial targeting sequence; TM: transmembrane helix; 
Ins2/3: kinase domain insertions; CTD: C-terminal domain. (B) SDS-PAGE analysis of 
His-SUMO TcPINK1 test expressions. P: insoluble pellet fraction; FT: flow-through not 
bound to nickel resin; E: eluted recombinant His-SUMO TcPINK1. (C) Test expression 
of His-SUMO TcPINK1 155-570. E: eluted protein.  
 
4.3.2 Large-scale expression of His-SUMO TcPINK1 155-570 (D359A) 
Large-scale expressions of His-SUMO-TcPINK1 155-570 (D359A) were carried out in E. 
coli BL21-CodonPlus cells and recombinant protein was purified by nickel affinity 
chromatography. Further purification was carried out using anion exchange 
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chromatography. The chromatogram showed a sharp symmetrical peak (Figure 4.8A) and 
SDS-PAGE analysis showed this peak contains TcPINK1 with some minor contaminants 
present (Figure 4.8B). Peak fractions were pooled and the His-SUMO tag was cleaved off. 
As a final purification step, the cleaved protein was subjected to gel filtration. The resulting 
chromatogram shows a single sharp peak with a small preceding shoulder (Figure 4.8C). 
SDS-PAGE analysis showed that both the main peak and the shoulder contained 
TcPINK1 of very high purity (Figure 4.8D). Peak fractions were pooled, avoiding fractions 
containing protein from the shoulder.  
 
Figure 4.8: Purification of His-SUMO TcPINK1 155-570 (D359A) 
(A) Chromatogram of HiTrap Q FF column anion exchange purification of His-SUMO-
TcPINK1. Blue trace: UV280 absorbance; green trace: Buffer B gradient. (B) SDS-PAGE 
analysis of anion exchange peak fractions. (C) Chromatogram of S-200 gel filtration 
purification. Blue trace: UV280 absorbance. (D) SDS-PAGE analysis of gel filtration peak 
fractions. 
 
4.3.3 Crystallisation screening of TcPINK1 155-570 (D359A) 
Protein was prepared for crystallisation trials and used at concentrations between 1 and 5 
mg/ml. Trays were set up with both the native protein and protein pre-incubated with one 
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of the following ligands: ATP, ADP or AMP-PNP, all with the counter-ion Mg2+. Initial 
crystallisation trials of TcPINK1 155-570 (D359A) identified tiny crystals that grew within 
3 days of setting up screens. Further screening led to the identification of multiple 
conditions in which tiny crystals formed in a manner generally not affected by the presence 
of absence of ligands (Figure 4.9A). Optimisation of all these hits using both grid and 
additive screening led to an improvement in the size of the crystals obtained in some cases. 
In other cases the original hit could not be reproduced or improved upon and so was not 
pursued further. Additional modifications to the screening protocol, including the inclusion 
of a high concentration of reducing agent (10 mM DTT) in the gel filtration buffer and the 
addition of the reducing agent β-mercaptoethanol to the reservoir solution generally led to 
a further increase in size and decrease in crystal number per drop. It should be noted that 
once a condition was found in which crystals grew, the presence and number of crystals 
was not very sensitive to variation of the crystallisation condition, with crystals usually 
being seen in most wells of a grid or additive screen for any given condition. For a full list 
of crystallisation screens set up with this construct, please refer to Appendix 6. The 
diffraction of crystals grown in a number of different conditions was tested and the 
diffraction limit of each of them was around 15-20 Å (Figure 4.9B&C). Extensive further 
screening was carried out to try and identify new hits and to improve on those already 
found, however it was not possible to improve the diffraction resolution to anything above 
~15-20 Å. 
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Figure 4.9: Crystals and diffraction pattern of TcPINK1 155-570 (D359A) 
(A) Representative initial crystals of TcPINK1 before optimisation. (B) Representative 
crystal of TcPINK1 after optimisation to improve size and diffraction. (C) Representative 
diffraction pattern of TcPINK1 155-570 crystals showing weak diffraction.  
 
4.3.4 Lysine methylation of TcPINK1 155-570 (D359A) 
An additional technique that can be employed in the event that well-diffracting crystals 
cannot be grown is di-methylation of surface exposed lysine residues on the target protein 
(Walter et al, 2006). This method reduces the surface charge of the protein by modifying 
positively charged lysine residues with two neutral methyl groups. This may in turn allow 
the protein molecules to pack more tightly together and form a better-ordered crystal. 
TcPINK1 155-570 (D359A) was purified by nickel affinity chromatography and anion 
exchange and the His-SUMO tag removed. The protein was then diluted and subjected to 
the methylation protocol. Following this reaction, the methylated protein was purified by 
gel filtration to remove any excess of methylation reagents or aggregated protein. The 
resulting chromatogram showed a large shoulder preceding the main peak (Figure 4.10A) 
and SDS-PAGE analysis showed that both the peak and shoulder contained TcPINK1 
(Figure 4.10B). Protein from the second half of the main peak was pooled to avoid 
contamination with the protein found in the shoulder. A sample of this protein was 
compared to the unmodified protein, and no degradation of the methylated sample was 
visible (Figure 4.10C). To determine the number of lysine residues modified in the course 
of the reaction, the methylated protein was analysed by MALDI mass spectrometry 
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(performed by Dr. Stella Ritorto). This revealed that 23 out of 27 lysine residues on 
TcPINK1 had become di-methylated (Figure 4.10D).  
 
The methylated protein was prepared for crystallisation and initial screens were set up at a 
concentration of 1.60 mg/ml both in the presence and absence of ADP and Mg2+. For a 
list of crystallisation screens set up with the methylated protein, please refer to Appendix 7. 
None of these screens produced any crystallisation hits, and since the gel filtration peak 
profile of the methylated protein was quite poor, this method was not pursued further.  
 
Figure 4.10: Purification of lysine methylated TcPINK1 155-570 (D359A) 
(A) Chromatogram of S-200 purification of methylated TcPINK1. Blue trace: UV280 
absorbance. (B) SDS-PAGE analysis of gel filtration fractions containing TcPINK1. (C) 
SDS-PAGE comparison of TcPINK1 before (-) and after (+) methylation reaction. (D) 
Performed by Dr. Stella Ritorto. MALDI mass spectra of unmethylated (top) and 
methylated (bottom) TcPINK1 showing the masses of the singly and doubly charged ions. 
An increase in molecular weight is visible in the methylated sample. 
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4.3.5 Large scale expression of His-SUMO TcPINK1 155-570 
A further strategy to try and obtain well-diffracting crystals of TcPINK1 was to try and 
purify wild type His-SUMO TcPINK1 155-570. Use of the wild type protein had 
previously been avoided since heterogeneous autophosphorylation might interfere with 
crystal formation. However, previous data had suggested that at least one 
autophosphorylation site might be important for maximal kinase activity (Figure 3.8). It 
was therefore decided to use the wild type protein in case a lack of autophosphorylation led 
to a loss of protein stability. 
 
Large-scale overexpression of His-SUMO TcPINK1 155-570 was performed in E. coli 
BL21-CodonPlus cells and the recombinant protein was purified by nickel affinity 
chromatography. The protein was further purified by anion exchange chromatography. 
The protein eluted at a higher salt concentration and showed a broader peak profile than 
seen for the kinase inactive protein (Figure 4.11A&B). Peak fractions were pooled and the 
His-SUMO tag was cleaved off. Finally, the cleaved protein was subjected to gel filtration. 
The resulting chromatogram shows a single peak with a large preceding shoulder not seen 
with the kinase inactive protein. SDS-PAGE analysis showed that both the main peak and 
the shoulder contained TcPINK1 (Figure 4.11C&D). Due to the poor gel filtration peak 
profile when compared to the kinase inactive protein, no further work was done with the 
wild type protein.  
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Figure 4.11: Purification of His-SUMO TcPINK1 155-570 
(A) Chromatogram of HiTrap Q FF column anion exchange purification of His-SUMO-
TcPINK1. Blue trace: UV280 absorbance; green trace: Buffer B gradient. (B) SDS-PAGE 
analysis of anion exchange peak fractions. (C) Chromatogram of S-200 gel filtration 
purification. Blue trace: UV280 absorbance. (D) SDS-PAGE analysis of gel filtration 
fractions containing TcPINK1. 
 
4.3.6 Test expressions of TcPINK1 with the His-SUMO tag system: constructs 
with N-terminal boundaries between residues 150 and 165 
Since work on the construct aa 155-570 had not yielded well-diffracting crystals, it was 
decided to design a range of new constructs to test. The N-terminal boundary of these 8 
new constructs ranged from aa 150 to 163, which surround the start of the kinase domain 
at aa 155 (Figure 4.12A). A small-scale test expression of each of these constructs was 
performed in E. coli BL21-CodonPlus cells. The resulting protein was purified with nickel 
affinity chromatography and analysed by SDS-PAGE (Figure 4.12B). As with the previous 
test expressions, the yield and purity of each construct was very similar. A large-scale 
expression and purification of each new construct was carried out. Based on the results of 
their purification (Appendix 5), no further work was done on the constructs beginning with 
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amino acids 153, 156, 157, 160 or 163. Construct 150-570 was selected for further 
optimisation. 
 
Figure 4.12: Test expression of His-SUMO-TcPINK1 (D359A) constructs 
(A) Schematic of TcPINK1 showing region containing N-terminal start sites of new 
constructs. MTS: mitochondrial targeting sequence; TM: transmembrane helix; Ins2/3: 
kinase domain insertions; CTD: C-terminal domain. (B) SDS-PAGE analysis of His-
SUMO-TcPINK1 test expressions. P: insoluble pellet fraction; FT: flow-through not 
bound to nickel resin; E: eluted recombinant His-SUMO-TcPINK1.  
 
4.3.7 Large-scale expression of His-SUMO TcPINK1 150-570 (D359A) 
A large-scale expression of His-SUMO-TcPINK1 150-570 (D359A) was carried out in E. 
coli BL21-CodonPlus cells and recombinant protein was purified by nickel affinity 
chromatography. Further purification was carried out using anion exchange 
chromatography. The chromatogram showed a sharp peak with a small shoulder after. 
SDS-PAGE analysis showed the peak contains TcPINK1 with some contaminants present 
(Figure 4.13A&B). Peak fractions were pooled and the His-SUMO tag was cleaved off. As 
a final purification step, the cleaved protein was subjected to gel filtration. The resulting 
chromatogram shows a single sharp peak with a small preceding shoulder (Figure 4.13C). 
SDS-PAGE analysis showed that both the main peak and shoulder contained TcPINK1 of 
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high purity (Figure 4.13D). Peak fractions were pooled, avoiding the fractions from the 
shoulder.  
 
Figure 4.13: Purification of His-SUMO TcPINK1 150-570 (D359A) 
(A) Chromatogram of HiTrap Q FF column anion exchange purification of His-SUMO-
TcPINK1. Blue trace: UV280 absorbance; green trace: Buffer B gradient. (B) SDS-PAGE 
analysis of anion exchange peak fractions. (C) Chromatogram of S-200 gel filtration 
purification. Blue trace: UV280 absorbance. (D) SDS-PAGE analysis of gel filtration 
fractions containing TcPINK1. 
 
4.3.8 Crystallisation screening of TcPINK1 150-570 (D359A) 
Pooled protein after gel filtration was concentrated to between 1.5 and 4.5 mg/ml.  
Trays were set up with both the native protein and protein pre-incubated with one of the 
following ligands: ATP, ADP or AMP-PNP, all with the counter-ion Mg2+. Since it had 
been previously noted that addition of 10 mM DTT to the gel filtration buffer and β-
mercaptoethanol to the crystallisation reservoir solution led to an increase in crystal size 
(Section 4.3.3), these were present for all crystal screening with TcPINK1 150-570 
(D359A). Initial crystallisation trials of TcPINK1 150-570 (D359A) identified small crystals 
that grew within 2-3 days of setting up screens (Figure 4.14). In general, optimisation of 
Chapter 4 – Crystallisation of a PINK1 orthologue from the insect species Tribolium 
castaneum 
	  
	  
 152 
these hits using both grid and additive screening led to a modest improvement in the size 
of the crystals obtained. As with crystals of the 155-570 (D359A) construct, it was noted 
that the presence and number of crystals was not very sensitive to variation of the 
crystallisation conditions, with crystals usually being seen in most wells of a grid or additive 
screen for any given condition. For a list of crystallisation screens set up with this 
construct, please refer to Appendix 8. The diffraction of crystals grown in a number of 
different conditions was tested and the diffraction limit of each of them was improved 
compared to crystals of the 155-570 construct, typically being around 10 Å (Figure 4.14) 
Further optimisation was carried out but this did not lead to an improvement in diffraction 
resolution. 
 
Figure 4.14: Crystals and diffraction pattern of TcPINK1 150-570 (D359A) 
(A) Representative crystal of TcPINK1 150-570 (D359A). (B) Representative diffraction 
pattern of TcPINK1 150-570 (D359A) crystals.  
 
4.3.9 Testing of alternative cryoprotectants for TcPINK1 150-570 (D359A) crystals 
A critical stage in the preparation of crystals for data collection is the cryoprotection step, 
which allows the crystal to remain intact during freezing to prevent x-ray damage. Incorrect 
cryoprotection can cause an otherwise well-diffracting crystal to diffract poorly. Therefore, 
a number of different cryoprotectants were tested for TcPINK1 150-570 (D359A) crystals 
to see if the diffraction of these crystals was being affected by the use of an incorrect 
cryoprotectant. A diverse range of cryoprotectants was selected and the required 
concentration of each to ensure the crystallisation mother liquor froze as a clear drop, free 
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of ice, was determined. Several crystals were frozen in each cryoprotectant and their 
diffraction was then tested and compared to the diffraction of crystals frozen in the 
original cryoprotectant, 20% 2-methyl-2, 4-pentanediol (MPD). This showed that changing 
the cryoprotectant did not make any dramatic difference to the diffraction limit of 
TcPINK1 crystals (Figure 4.15), since all the crystals tested still only diffracted to around 
10 Å or less.  
 
Figure 4.15: Analysis of the effect of different cryoprotectants on TcPINK1 150-570 
(D359A) crystal diffraction 
(A) Cryoprotection with 20% 2-methyl-2, 4-pentanediol (MPD), (B) 25% dimethyl 
sulfoxide (DMSO), (C) 25% glycerol, (D) saturated Li2SO4, (E) paraffin oil, (F) 35% 
propan-2-ol, (G) 35% sucrose, (H) 35% xylitol.  
 
4.3.10 Lysine methylation of TcPINK1 150-570 (D359A) 
As an additional attempt to improve the diffraction of the crystals obtained, the protein 
was modified by lysine di-methylation, as described in Section 4.3.4. The methylated 
protein was purified by gel filtration to remove aggregates and excess methylation reagents, 
resulting in a sharp peak with a small shoulder (Figure 4.16A). SDS-PAGE analysis showed 
the peak and shoulder contained TcPINK1 (Figure 4.16B). Peak fractions were pooled, 
avoiding contamination with fractions from the shoulder. A sample of methylated protein 
was compared to the unmodified protein. The methylated protein appears to run at a 
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higher molecular weight than the unmodified protein due to the increase in mass caused by 
the addition of methyl groups. No degradation of the methylated sample is visible (Figure 
4.16C). To assess the number of lysine residues modified, a sample was analysed by 
MALDI mass spectrometry (performed by Dr .Stella Ritorto), which confirmed that 26 out 
of 27 lysine residues in TcPINK1 were modified (Figure 4.16D).  
 
The methylated protein was prepared for crystallisation and initial screens were set up at a 
concentration of 1.6 mg/ml in the presence or absence of ADP + Mg2+. Tiny crystals grew 
in several conditions after 2-3 days, but disappeared again after about 1 week, and attempts 
to reproduce these crystals or to find other growth conditions were not successful. For a 
list of crystallisation screens set up with this construct, please refer to Appendix 9. 
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Figure 4.16: Purification of lysine methylated TcPINK1 150-570 (D359A) 
(A) Chromatogram of S-200 purification of methylated TcPINK1. Blue trace: UV280 
absorbance. (B) SDS-PAGE analysis of gel filtration fractions containing TcPINK1. (C) 
SDS-PAGE comparison of TcPINK1 before (-) and after (+) methylation reaction. (D) 
Performed by Dr. Stella Ritorto. MALDI mass spectra of unmethylated (top) and 
methylated (bottom) TcPINK1 showing the masses of the singly charged ions. An increase 
in molecular weight is visible in the methylated sample.  
 
4.3.11 Test expressions of TcPINK1 with the His-SUMO tag system: Constructs 
with N-terminal boundaries between residues 145 and 154 
Since work on TcPINK1 150-570 (D359A) had not led to well diffracting crystals and 
none of the other constructs tested had yielded high-quality protein, more constructs were 
designed and tested. These 7 constructs were designed with N-terminal starting residues 
surrounding aa 150, ranging from aa 145 to 154 (Figure 4.17A). Each of these new 
constructs was expressed on a small scale in E. coli BL21-CodonPlus cells and recombinant 
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protein was purified by nickel affinity chromatography. The yield and purity of each 
construct was judged by SDS-PAGE analysis, showing that each construct expressed to a 
similar level and purity (Figure 4.17B). A large-scale expression and purification of these 
constructs was carried out. Based on the results of this (Appendix 5), no further work was 
done on constructs 147-570 or 152-570. Constructs beginning with amino acids 145, 146 
and 154 were not tested due to a lack of time. Constructs 149-570 and 151-570 were 
chosen for further optimization.  
 
 
Figure 4.17: Test expression of His-SUMO-TcPINK1 (D359A) constructs 
(A) Schematic of TcPINK1 showing region containing N-terminal start sites of new 
constructs. MTS: mitochondrial targeting sequence; TM: transmembrane helix; Ins2/3: 
kinase domain insertions; CTD: C-terminal domain. (B) SDS-PAGE analysis of His-
SUMO-TcPINK1 test expressions. P: insoluble pellet fraction; FT: flow-through not 
bound to nickel resin; E: eluted recombinant His-SUMO-TcPINK1.  
 
4.3.12 Large-scale expression of His-SUMO TcPINK1 149-570 (D359A) and 
preliminary crystallisation screening 
A large-scale expression of His-SUMO-TcPINK1 149-570 (D359A) was carried out in E. 
coli BL21-CodonPlus cells and recombinant protein was purified by nickel affinity 
chromatography. Further purification was carried out using anion exchange 
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chromatography. The chromatogram showed a single peak that tailed towards the end, and 
SDS-PAGE analysis showed the peak contained TcPINK1 with some minor contaminants 
still present (Figure 4.18A&B). Peak fractions were pooled and the His-SUMO tag cleaved 
off. The protein was then further purified by gel filtration, and the resulting chromatogram 
showed a sharp peak with a preceding shoulder (Figure 4.18C). SDS-PAGE analysis 
showed that both the main peak and shoulder contained TcPINK1 of very high purity 
(Figure 4.18D). Peak fractions were pooled, avoiding contamination with fractions from 
the shoulder. Protein was prepared for crystallisation and initial screens were set up at a 
concentration of 1.7 mg/ml in the presence or absence of ADP and Mg2+. For a list of 
crystallisation screens set up with this construct, please refer to Appendix 10. Small crystals 
grew in several conditions after a few days, however further optimization was not carried 
out due to a lack of time.  
 
Figure 4.18: Purification of His-SUMO TcPINK1 149-570 (D359A) 
(A) Chromatogram of HiTrap Q FF column anion exchange purification of His-SUMO-
TcPINK1. Blue trace: UV280 absorbance; green trace: Buffer B gradient. (B) SDS-PAGE 
analysis of anion exchange peak fractions. (C) Chromatogram of S-200 gel filtration 
purification. Blue trace: UV280 absorbance. (D) SDS-PAGE analysis of gel filtration 
fractions containing TcPINK1. 
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4.3.13 Large-scale expression of His-SUMO TcPINK1 151-570 (D359A) and 
preliminary crystallisation screening 
A large-scale expression of His-SUMO-TcPINK1 151-570 (D359A) was carried out in E. 
coli BL21-CodonPlus cells and recombinant protein was purified by nickel affinity 
chromatography. Further purification was carried out using anion exchange 
chromatography. The chromatogram showed a single peak with a shoulder towards the end 
(Figure 4.19A). SDS-PAGE analysis showed the peak contained TcPINK1 with some 
minor contaminants still present (Figure 4.19B). Peak fractions were pooled, avoiding the 
shoulder and the His-SUMO tag was cleaved off. The protein was then further purified by 
gel filtration. The resulting chromatogram shows a sharp peak and SDS-PAGE analysis 
showed the peak contained TcPINK1 of high purity (Figure 4.19C&D). Protein was 
prepared for crystallisation and initial screens were set up at a concentration of 1.7 mg/ml 
in the presence or absence of ADP and Mg2+. For a list of crystallisation screens set up 
with this construct, please refer to Appendix 11. Small crystals grew in several conditions 
after a few days, however a lack of time prevented further optimization of these hits.  
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Figure 4.19: Purification of His-SUMO TcPINK1 151-570 (D359A) 
(A) Chromatogram of HiTrap Q FF column anion exchange purification of His-SUMO-
TcPINK1. Blue trace: UV280 absorbance; green trace: Buffer B gradient. (B) SDS-PAGE 
analysis of anion exchange peak fractions. (C) Chromatogram of S-200 gel filtration 
purification. Blue trace: UV280 absorbance. (D) SDS-PAGE analysis of gel filtration 
fractions containing TcPINK1. 
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4.4 Discussion: 
Several constructs of PINK1 from the species Tribolium castaneum (TcPINK1) were 
expressed in E. coli with a His-SUMO tag and were purified by nickel affinity purification, 
anion exchange and gel filtration to yield protein of a suitable quality for crystallisation 
trials. Many conditions were discovered in which small crystals of TcPINK1 grew. This is, 
to my knowledge, the first successful attempt to obtain PINK1 crystals. However, despite 
extensive optimisation it was not possible to improve the resolution of the TcPINK1 
crystals above ~10 Å and therefore it was not possible to determine the crystal structure of 
TcPINK1.  
 
4.4.1 Why was it not possible to obtain well-diffracting crystals of TcPINK1? 
The key factor for determining how well a crystal diffracts is the uniform or tight packing 
of the protein molecules that form the three-dimensional lattice of the crystal. In practice, 
crystals of macromolecules like proteins or nucleic acids contain irregularities. The 
molecules in protein crystals are held together by weak hydrogen bonding, which gives rise 
to these irregularities in the lattice structure of the crystal. In theory, the lesser this 
irregularity and the more tightly packed the molecules in the crystal, the better a crystal will 
diffract. However, in reality it is often not possible to know why a particular protein fails to 
produce well-diffracting crystals. 
 
Heterogeneity in the protein sample to be used for crystallisation, for example caused by 
post-translational modification (PTMs), oxidation or degradation, can prevent crystal 
growth or lead to poor quality crystals forming. Since it is known that TcPINK1 is able to 
autophosphorylate (Section 3.5), in most cases a kinase inactive mutant that is incapable of 
autophosphorylation was used. When the wild type enzyme was purified, a large shoulder 
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was present on the gel filtration chromatogram that may indicate the presence of protein 
complexes or aggregates in the sample (Figure 4.11). To minimise degradation or oxidation, 
the purification protocol was performed in such a way to minimize the time between cell 
lysis and setting up of crystal trays and in addition, reducing agent was present throughout 
the purification with a higher concentration being used in the gel filtration buffer in which 
the protein was crystallised.  
 
Conformational flexibility of the protein molecules can also interfere with the formation of 
a well-diffracting crystal. TcPINK1 belongs to the protein kinase family, which is well 
known to undergo a dramatic conformational change upon moving from the active to the 
inactive conformation (reviewed in (Huse & Kuriyan, 2002)). The existence of multiple 
protein conformations in a crystallisation sample is likely to be detrimental to the chances 
of obtaining a high quality crystal. To counteract this potential problem, a ligand such as a 
substrate or cofactor, can be included in the crystallisation screen. Binding of such a 
molecule to the protein might lock it into a single conformation and subsequently aid the 
formation of a well-diffracting crystal. All crystallisation screens for TcPINK1 were 
performed both in the presence and absence of a ligand (ADP, ATP and the non-
hydrolysable ATP analog AMP-PNP along with the counter ion Mg2+). Crystal formation 
and diffraction did not seem to be in any way influenced by the presence of these ligands. 
In addition, flexibility or disorder in specific regions of the protein, such as flexible loops, 
can also lead to a poorly diffracting crystal since they can impede tight crystal packing. 
TcPINK1 was selected for crystallisation studies due to its lack of the first insertion in the 
kinase domain and was truncated to remove regions prior to the kinase domain that might 
be disordered. However, it is possible that the remaining second and third insertions might 
be flexible enough to interfere with crystal formation.  
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Charged regions on the surface of the protein molecules cause electrostatic repulsion 
between the protein molecules, preventing them from coming together to form a well-
ordered lattice. One method for circumventing this issue is to modify or remove charged 
surface residues from the target protein, for example by methylation of surface-exposed 
lysine residues, which neutralises their positive charge (Walter et al, 2006). This method 
was applied to TcPINK1 (Figure 4.10 & Figure 4.16) with the majority of lysine residues 
becoming successfully modified, although screening with these modified proteins did not 
yield any crystals. There is a possibility that the reduced surface charge will lead to reduced 
protein solubility and stability. For both the TcPINK1 constructs modified by methylation, 
a shoulder was present on the gel filtration chromatogram (Figure 4.10A & Figure 4.16A) 
that may indicate the presence of aggregated protein.  
 
Finally, an otherwise high quality crystal can end up diffracting poorly due to the way it is 
prepared for a diffraction experiment. It is usual to cool crystals to a very low temperature 
using a liquid nitrogen cryostream during the course of a diffraction experiment to protect 
the crystal from radiation damage. To avoid the water molecules in the mother liquor in 
which the crystal is contained from freezing and destroying the crystal, it is common 
practice to cryoprotect the crystal before freezing (Hope, 1988; Vera & Stura, 2013). 
During cryoprotection, the water molecules surrounding the crystal are partially replaced 
with molecules such as sugars, certain salts or organic compounds that prevent the 
formation of ice and maintains the native structure of the protein molecules in the crystal. 
The crystal can then safely be frozen and placed in the cryostream to keep it cold 
throughout the experiment. Initially, 20% MPD was utilised as a cryoprotectant for 
TcPINK1 crystals, since this compound is present in several of the conditions in which 
TcPINK1 crystals grow. Subsequently, a variety of alternate cryoprotectants were tested, 
however none of these different cryoprotectants led to any improvement in the diffraction 
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of the TcPINK1 crystals (Figure 4.15). This suggests either that crystals of TcPINK1 are of 
low quality, or that they cannot withstand freezing with any of the tested cryoprotectants. 
To determine which is the case, it would be necessary to carry out a diffraction experiment 
at room temperature using unfrozen crystals. If the crystals diffracted well at room 
temperature, then the freezing protocol would need further optimisation. If not, then a 
higher quality crystal form would be required. 
 
4.4.2 What could be done to obtain higher quality TcPINK1 crystals? 
In future, it would be important to try alternate methods to improve the resolution of 
diffraction that are not solely focused on modification of the crystallisation condition itself. 
Mutagenesis of charged residues, in particular lysine and glutamic acid, which are predicted 
to be surface exposed can reduce the entropy of crystal formation and can permit the 
formation of crystal contacts that help hold molecules in the crystal together (Derewenda, 
2004). This approach has been shown to yield well-diffracting crystals of otherwise difficult 
proteins and a web server, SERp, is available to aid in the design of such mutations for a 
given target protein (Goldschmidt et al, 2007). Dehydration of existing crystals has also 
been shown to dramatically improve their diffraction in certain cases. Dehydration of the 
crystal reduces the solvent content and leads to tighter packing of the protein molecules in 
the crystal, which can in turn increase the resolution of diffraction. This dehydration is 
often achieved in a controlled fashion by equilibration of previously grown crystals in a 
small drop against a larger reservoir of a dehydrating solution. This leads to transfer of 
water from the small drop to the reservoir and if performed in incremental steps over a 
sufficiently long period of time can lead to dehydration of the crystal without damage 
(Hagelueken et al, 2012; Heras et al, 2003). An alternative, more hi-tech approach is the use 
of a humidity-controlled beamline at a synchrotron facility, which allows alteration of the 
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humidity of the gas surrounding a mounted crystal (Russi et al, 2011). In short, incremental 
changes in humidity can be made and the diffraction of the crystal (or crystals, since these 
experiments often require multiple crystals) can be assessed at each stage. If a positive 
change is observed, a higher-resolution dataset can then be collected at the required relative 
humidity.  
 
Many constructs were tested in the course of identifying those that yielded protein of a 
sufficient quality to begin crystallisation trials. The identification of the optimal construct is 
not always straightforward, as in this case where many of the constructs initially tested 
expressed to the same level and purity and could only be assessed properly after further 
purification attempts. The two most successful constructs, 150-570 and 155-570 both have 
their N-terminal start sites around the beginning of the TcPINK1 kinase domain. Two 
further constructs were tested briefly, 149-570 and 151-470 and appear to behave very 
similarly to the 150-570 construct (Figure 4.18 & Figure 4.19). Nevertheless, in future it 
would be important not only to continue work with these constructs, but to also continue 
testing additional new constructs since the difference between success and failure can be in 
the presence or absence of only one or two extra amino acids.  It would also be possible to 
continue exploiting the approach of using PINK1 orthologues from different species in 
order to increase the chances of obtaining well-diffracting PINK1 crystals. TcPINK1 was 
selected for this study due to its lack of the variable first insertion within the kinase 
domain, however other criteria could be used to select potential targets for crystallization. 
PINK1 is present in many other organisms that are more closely related to humans, such 
as fish or mammals, as well as those that are more distantly related, such as the nematode 
worm Caenorhabditis elegans. Selecting PINK1 orthologues from a range of different 
branches of the animal kingdom might maximize the chances of success. 
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4.4.3 What are the predicted structural effects of Parkinson’s disease-linked 
PINK1 mutations? 
Although it was not possible to determine the crystal structure of TcPINK1, it is still 
possible to rationalize the likely structural effects of Parkinson’s disease-linked mutations 
found within the protein kinase domain. The protein kinase fold is highly conserved 
amongst all members of the family, with invariant secondary structure elements being 
present in all but the most atypical kinases (Hanks & Hunter, 1995). In addition, multiple 
structures of protein kinases have been determined and extensive studies on the functional 
role of many conserved motifs and features had been carried out. There is therefore a 
wealth of information on how kinase structure informs function and activity. Therefore by 
comparing the primary amino acid sequence of PINK1 to one of the most well-
characterised protein kinases, PKA (cAMP-dependent protein kinase) it is possible to 
speculate how mutations within the PINK1 kinase domain might disrupt its function. 
Almost 100 sequence variants of PINK1 have been described (Appendix 1), however only 
those that are found in Parkinson’s patients in either the homozygous or compound 
heterozygous state can be unequivocally linked to Parkinson’s disease. Only the likely 
structural effects of selected PINK1 heterozygous or compound homozygous PINK1 
mutations will be discussed further.  
 
To use the available knowledge relating to PKA to understand the potential effect of PD-
linked mutations on PINK1, it is necessary to be able to directly compare the sequences of 
PKA and hPINK1. To this end, an alignment of the kinase domains of PINK1 and PKA 
was prepared (Figure 4.20), showing the locations of each of the PINK1 disease mutations. 
In addition, conserved kinase motifs, the secondary structure of PKA (based on PDB ID: 
1ATP (Zheng et al, 1993)) and kinase subdomain boundaries are annotated to allow easy 
comparison between the two proteins. 
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Figure 4.20: Sequence alignment of the kinase domains of PKA and human PINK1 
Conserved kinase motifs are coloured as follows: Gly-rich loop: yellow; ATP-binding 
lysine: orange; HRD catalytic motif: red; DFG activation loop anchor: purple; APE 
activation loop anchor: green. PINK1 disease mutations are highlighted in pink and 
labelled (numbering according to hPINK1), residues conserved between hPINK1 and 
PKA are indicated with an asterisk. The secondary structure of PKA and the conserved 
kinase subdomains are shown underneath. Black arrows: β-strands; grey cylinders: α-
helices. PDB ID: 1ATP 
 
Two residues mutated in PD, Val170 (V170G) and Ala217 (A217D), contribute to the 
hydrophobic portion of the ATP binding pocket that accommodates the adenine moiety 
(Hanks & Hunter).  In addition, they form part of a conserved network of hydrophobic 
residues stretching throughout the protein kinase. It begins at the C-terminus of the αF 
helix, traverses both the N- and C-lobes, and is known as the catalytic, or C-spine (Kornev 
et al, 2008). Val170 and Ala217 are the most N-terminal of these C-spine residues and 
form the topmost part of the C-spine together with the adenine moiety of ATP (Figure 
4.21A). In this way, assembly of this stabilising structure and therefore the switching of the 
kinase to the active conformation is directly linked to binding of ATP (Kornev et al, 2008).  
Val170 was identified as being mutated to glycine in PD, which is a polar and highly 
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flexible residue, suggesting that this mutation might reduce the hydrophobicity of the 
adenine pocket and/or prevent formation of a rigid C-spine structure. However, the effect 
of this mutation on in vitro kinase activity is not known. Ala217 is mutated to aspartic acid 
in PD, which is a change from a small hydrophobic to a larger and negatively charged 
residue. This would most likely prevent binding of ATP in the ATP binding pocket, and 
would also be disruptive to the formation of the C-spine, explaining why this mutation 
leads to a loss of TcPINK1 kinase activity.  
 
Residue Glu240 (E240K) forms an important ionic interaction that stabilises the N-lobe in 
the ATP-bound conformation (Hanks & Hunter, 1995). It is located in the αC helix and 
forms a salt bridge with another highly conserved N-lobe residue, K219, found in β3, 
which interacts with the α- and β-phosphates of the ATP molecule, orientating it properly 
for catalysis (Figure 4.21B). The formation of this bond is critical for kinase activity and so 
it is not surprising that the PD-linked mutation of Glu240 to lysine, which has the opposite 
charge, leads to a complete loss of kinase activity.  
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Figure 4.21: Depiction of the structure of PKA in the active conformation showing 
selected residues and motifs homologous to PD-mutated residues in PINK1 
(A) Structure of PKA depicting the catalytic spine (C-spine). Residues that make up the C-
spine are shown as spheres and are coloured according to the secondary structure element 
they reside in – blue: β2 strand; teal: β3 strand; orange: β6 strand; yellow: αD helix; 
raspberry: αF helix. The adenine moiety of ATP that completes the C-spine is depicted as 
cyan spheres. Amino acid V57 is V170 in hPINK1, V170G in PD, A70 is A217/A217G. 
(B) The K72-E91 ionic interaction in PKA (equivalent to K219-E240 in hPINK1, E240 is 
E240K in PD). PKA is shown in cartoon representation. The αC helix and E91 are shown 
in green, and the β3 strand and K72 are shown in teal. Interactions between these residues 
and ATP (orange/cyan sticks) are shown in red. In both figures, PDB ID: 1ATP.  
 
Gly386 (G386A) is part of the DFG motif, which makes up the N-terminal anchor of the 
kinase activation loop. This residue has been shown to undergo a dramatic rotation of its 
main chain upon a kinase adopting the inactive conformation (Kornev et al, 2006), with its 
dihedral phi-angle changing by approximately 140°. This rotation leads to a change in 
conformation of the nearby aspartic acid, preventing it from coordinating the ATP-
stabilising Mg2+ ions, and breaks a hydrogen bond between this residue and the Gly386 
main chain (Figure 4.22). In this way, the conformation of this glycine residue acts as a 
switch between the active and inactive conformations and only glycine is able to undergo 
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the extreme rotation necessary for this due to its lack of a side chain (Kornev et al, 2006). 
Gly386 is mutated to alanine in PD and leads to a loss of kinase activity. Despite the small 
size of the alanine side chain, it would not be able to undergo the required drastic 
conformational change and would prevent PINK1 from moving between the active and 
inactive conformations.  
 
Figure 4.22: Conformation of the magnesium loop segment in both active and 
inactive PKA structures 
(A) Active PKA segment is shown as sticks. G186 (G386 in hPINK1) forms a hydrogen 
bond (shown in red) via its main chain with D184 (384 in hPINK1). Phi and psi angles 
(shown in red) for G186 are -52 and -32 respectively. PDB ID: 1ATP (B) Upon assuming 
the inactive conformation, the main chain of G186 undergoes a dramatic twist. The phi 
and psi angles of this residue are now -87 and 106 respectively. The hydrogen bond 
between G186 and D184 is broken. PDB ID: 4DFY 
 
Residue Glu417 (E417G) is predicted to form a salt bridge to another highly conserved 
residue, Arg497 (Arg280 in PKA), which helps stabilise the C-lobe of the kinase and which 
has been shown to be essential for maximal kinase activity (Figure 4.23A) (Yang et al, 
2012). PD-linked mutation of this residue to glycine leads to a loss of this bond since 
glycine is not capable of forming the necessary ionic interaction and therefore a loss of 
PINK1 kinase activity.  
Residues Trp437 (W437R) and Gly440 (G440E) are both found in the αF helix and their 
homologous residues in PKA, along with several other hydrophobic residues, form a tight 
interaction with residues from the αH helix, including Leu489 (L489P), also mutated in PD 
(Figure 4.23). This interaction between the αF and αH helix is critical for stabilising the 
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hydrophobic core of the protein, based around the αF helix. This helix is the nucleation 
site for the previously mentioned C-spine, and also for another similar hydrophobic 
network of residues that come together in a manner dependent on activation loop 
conformation, the R-spine (Kornev et al, 2008). Stability of the αF helix is therefore 
important for the subsequent ability of the kinase to assume the active conformation. 
Trp437 is a highly conserved residue that not only interacts with the αH helix, but also 
interacts with and stabilises the alanine and proline of the APE motif (Kornev et al, 2008). 
Trp437 is mutated to arginine in PD, changing a large hydrophobic residue to a positively 
charged one. Although the effect of this substitution on PINK1 activity is unknown, it 
seems likely that the substitution of an amino acid forming such critical interactions would 
lead to a loss of activity. Gly440 is strongly conserved throughout protein kinases and 
analysis of the structure of PKA (Zheng et al, 1993) shows that its tiny side chain allows 
the formation of a pocket for a nearby leucine residue (Kornev et al, 2008). Therefore, the 
PD-linked mutation of Gly440 to glutamic acid, a large, negatively charged residue would 
completely disrupt this hydrophobic arrangement and lead to the observed loss of kinase 
activity. Leu489 is found in the αH helix and helps form a hydrophobic shield surrounding 
the αF helix (Kornev et al, 2008). This residue is mutated to proline in PD and leads to a 
loss of kinase activity, presumably due to destabilization of the interface between the αF 
and αH helices. 
 
 
Chapter 4 – Crystallisation of a PINK1 orthologue from the insect species Tribolium 
castaneum 
	  
	  
 171 
 
Figure 4.23: Depiction of the structure of PKA in the active conformation showing 
residues and motifs homologous to PD-mutated residues in hPINK1 
(A) Stabilising interaction between E208 and R280 in PKA (E417 and R497 in hPINK1, 
E417G in PD). The structure of PKA is shown in cartoon representation. The APE motif 
is coloured cyan and E208 is shown in cyan sticks. R280 is shown in white sticks and the 
hydrogen bond between the two residues is shown in red. Secondary structure elements of 
the C-lobe are labeled and coloured as follows: αE helix: orange; P-loop/activation loop: 
pale cyan; αF helix: dark red; αG helix: violet; αH helix: purple; αI helix: indigo. (B) 
Stabilising interaction between αF and αH helices. The structure of PKA is shown in 
cartoon representation. Contributing residues from the αF and αH helices are coloured 
pink and purple respectively and shown as spheres. PKA equivalents of residues mutated 
in PINK1 are labeled as follows: W222, dark pink, is hPINK1 W437, W347R in PD; G225, 
light pink, is hPINK1 G440, G440E in PD; L272, partially hidden and light purple, is 
hPINK1 L489, L489P in PD. The lack of space for a larger side chain in the space 
occupied by G225 is visible. For both figures, PDB ID: 1ATP 
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4.5 Conclusions 
After the discovery of PINK1 from the insect species Tribolium castaneum (TcPINK1) as a 
valid and well-characterised model for human PINK1 (hPINK1), it has been possible for 
the first time to obtain highly pure PINK1 protein and furthermore to conduct 
crystallisation screens with this protein. Several constructs were tested that yielded crystals 
growing in multiple conditions. The diffraction of these crystals was poor and despite 
extensive optimisation attempts, it was not possible to overcome this problem and as a 
result the structure of TcPINK1 has not yet been determined.  The crystal structure of 
PINK1 would resolve many unanswered questions, such as the structure and topology of 
the unique PINK1 insertions and C-terminal domain and furthermore their functional role, 
which can sometimes be understood from the structure. In addition it would provide a 
conclusive explanation for the effect of PD-linked mutations.  
 
However, there are some questions that it is possible to speculate upon even in the absence 
of a PINK1 crystal structure. There is a wealth of knowledge about the structure and 
function of protein kinases, from the role of individual amino acids and motifs to whole 
networks of residues and structural elements. This information can be transferred to even 
distantly related kinases such as PINK1 due to the high conservation of the protein kinase 
fold. Even in the absence of strong sequence similarity, many features are universally 
present in all kinases and much can be understood from analyzing these differences and 
similarities.  
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5 Regulation of Parkin by PINK1 phosphorylation of the Ubl 
domain and ubiquitin 
5.1 Introduction 
Parkin is a ubiquitin E3 ligase which, like PINK1, was first linked to Parkinson’s disease 
through genetic analysis of familial cases (Kitada et al, 1998). Moreover, Parkin mutations 
are numerically significant and represent the most common cause of autosomal recessive 
Parkinson’s disease. Cell biological analyses have implicated Parkin along with PINK1 in 
the regulation of mitophagy, ensuring damaged mitochondria are removed from the cell 
(Matsuda et al, 2010; Narendra et al, 2008; Narendra et al, 2010; Okatsu et al, 2012). 
PINK1 is constitutively degraded under normal conditions and Parkin is kept in an 
autoinhibited, inactive state. However, when the mitochondrial membrane potential is lost, 
PINK1 becomes stabilised and this leads to recruitment of Parkin from the cytosol to the 
mitochondria, where it then becomes activated. Although the mechanism of Parkin 
recruitment is unknown, it has been shown that PINK1 regulates the activity of Parkin by 
phosphorylation, leading to its activation. PINK1 exerts a dual regulatory effect over 
Parkin activity. Firstly, it phosphorylates Parkin at residue Ser65 in its N-terminal Ubl 
(ubiquitin-like) domain (Kondapalli et al, 2012), and secondly it phosphorylates ubiquitin, 
also at Ser65 (Kane et al, 2014; Kazlauskaite et al, 2014b; Koyano et al, 2014). Examination 
of the crystal structure of ubiquitin (Vijay-Kumar et al, 1987) and the solution NMR 
structure of the isolated Ubl domain (Sakata et al, 2003) shows that Ser65 is located in the 
same position in these two proteins, which is not surprising since they both share the 
conserved ubiquitin fold (Appendix 12). The effect of both of these phosphorylation 
events in vitro is to activate Parkin, with each individual phosphorylation leading to a degree 
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of activation and maximal activation being achieved when both sites are phosphorylated 
(Kazlauskaite et al, 2014b; Ordureau et al, 2014).  
 
The precise mechanism by which this activation occurs is unclear, however a small amount 
of information is available. Multiple crystal structures of Parkin have recently been 
determined, including several high-resolution truncated structures lacking the Ubl domain 
(Riley et al, 2013; Spratt et al, 2013; Trempe et al, 2013; Wauer & Komander, 2013) and a 
lower-resolution full-length structure (Trempe et al, 2013). From the examination of these 
structures, it has become apparent that multiple intramolecular interactions keep Parkin in 
a complex autoinhibited state (Figure 5.1). An interaction between the RING0 domain and 
the RING2 domain obscures the catalytic cysteine, Cys431, and an interaction between the 
Ubl domain, RING1 domain and the REP (regulatory element of Parkin) helix blocks what 
is predicted to be the E2 binding site (Trempe et al, 2013). In addition, modelling of a 
Parkin:E2~Ub complex showed that the active sites of the E2 (UBE2D2) and Parkin 
would be around 50 Å apart, with the active site of the E2 pointing away from the Parkin 
active site (Wauer & Komander, 2013). This data suggests that significant conformational 
rearrangements must occur to bring Parkin into a conformation that is catalytically 
competent; firstly making the E2 binding site accessible, followed by E2 binding and 
subsequently the E2 and E3 active sites moving in close enough proximity to allow 
ubiquitin transfer to occur.  
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Figure 5.1: Crystal structure of autoinhibited full-length Parkin showing the 
location of Ser65, Cys431 and potential E2 binding site 
Turquoise: Ubl domain; green: RING0; gold: RING1; pink: IBR; red: REP helix; blue: 
RING2. Ser65 is shown as pink sticks, Cys431 is shown as orange sticks. Zinc ions are 
shown as grey spheres. The predicted E2 binding region (Wauer & Komander, 2013) is 
shown with a red dotted circle. PDB ID: 4K95. 
 
Since PINK1 phosphorylation of the Ubl domain and ubiquitin is sufficient to activate 
Parkin, these rearrangements must be mediated by these two phosphorylation events. An 
initial hypothesis proposed that opening of the Parkin structure was mediated by 
electrostatic repulsion between the PINK1-phosphorylated Ubl domain and the RING0 
domain. However, examination of the full-length, low resolution Parkin structure shows 
that the PINK1 phosphorylation site, Ser65, is not found at the interface between the Ubl 
and the RING1 domain (Figure 5.1). This suggests that the initial hypothesis was incorrect 
and a more complex mechanism must be responsible. Further examination of the Parkin 
structure suggests how this might occur.   
 
Three basic regions (referred to as pocket 1, 2 and 3) on the surface of Parkin that bind to 
negatively charged sulphate ions are visible in the crystal structure (Figure 5.2). Pocket 1 is 
specifically highlighted in one of the papers describing a truncated Parkin crystal structure, 
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where the authors suggest it might be responsible for recruitment of Parkin to the 
mitochondria via the binding of PINK1 autophosphorylation sites (Wauer & Komander, 
2013). However, such pockets could also plausibly act as binding sites for the 
phosphorylated Ubl domain or phospho-ubiquitin. Binding of one of these phosphorylated 
ligands might serve as a mechanism by which the activating phosphorylation signal could 
be spread throughout the Parkin molecule and lead to the required conformational 
changes.  
 
Pocket 1 consists of residues K161, R163 and K211, all of which are located in the RING0 
domain. Interestingly, two PD-linked Parkin mutations, K161N and K211N, affect 
residues found in pocket 1 and have been shown to prevent the mitochondrial localisation 
of Parkin (Matsuda et al, 2010). This makes pocket 1 a likely candidate for a regulatory 
binding site. Pocket 2 consists of residues K151, H302, R305 and Q316. K151 is in the 
RING0 domain, the remaining residues are found in the RING1 domain, with pocket 2 
being situated at an interface between these two domains. This makes pocket 2 interesting 
since any regulatory binding event here would involve both RING1, where the E2 binds, 
and RING0, which blocks the active site. Finally pocket 3 consists solely of residue R455 
and forms only a superficial surface interaction with a sulphate ion in the crystal structure. 
For this reason, it is unlikely to act as a binding site for phospho-proteins. The amino acid 
residues making up each of these pockets are highly conserved between species, further 
indicating that they might be of functional relevance (Appendix 13).   
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Figure 5.2: Crystal structure of ΔUbl Parkin showing potential phosphate binding 
pockets 
Main panel shows the cartoon structure of ΔUbl Parkin and the location of bound sulphate 
ions. Green: RING0; gold: RING1; pink: IBR; red: REP helix; blue: RING2. Sulphate ions 
are shown as yellow/red spheres and zinc ions are shown as grey spheres. Inset panels 
show residues forming each of the putative phosphate-binding pockets. Colouring is the 
same as in the main panel. PDB ID: 4BM9. 
 
In order to understand more about the regulation of Parkin by PINK1, it was decided to 
study the binding of the phospho-Ubl domain to Parkin. In order to do this, it was 
necessary to produce a supply of homogeneous Ser65-phosphorylated Ubl domain, which 
was attempted by two different methods.  
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5.2 Production of Ser65-phosphorylated Ubl domain 
5.2.1 Anion exchange purification of Ser65-phosphorylated Ubl domain 
The Ubl domain of Parkin (1-76) was overexpressed in E. coli with a His-SUMO tag and 
purified using nickel affinity chromatography and cation exchange. It was subsequently 
phosphorylated with MBP-TcPINK1 128-570. After phosphorylation, the Ubl domain was 
separated from MBP-TcPINK1 using a centrifugal concentrator. The resulting mixture of 
phospho and de-phospho Ubl domain was then further purified with high-resolution anion 
exchange chromatography, yielding several peaks with baseline separation, corresponding 
to the phospho and de-phospho Ubl domain and a contaminant. The purity of each peak 
was assessed by immunoblotting and SDS-PAGE analysis (Figure 5.3). Western blot 
analysis showed that both the first and second peaks contained phosphorylated Ubl 
domain.  
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Figure 5.3: Ion exchange purification of in v i tro  Ser65-phosphorylated Ubl domain 
(A) Chromatogram of ion exchange purification. Blue: UV280 absorbance; green: % buffer 
B. (B) SDS-PAGE analysis of fractions from ion exchange purification. (C) Western 
blotting of protein-containing fractions from (B). Top panel: phospho-Ser65 antibody. 
Bottom panel: total anti-Parkin antibody.  
 
In order to determine what proportion of each peak was phosphorylated, MALDI mass 
spectrometry was carried out on samples from each of the peak fractions. This revealed 
that the input sample contained approximately a 1:1 ratio of phospho- to dephospho-Ubl. 
The first peak (fractions A3-A5, A9-A11) contained a mixture of phospho and dephospho-
Ubl and the second peak contained only phospho-Ubl domain (Figure 5.4). A trace 
quantity of dephospho-Ubl domain was present in the most concentrated fraction (B10) 
from the second peak.  This purification was repeated several times with similar results, 
showing that the purification of homogeneous phospho-Ubl domain is possible. However, 
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the yield was very low, with only around 200-500 µg of pure phosphorylated protein being 
obtained using starting material from a 12 L E. coli culture.  
 
Figure 5.4: MALDI analysis of ion exchange fractions from Ser65-phosphorylated 
Ubl domain purification  
Performed by Dr. Stella Ritorto. Input: Protein before high-resolution anion exchange 
purification. Fractions A3-A5, A9-A11: Peak 1; Fractions B8-B11: Peak 2.  
 
5.2.2 Production of Ser65-phosphorylated Ubl domain using genetically encoded 
phosphoserine incorporation 
In recent years it has become possible to genetically engineer organisms such as E. coli to 
allow them to utilise an expanded genetic code and subsequently to incorporate non-
natural amino acids into proteins as they are synthesised by the ribosome (Chin, 2014). 
This technology has been applied to allow the insertion of phosphoserine (Sep) into a 
target protein, permitting the expression of phosphorylated proteins and the study of their 
properties (Park et al, 2011). This method provides several advantages compared to 
Chapter 5 – Regulation of Parkin by PINK1 phosphorylation of the Ubl domain and 
ubiquitin 
	  
	  
 182 
previous approaches used to study the effects of phosphorylation. An upstream kinase to 
phosphorylate the target protein is not required and the introduction of phosphoserine 
accurately recapitulates the effects of biological phosphorylation, whereas the commonly 
used serine/threonine to glutamic acid phosphomimetic mutation often does not. 
Phosphoserine has been successfully inserted into GFP (green fluorescent protein), WNK4 
(with no lysine 4) and MEK1 (mitogen activated ERK-activating kinase 1) (Heinemann et 
al, 2012; Park et al, 2011). In particular, it has been shown that MEK1 with Sep inserted at 
a physiological phosphorylation site is many times more active than both the wild type 
protein and the corresponding glutamic acid mutant, validating the utility of this approach 
(Park et al, 2011). 
 
Sep insertion into recombinant proteins is achieved by repurposing the amber stop codon 
(TAG/UAG) to encode for the anticodon of an orthogonal tRNA conjugated to Sep 
(tRNASep) that can then be used for protein synthesis (Figure 5.5). An orthogonal 
aminoacyl tRNA synthetase (SepRS) has been produced that allows the synthesis of 
tRNASep along with an EF-Tu (Elongation factor-Tu) that has been engineered to accept 
tRNASep (EF-Sep) and allow its incorporation into polypeptides (Park et al, 2011). Further 
improvements to this system resulted in the EcAR7 strain of E. coli, which has the gene 
encoding RF-1 (release factor-1) knocked out. RF-1 terminates polypeptide synthesis at 
amber stop codons (TAG) and its absence should increase the efficiency of Sep-containing 
protein synthesis. In addition, the terminating TAG codons of seven essential genes are 
reassigned to TAA to counteract the lethality associated with RF-1 knockout (Heinemann 
et al, 2012).  
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Figure 5.5: Schematic of Sep insertion into recombinant proteins 
An orthogonal aminoacyl tRNA synthetase (RS-Sep, olive) synthesizes tRNASep from the 
cellular pool of orthogonal tRNA (black clover-leaf shape) and Sep (green sphere). tRNASep 
then pairs with the amber stop codon on an mRNA molecule and Sep is incorporated into 
the nascent polypeptide (grey spheres) by the ribosome (not pictured) and an elongation 
factor that has been modified to accept tRNASep (EF-Sep, blue). 
 
In collaboration with the laboratory of Dr. Jesse Rinehart (Yale University), who provided 
reagents, this technology was applied to the Ubl domain of Parkin to generate Ser65-
phosphorylated Ubl domain (Sep65 Ubl, to distinguish from in vitro-phosphorylated Ubl 
domain). A GST-tagged Ubl domain construct (1-76) containing a TAG codon for residue 
65 was transformed into EcAR7 cells along with a plasmid carrying the orthogonal tRNA, 
RS-Sep and EF-Sep. Recombinant GST-Sep65 Ubl domain was expressed and purified 
with glutathione resin. The GST tag was removed overnight with GST-PreScission 
protease (GST-PP) and the resulting cleaved protein was then eluted. This was done in 
parallel with the wild type GST-Ubl domain in order to compare the yield, purity and levels 
of Sep incorporation achieved. Both wild type and Sep65 Ubl domain were obtained, 
however they were contaminated with the cleaved GST tag and GST-PP (Figure 5.6). 
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Figure 5.6: Recombinant expression of Ubl and Sep65 Ubl in EcAR7 cells 
(A) Expression and purification of wild type Ubl domain. (B) Expression and purification 
of Sep65 Ubl domain. P: insoluble pellet fraction; FT: flowthrough not bound to 
glutathione resin; E1-4: eluted fractions 1-4; GST-PP: GST-PreScission protease. 
 
In order to confirm the phosphorylation of the Sep65 Ubl domain, both the wild type and 
Sep65 Ubl domain proteins were analysed by LC-MS to determine their precise molecular 
weights (Figure 5.7). This analysis revealed that the wild type Ubl domain had the expected 
molecular weight of 9235 Da. However, the Sep65 Ubl sample contained a mixture of two 
different species.  One of these was the Sep65 Ubl domain, with a molecular weight of 
9315 Da. The other was Ubl domain in which the Sep incorporation site had been skipped 
by the translation machinery, producing a shorter protein lacking the phosphoserine with a 
molecular weight of 9148 Da. There was a significant quantity of the skipped Ubl domain 
present in the Sep65 Ubl sample, suggesting that this technology is not currently suitable 
for producing pure and homogeneously phosphorylated Ubl domain.  
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Figure 5.7: LC-MS analysis of wild type and Sep65 Ubl domain  
(A) Mass spectra of wild type Ubl domain sample. Inset shows deconvoluted spectrum and 
observed molecular weight. (B) Mass spectra of Sep65 Ubl domain sample. Top panel 
corresponds to peak containing Sep65 Ubl domain. Deconvoluted spectrum and observed 
molecular weight shown in inset. Bottom panel corresponds to peak containing Ubl 
domain with 65 position skipped. Deconvoluted spectrum and observed molecular weight 
shown in inset. (C) Table showing observed and expected molecular weights of all Ubl 
species observed.  
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5.3 Analysis of binding of the phospho-Ubl domain to Parkin  
5.3.1 Establishment of the AlphaScreen assay to study binding to ΔUbl Parkin 
Ser65-phosphorylated Ubl domain that had been phosphorylated in vitro with TcPINK1 
and purified by ion exchange (Section 5.2.1) was used in studies to determine whether the 
phospho-Ubl domain is capable of binding to the same site on Parkin occupied by the 
non-phosphorylated Ubl domain. In order to determine this, an AlphaScreen assay was 
established and employed (Figure 5.8). Dr. Jinwei Zhang performed all AlphaScreen 
experiments described in this thesis.  
 
The methodology and applications of the AlphaScreen assay, including the measurement of 
protein-protein interactions, are reviewed in (Taouji et al, 2009). The AlphaScreen is a 
bead-based proximity assay whereby two tagged proteins, in this instance GST-Ubl (1-76) 
and ΔUbl Parkin-biotin (80-465), are incubated with each other and subsequently with two 
types of bead; the donor beads (streptavidin-coated) and the acceptor beads (glutathione-
coated). If the two proteins interact, the two beads are brought into close proximity via 
binding between their coatings and the protein affinity tags. The donor bead can be excited 
with a wavelength of 680 nm, leading to the generation of singlet oxygen (an excited state 
of O2). This can diffuse for up to 200 nm in solution and if the acceptor bead is within that 
radius (i.e. if the two proteins are interacting), then the acceptor bead will be stimulated to 
emit light at 520-620 nm. This assay can be further utilised to test the binding of an 
additional ligand to either component. For example, if untagged Ubl domain was added, it 
would compete out the GST-Ubl by binding to ΔUbl Parkin-Biotin, reducing the 
fluorescent signal. If a ligand is added and no binding occurs, no loss of fluorescent signal 
will be seen.  
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Figure 5.8: Schematic of AlphaScreen assay 
Two tagged proteins (GST and biotin tags) are mixed together and are then incubated with 
glutathione-coated donor beads and streptavidin-coated acceptor beads. If the proteins 
interact, the donor and acceptor beads will be brought into close proximity and excitation 
of the donor bead will transfer to the acceptor bead, leading to a signal being emitted.  
 
 
Before utilising the AlphaScreen to study the binding between Parkin and the phospho-Ubl 
domain, the validity and specificity of this assay was established. In order to determine that 
the assay was suitable for measuring interactions between Parkin and the Ubl domain, wild 
type GST-tagged Ubl domain and ΔUbl Parkin-biotin were incubated together at a 
constant concentration and the concentration of untagged wild type Ubl domain was 
increased. As expected, as the concentration of untagged Ubl domain added to the assay 
increased, the fluorescent signal measured was decreased, demonstrating that untagged Ubl 
domain is able to compete out the interaction between the GST-Ubl domain and ΔUbl 
Parkin-biotin (Figure 5.9A&C). To test the specificity of this assay, the same experiment 
was repeated but with the addition of an unrelated protein, SrtA (Sortase A), in the place of 
untagged Ubl. The addition of SrtA to the assay did not lead to any decrease in the 
fluorescent signal measured (Figure 5.9B). This indicates that SrtA is not able to displace 
the GST-Ubl domain from ΔUbl Parkin-biotin and therefore that any displacement seen in 
this assay is the result of a specific interaction between Parkin and the titrated protein.  
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Figure 5.9: Establishment of AlphaScreen assay  
Performed by Dr. Jinwei Zhang (A) Raw data showing fluorescent signal generated by 
interaction between GST-Ubl (0.3 µM) and ΔUbl Parkin-biotin (0.1 µM) as increasing 
concentrations of Ubl (0.1 – 10 µM) are added. (B) Raw data showing fluorescent signal 
generated by interaction between GST-Ubl (0.3 µM) and ΔUbl Parkin-biotin (0.1 µM) as 
increasing concentrations of His-SrtA  (0.1 – 10 µM) are added. (C) Processed data 
showing kinetics of displacement of GST-Ubl by untagged Ubl domain, with an IC50 value 
of 1.64 µM. (D) SDS-PAGE showing proteins used in this study. BAP: biotin acceptor 
peptide.  
 
 
5.3.2 Analysis of the binding of the phospho-Ubl domain to Parkin 
Subsequently, the AlphaScreen assay was used to determine if the phospho-Ubl domain 
was able to displace the binding of the GST-Ubl domain from ΔUbl Parkin-biotin. Wild 
type untagged Ubl domain was used as a control, as this has been shown to displace the 
GST-tagged Ubl domain from ΔUbl Parkin (Figure 5.9). In addition, unphosphorylated 
Ubl domain from the first peak of the anion exchange purification (Figure 5.3) was 
included to confirm that this step had not altered the properties of the Ubl domain. The 
concentrations of ΔUbl Parkin-biotin and GST-Ubl were kept constant, the concentration 
of either wild type or phospho-Ubl was increased and the fluorescent signal was measured. 
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IC50 values for the wild type and phosphorylated Ubl domain were determined, indicating 
the concentration required to displace 50% of the GST-Ubl domain from ΔUbl Parkin. 
This experiment revealed that the wild type Ubl domain is able to displace GST-Ubl 
binding from ΔUbl Parkin and has an IC50 of 2.95 µM (Figure 5.10A&D). Likewise, the 
dephospho-Ubl from the anion exchange purification was able to displace GST-Ubl from 
ΔUbl Parkin with an IC50 value of 6.18 µM (Figure 5.10B&E), suggesting that the anion 
exchange procedure had not interfered with the integrity of the Ubl domain. In contrast, 
the Ser65-phosphorylated Ubl domain was completely unable to displace the GST-Ubl 
from ΔUbl Parkin (Figure 5.10C) and so an IC50 value could not be determined.  
 
Figure 5.10: Measurement of interactions between ΔUbl Parkin and wild type and 
Ser65-phosphorylated Ubl domain 
Performed by Dr. Jinwei Zhang (A) Raw data showing fluorescent signal generated by 
interaction between GST-Ubl (0.3 µM) and ΔUbl Parkin-biotin (0.1 µM) as increasing 
concentrations of Ubl (0.1 – 10 µM) are added. (B) Raw data showing fluorescent signal 
generated by interaction between GST-Ubl (0.3 µM) and ΔUbl Parkin-biotin (0.1 µM) as 
increasing concentrations of Ubl from pooled ion exchange fractions (A6 & A7) (0.1 – 12 
µM) are added. (C) Raw data showing fluorescent signal generated by interaction between 
GST-Ubl (0.3 µM) and ΔUbl Parkin-biotin (0.1 µM) as increasing concentrations of Ser65 
phospho-Ubl from pooled ion exchange fractions (B8 & B9) (0.1 – 10 µM) are added. (D) 
Processed data showing kinetics of displacement of GST-Ubl by untagged Ubl domain, 
with an IC50 value of 2.95 µM. (E) Processed data showing kinetics of displacement of 
GST-Ubl by untagged Ubl domain (fractions A6 & A7), with an IC50 value of 6.18 µM. (F) 
SDS-PAGE of Ubl proteins used in this experiment.  
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5.4 Discussion 
It has been shown that PINK1 is able to activate the E3 ligase activity of Parkin in two 
ways: by phosphorylating Parkin in its N-terminal Ubl domain and by phosphorylating 
ubiquitin. Both of these PINK1 substrates are phosphorylated at residue Ser65 and both of 
these phosphorylation events are required to achieve maximum activation of Parkin. 
However, the molecular mechanisms by which these two phosphoproteins orchestrate 
Parkin activation were unclear. Studies with stoichiometrically phosphorylated Ubl domain 
(Figure 5.3) have demonstrated that phosphorylation of the Ubl domain by PINK1 appears 
to prevent its binding to Parkin at the site where the unphosphorylated Ubl domain 
normally binds (Figure 5.10), most likely the RING1 domain. Studies have shown that 
addition of the phospho-Ubl domain in trans is only able to activate ΔUbl Parkin, not the 
full-length enzyme (Kazlauskaite et al, 2014b). This suggests that the phospho-Ubl domain 
is only able to activate Parkin when the unphosphorylated Ubl domain is not bound to 
Parkin.  
 
These studies, and the AlphaScreen studies described in this thesis (Figure 5.10), were 
conducted with phospho-Ubl domain added in trans to ΔUbl Parkin, whereas the Ubl 
domain in full-length Parkin is fused to the rest of the Parkin protein. An additional study 
utilising PINK1-phosphorylated Parkin and ubiquitin determined that, at least with respect 
to in vitro ubiquitin chain synthesis, phosphorylation of the Ubl domain in intact Parkin 
appears to be the primary Parkin-activating force (Ordureau et al, 2014). The rate constants 
of chain synthesis were 1.5- to 10-fold lower (depending on chain type) when full-length 
Parkin was activated only by phospho-ubiquitin compared to when it was activated by 
near-stoichiometric Ubl domain phosphorylation. Interestingly, it was also shown that 
phospho-Ubl domain addition in trans to ΔUbl Parkin led to weaker activation than the 
addition of phospho-ubiquitin, suggesting that it is important for the phospho-Ubl domain 
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to be contiguous with the rest of the Parkin molecule for it to exert its maximum activating 
effect (Ordureau et al, 2014). This can be explained by the fact that the Ubl domain is 
attached to the rest of Parkin by a flexible linker region and so upon its phosphorylation 
and dissociation from the RING1 domain, it is still tethered to Parkin, greatly increasing 
the effective local concentration and making any subsequent binding event more probable 
compared to when it is added in trans. It was not possible to detect binding of the 
phospho-Ubl to regions outside of the dephospho-Ubl binding site with the AlphaScreen 
methodology and so the binding and subsequent affinity of any interaction between the 
phospho-Ubl and Parkin is not known. In order to determine this, it would be necessary to 
perform further binding studies, such as isothermal calorimetry (ITC), between the 
phospho-Ubl and ΔUbl Parkin, which would mimic the situation in which the Ubl domain 
has already been displaced from its binding site on Parkin after PINK1 phosphorylation.  
 
Molecular dynamics simulations carried out with a model of full-length phosphorylated 
Parkin have suggested that PINK1 phosphorylation of the Ubl domain acts as a trigger to 
begin several rearrangements that lead to Parkin assuming an active conformation 
(Caulfield et al, 2014). The authors of this paper suggest that firstly, the phospho-Ubl 
dissociates from RING1, followed by the REP helix moving away from the E2 site on 
RING1 and finally the RING0 domain moves away from RING2, exposing the catalytic 
cysteine. Interestingly, further simulations of an E2~Ub complex binding to this activated 
Parkin model shows that the bound E2 continues to slide across the surface of Parkin, 
bringing the conjugated ubiquitin molecule in close proximity to the active site cysteine 
(Caulfield et al, 2014). This simulation addresses the issue of the apparent great distance to 
be bridged between the E2 binding site and the active site in the autoinhibited Parkin 
structure (Wauer & Komander, 2013), however it does not take into account the additional 
activating effects of phospho-ubiquitin on Parkin (Kazlauskaite et al, 2014b; Ordureau et 
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al, 2014). Furthermore, studies on the binding of phospho-ubiquitin to Parkin and Ser65- 
phosphorylated Parkin have shown that Ser65 Ubl domain phosphorylation appears to 
increase the affinity of the interaction between phospho-ubiquitin and Parkin by 
approximately 21-fold; phospho-ubiquitin binds to Parkin with an affinity of 365 nM but 
to phospho-Parkin with an affinity of 17 nM, as determined by ITC studies (Ordureau et 
al, 2014).  
 
Several unanswered questions remain. Firstly, what is the affinity of the interaction between 
the isolated phospho-Ubl domain and Parkin and what can be understood from this about 
the differing contributions of phospho-ubiquitin and the phospho-Ubl domain to Parkin 
activation? Secondly, where on Parkin do the phosphorylated Ubl domain and phospho-
ubiquitin bind? The putative phosphate-binding pockets (Figure 5.2) make compelling 
candidates, however, there is currently no data to support this hypothesis. Finally, the 
precise molecular mechanisms by which phospho-ubiquitin and Ubl domain 
phosphorylation lead to the rearrangement of Parkin into an active conformation remain to 
be defined.  
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5.5 Conclusions: 
For many years there has been accumulating evidence pointing towards a link between 
PINK1 and Parkin, beginning with the observed similarity between the respective patient 
phenotypes and continuing with the genetic link established by studies in Drosophila. 
Further pieces of this puzzle fell into place when it was discovered that PINK1 and Parkin 
act as a mitochondrial surveillance system, with PINK1 recruiting Parkin to damaged 
mitochondria and eventually with the discovery that PINK1 directly regulates Parkin 
activity by phosphorylation in its N-terminal Ubl domain. A further twist was added to this 
mechanism by the discovery that PINK1 also phosphorylates ubiquitin, which then acts in 
an allosteric fashion to control Parkin activity. This combination of Ubl domain 
phosphorylation and phosphorylated ubiquitin is known to be necessary for maximum 
Parkin activation, however the molecular mechanism of this activation remains unclear. 
The biophysical studies described in this chapter have provided initial insight, showing that 
phosphorylation of the Ubl domain displaces it from its binding site on Parkin. However, 
much work remains to be done to further unravel the precise events and molecular 
rearrangements that shift Parkin from its autoinhibited to fully active conformation. 
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6 Appendix – List of supporting figures  
	  
	  
 
Figure 6.1 – continued on next page 
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Figure 6.1 – continued on next page 
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Figure 6.1: Full list of reported PINK1 sequence variations 
PINK1 mutations (numbering according to hPINK1) are listed along with mode of 
inheritance (HET: heterozygous; HOM: homozygous; CH: compound heterozygous),  
conservation in TcPINK1, location in TcPINK1 (MTS: mitochondrial targeting sequence; 
TM: transmembrane helix; KD: kinase domain, I-VII: conserved kinase subdomains) and 
any conserved kinase motif affected. PubMed ID (PMID) of the publication describing the 
identification of each variant is also listed. Green: HOM/CH, conserved in TcPINK1; 
orange: HOM/CH, not conserved in TcPINK1. 
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Figure 6.2: PINKtide ScanSite matrix  
(A) Weighted matrix for searching the ScanSite database determined from Figure 3.10 
showing the preference for each amino acid at a given position within a substrate peptide. 
(B) Results from using ScanSite to search SwissProt for mammalian proteins matching the 
matrix shown in (A).  
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Figure 6.3: Effect of Parkinson’s disease-linked mutations in TcPINK1 against 
myelin basic protein 
(A) Full-length MBP-tagged TcPINK1 enzymes containing point mutations (1 µg) were 
incubated in presence of myelin basic protein (5 µg) and [γ32P] ATP for 30 min. Reactions 
were terminated by spotting onto P81 paper, and quantified by scintillation counting. The 
results are presented as ± SD for three experiments undertaken in duplicate (upper panel). 
In the lower panel, representative Coomassie stained gels showing the relative amounts of 
PINK1 enzyme used for each assay are shown. (B) Full-length MBP-tagged TcPINK1 
enzymes containing point mutations (1 µg) were incubated in presence of myelin basic 
protein (5 µg) and [γ32P] ATP for 30 min. Reactions were terminated by spotting onto P81 
paper, and quantified by scintillation counting. The results are presented as ± SD for three 
experiments undertaken in duplicate (upper panel). In the lower panel, representative 
Coomassie stained gels showing the relative amounts of PINK1 enzyme used for each 
assay are shown.  
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Figure 6.4 Activity of Zebrafish PINK1 and TcPINK1 Y419X mutant against Ubl 
domain  
(A) Full-length MBP-tagged wild type, kinase inactive (D372A) ZfPINK1, Y431X mutant 
and TcPINK1 wild type and kinase inactive (D359A) (1µg) were incubated in the presence 
of [γ32P] ATP and Ubl domain (2 µM) for 30 min at 30°C. Assays were terminated by 
addition of loading buffer and separated by SDS-PAGE. Proteins were detected by 
Coomassie staining (upper panel) and incorporation of [γ32P] ATP was detected by 
autoradiography (lower panel). Fine dividing lines indicate that reactions were resolved on 
separate gels and grouped in the final figure. Phosphorylation was quantified by 
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scintillation counting of excised gel bands. (B) Full-length MBP-tagged wild type and 
kinase inactive (D359A) TcPINK1 and Y419X mutant (1µg) were incubated in the 
presence of [γ32P] ATP and MBP (2 µM) for 30 min at 30°C. Assays were terminated by 
addition of loading buffer and separated by SDS-PAGE. Proteins were detected by 
Coomassie staining (upper panel) and incorporation of [γ32P] ATP was detected by 
autoradiography (lower panel). Fine dividing lines indicate that reactions were resolved on 
separate gels and grouped in the final figure. Phosphorylation was quantified by 
scintillation counting of excised gel bands.  
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Figure 6.5 – continued on next page 
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Figure 6.5 – continued on next page 
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Figure 6.5: Purification of His-SUMO TcPINK1 constructs not used for 
crystallization trials 
Anion exchange and gel filtration chromatograms and SDS-PAGE gels for the indicated 
constructs are shown. For chromatograms, blue: absorbance at 280 nm; green: % buffer B. 
For SDS-PAGE gels, Input: protein before purification; FT: flow through not bound to 
column; TcPINK1 peak: peak fractions.  
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Figure 6.6 – continued on next page 
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Figure 6.6: List of crystallization screens set up for TcPINK1 155-570 (D359A) 
The name/type of each screen is given along with ligands included and details in the case 
of grid screens and additive screens. This list is not exhaustive and screens may have been 
set up more than once, for example with variations in protein concentration. 
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Figure 6.7: List of crystallization screens set up for lysine methylated TcPINK1 155-
570 (D359A) 
The name/type of each screen is given along with ligands included and details in the case 
of grid screens and additive screens. This list is not exhaustive and screens may have been 
set up more than once, for example with variations in protein concentration. 
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Figure 6.8 – continued on next page 
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Figure 6.8: List of crystallization screens set up for TcPINK1 150-570 (D359A) 
The name/type of each screen is given along with ligands included and details in the case 
of grid screens and additive screens. This list is not exhaustive and screens may have been 
set up more than once, for example with variations in protein concentration. 
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Figure 6.9: List of crystallization screens set up for lysine methylated TcPINK1 150-
570 (D359A) 
The name/type of each screen is given along with ligands included and details in the case 
of grid screens and additive screens. This list is not exhaustive and screens may have been 
set up more than once, for example with variations in protein concentration. 
  
Appendix 
	  
	  
 211 
 
 
 
Figure 6.10: List of crystallization screens set up for TcPINK1 149-570 (D359A) 
The name/type of each screen is given along with ligands included and details in the case 
of grid screens and additive screens. 
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Figure 6.11: List of crystallization screens set up for TcPINK1 151-570 (D359A) 
The name/type of each screen is given along with ligands included and details in the case 
of grid screens and additive screens. 
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Figure 6.12: Sequence alignment and structure of Ubl domain and ubiquitin 
(A) Sequence alignment of Ubl domain of Parkin and ubiquitin, with Ser65 highlighted in 
pink. (B) Crystal structure of ubiquitin with S65 highlighted in pink. PDB ID: 1UBQ. (C) 
Solution NMR structure of Ubl domain with S65 highlighted in pink. PDB ID: 1IYF.  
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Figure 6.13: Multiple sequence alignment of Parkin 
Multiple sequence alignment of human Parkin with sulphate-binding pockets highlighted. 
Orange: Pocket 1 (K161, R163, K211); blue: Pocket 2 (K151, H302, R305, Q316); green: 
Pocket 3 (R455).  
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